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"Fatness and flabbiness are to blame.  
The womb is unable to receive the semen  
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ART  assisted reproductive techniques 
BMI   body mass index  
CT   abdominal computerised tomography scan 
DEXA  dual-energy X-ray absorptiometry 
DOHaD  developmental origin of health and adult disease 
ESHRE  European Society of Human Reproduction and Embryology 
FFA   free fatty acid 
GEE  generalised estimating equations 
HMW  high molecular weight 
HOMA-IR homeostasis model assessment score for insulin resistance 
IR   insulin resistance 
IL-6   interleukin-6 
IAF   intra-abdominal fat 
LAGB  laparoscopic adjustable gastric banding 
LRYGB  laparoscopic Roux-en-Y gastric bypass 
LSG   laparoscopic sleeve gastrectomy 
MRI   magnetic resonance imaging  
NTD  neural tube defects 
PCOS  polycystic ovary syndrome 
SHBG  sex hormone-binding globulin 
ssCT  single-sliced abdominal CT scan 
RCT  randomised controlled trial  
SAF   subcutaneous abdominal fat 
SFT   skinfold thickness 
TNFα  tumour necrosis factor α 
UMCG  University Medical Center Groningen 
US   abdominal ultrasound 
Wc   waist circumference 




























In the past 30 years, the prevalence of overweight (BMI ≥ 25 kg/m2) and obesity (BMI ≥30 
kg/m2) (see Table 1 for weight categories in adults) is on the rise worldwide, and due to its 
impact on health and disease it constitutes a global epidemic according to the World Health 
Organisation (WHO) (WHO, 2000).  
The prevalence of obesity in women older than 15 years varies between regions (Figure 
1A) and also between developed countries (Figure 1B) (WHO, 2012). In 2010, of all 
women in The Netherlands between the ages of 30 to 40 years, 32.2% were suffering from 
overweight and 9% from obesity (CBS, 2010). Considering the even stronger increase in 
the prevalence of childhood obesity in The Netherlands, a significant increase in obesity-
related infertility can be anticipated in the future (Schokker et al., 2007). Gynaecologists 
will encounter the consequences associated with obesity more often due to a higher 
frequency of these women presenting with infertility or complications occurring during 
pregnancy. 
 
Obesity and female fertility 
Polycystic Ovary Syndrome (PCOS) is the most common cause of anovulation. It affects 
4‒7% of women of reproductive age and 61% of these women are overweight or obese 
(Pasquali et al., 2006). The association between obesity and ovulatory dysfunction has been 
well documented in the literature (Table 2).  
Obesity in women with PCOS aggravates the underlying insulin resistance (IR) and the 
resulting hyperinsulinaemia and hyperandrogenaemia contribute to anovulation, although 
other obesity-related mechanisms contributing to anovulation cannot be excluded (Pasquali 
et al., 2006). Leptin, a peptide secreted by adipose tissue, may exert a direct inhibitory 
effect on ovarian function and interfere with the development of the dominant follicle and 
oocyte maturation (Duggal et al., 2000). The increased time to pregnancy (reduced fertility) 
observed in women with obesity is not solely attributable to anovulation, because obesity 
also decreases the chances of spontaneous conception in ovulatory women (Table 2) 
(Jensen et al., 1999, van der Steeg et al., 2008). 
       
 
Table 1.  WHO classification of weight categories in adults (adapted from WHO, 2010) 
 
BMI Classification 
BMI <18.5  underweight 
BMI    18.5‒24.9  normal weight 
BMI   25‒29.9  overweight 
BMI   30‒34.9 class I obesity 
BMI   35‒39.9 class II obesity 
BMI       ≥40 class III obesity (morbid obesity) 
























Obesity can also have an unfavourable effect on the outcome of fertility treatment. Obesity 
is considered an important predictor of unsuccessful ovulation induction in women with 
anovulatory infertility (Mulders et al., 2003). The effect of obesity on the pregnancy rate 
and live birth rate after ART (Assisted Reproductive Techniques) has been summarised in 
Tabel 2. There is an increased requirement for using gonadotrophins (gonadotrophin-based 
fertility-enhancing drugs), a higher miscarriage rate and a significant decrease in live birth 
rate with increasing BMI. The effect of obesity on live birth rate after ART was less 
pronounced in older women (>35 years) (Sneed et al., 2008; Luke et al., 2011), suggesting 
that the effect of age on the oocyte quality has a more detrimental effect on the live birth 
rate in older women than BMI. Not all studies agree whether the decrease in pregnancy rate 
and live birth rate after ART in women with obesity is determined by embryo quality , 
(Metwally et al., 2007; Bellver et al., 2010). Some studies in donoroocyte programs did not 
find a negative effect of obesity in the acceptor on pregnancy rates (Wattanakumtornkul et 
al., 2003; Styne-Gross et al., 2005), but others revealed a significant decrease in ongoing 
pregnancy rates with increasing BMI of the acceptor, in spite of no difference in embryo 
quality (Bellver et al., 2007). The high insulin levels as well as the changed serum 
adipokine levels (secretory products of adipose tissue) in women with obesity could 
influence the receptivity of the endometrium. IR has been shown to be an independent risk 
factor for spontaneous abortion (Tian et al., 2007). Hyperinsulinaemia leads to reduced 
glycodelin and insulin growth factor binding protein, both associated with the disruption of 
the adhaesion at the embryo-maternal interface (Carrington et al., 2005). 
Figure 1.  Prevalence of obesity in women older than 15 years of age in different regions (A) and in 




















































A limited amount of studies could not show an increase in complication rates following 
ART (such as haemorrhage, infection and injury to pelvic structures) in women who are 
overweight or obese compared to women of normal weight (Koning et al., 2012). 
Considering the small sample size of above-mentioned studies, more studies are needed to 
confirm that complication rates following ART are not increased in women who are 
overweight or obese.   
 
Obesity and pregnancy 
Women with obesity are more likely to experience miscarriages after spontaneous 
conception as well as after ART, and women with obesity and recurrent miscarriages have a 
significantly higher chance of miscarriage in a subsequent pregnancy compared to women 
of normal weight (Metwally et al., 2010) (Table 2).  
Maternal obesity has a detrimental effect on fetal development resulting in an increased risk 
of congenital anomalies, especially neural tube defects (NTD) and cardiac malformations 
(Table 2). Folic acid fortification to decrease the risk of NTD has lower benefit in obese vs. 
non-obese women (Werler et al., 1996; Ray et al., 2005).  Prenatal diagnosis of congenital 
abnormalities is less accurate in women with obesity due to poor ultrasound visualisation 
(Hendler et al., 2004; Hendler et al., 2005). The obese pregnant woman is exposed to 
increased risks during pregnancy, delivery and in the postpartum period (Table 2). The 
obstetric anaesthesia-related problems of obesity, like failed epidural or spinal anaesthesia 
and failed intubation, often performed under emergency circumstances, poses serious risks 
to the mother and the fetus (Hall and Neubert, 2005). The Confidential Enquiry into 
Maternal and Child Health in the United Kingdom indicates that 35% of the maternal 
deaths were obese compared to 23% of women of the general population, and that more 
than 25% of maternal deaths had a BMI >35 kg/m2 (Lewis, 2007). 
An additional concern of maternal obesity is that it may predispose to long-term disease in 
the offspring due to the developmental origin of health and adult disease (DOHaD) 
(Wadhwa et al., 2009), also known as the ‘Barker’s hypothesis’ (Barker et al., 1989; Barker 
et al., 1993). According to the DOHaD hypothesis, the intra-uterine environment may 
induce fetal adaptive responses leading to altered physiologic and homeostatic set points 
mediated by epigenetic changes and contributing to the risk of adult onset of disease 
(Symonds et al., 2009; Wadhwa et al., 2009; Hanson et al., 2011). Research in animal 
models reveal that maternal hyperglycaemia contributes to adult onset IR and liver-fat 
accumulation as well as compromised long-term bone health in the off-spring (Zhao and 
Weiler, 2010; Song et al., 2012,).  
In conclusion, maternal obesity contributes to adverse perinatal outcomes as well as to an 
increase in maternal morbidity and mortality. The female obesity-related reproductive 






Body-fat distribution and abdominal fat compartments  
Obesity is a heterogeneous condition and 20% of obese individuals have a metabolically 
healthy obese phenotype, which does not have the burden of obesity-associated cardio-
metabolic risk factors (Hayes et al., 2010). It has been hypothesized that the detrimental 
effects of obesity on short- and long-term health risks are especially determined by 
differences in body-fat distribution. Accumulation of fat predominantly on the hips and 
thighs, called peripheral or gynaecoid obesity, poses little metabolic risks (Haslam and 
James, 2005; Despres et al., 2008). Accumulation of fat around the abdomen, called 
abdominal obesity (also called android or upper body obesity) is associated with metabolic 
complications such as cardiovascular disease and type 2 diabetes mellitus (Haslam and 
James, 2005; Hayes et al., 2010). Moreover, abdominal obesity also plays a role in female 
infertility and pregnancy complications (Pasquali et al., 2003; Carmina et al., 2007; Nelson 
and Fleming, 2007). Abdominal obesity contributes to reproductive dysfunction mainly by 
contributing to increased IR. High insulin levels interfere with intra-ovarian steroidogenesis 
leading to hyperandrogenaemia and arrest of follicle growth (Franks et al., 2008). 
Hyperandrogenaemia may alter adipose tissue mass in a depot-specific manner. The 
mechanism of this effect is not clear yet, but may be based on site-specific modulation of 
preadipocyte proliferation and/or differentiation as well as lipid synthesis and/or lipolysis in 
mature adipocytes (Blouin et al., 2008). Chronic hyperandrogenaemia may favour 
abdominal fat accumulation in women, triggering a vicious circle of abdominal obesity, 
hyperinsulinaemia and hyperandrogenaemia (Pasquali et al., 2006). 
Abdominal fat consists of an intra-abdominal fat (IAF) and a subcutaneous fat (SAF) 
compartment. IAF consists mostly of mesenteric and omental fat. The products of IAF 
enter the portal venous system and arrive firstly at the liver, whereas the venous drainage of 
SAF is into the peripheral circulation. IAF and SAF also show differences in metabolic 
activity. Compared to SAF, IAF shows higher lipolytical activity (Weiss, 2007). Therefore, 
in women with an enlarged IAF mass, the elevated portal flux of free fatty acids, glycerol 
and other substances have a detrimental effect on hepatic metabolism leading to increased 
gluconeogenesis, decreased insulin clearance and decreased production of sex hormone 
binding globulin (Weiss, 2007). SAF on the other hand acts as a metabolic sink by 
buffering elevated postprandial fatty acid and lipid fluxes and by storage of excess 
triglycerides (Weiss, 2007; Koska et al., 2008). It has been shown that an excess of IAF 
contributes to an increased risk of developing cardio-metabolic disorders (Hayes et al., 
2010). In premenopausal women with abdominal obesity, IAF is associated with IR even 
after correcting for SAF (Ross et al., 2002). Studies on the role of IAF on female 
reproduction are limited. IAF is considered a marker for IR and cardiovascular risk in obese 
women with PCOS (Lord et al., 2006). Increased IAF during early pregnancy is associated 






and it has also been shown to predict glucose intolerance in later pregnancy (Bartha et al., 
2007; Martin et al., 2009).  
Only limited studies have been performed to assess whether accumulation of IAF during 
the pre-conception period and in pregnant women has an adverse influence on reproductive 
and fetal outcome. No previous studies have been performed on the effect of lifestyle 
intervention on IAF accumulation and the outcome in infertile and pregnant women with 
obesity. 
 
Measurement of body-fat distribution and of IAF and SAF 
Methods available to measure obesity and body-fat distribution differ in accuracy, 
feasibility, safety and costs. BMI as a crude measure of obesity gives no information on 
body-fat distribution (National Heart, Lung and Blood Institute/National Institutes of 
Diabetes and Digestive and Kidney diseases, 1998; Prentice and Jebb, 2001). In 
epidemiological studies, waist circumference measurement is used to identify individuals 
with abdominal obesity (Janssen et al., 2002; Zhang et al., 2008), but it cannot distinguish 
IAF from SAF (Despres, 2006; Weiss, 2007; Jensen, 2008). Dual-energy X-ray 
absorptiometry (DEXA) scan can quantify body-fat distribution accurately, but it cannot 
distinguish between IAF and SAF. Abdominal Computerised Tomography scan (CT) or 
Magnetic Resonance Imaging (MRI) are the gold standards for the measurement of IAF and 
SAF (Figure 2), but pose limitations due to radiation exposure, costs and access to the 
equipment (Seidell et al., 1990). Several studies in different populations have confirmed 
that abdominal ultrasound (US) is a reliable and valid tool for the measurement of IAF and 
SAF when compared to CT and MRI (Armellini et al., 1993; Stolk et al., 2001; Gradmark 
et al., 2010).  These studies were performed in populations with increased metabolic risk, 
but not in women of reproductive age with overweight or obesity. Furthermore, only one 
study tried to validate the measurement of the changes of IAF and SAF between US and CT 
in study subjects undergoing weight loss (Armellini et al., 1991). Before the 
implementation of US to measure IAF and SAF in women of reproductive age, validation 
studies are needed because body composition and abdominal fat distribution change with 
age and vary between different populations.  
 
Adipose tissue as an endocrine organ 
Adipose tissue was traditionally thought to be a passive reservoir used for energy storage, 
but it is now known to be a complex and highly active endocrine organ (Kershaw and Flier, 
2004). Besides adipocytes and pre-adipocytes, adipose tissue consists of connective tissue 
matrix, nerve tissue, stromovascular and immune cells. Adipose tissue contains enzymes 
involved in the metabolism of steroid hormones, and it produces various proteins and 






al., 2010). Adipokine quantities may vary by the metabolic activity of the adipose tissue, 
per fat compartment (IAF versus SAF) and per stage of cell development (preadipocytes 
versus adipocytes). Adipokines, like leptin, adiponectin, interleukin-6 and tumor necrosis 
factor α, act in an autocrine and paracrine fashion on adipose tissue itself, and in an 
endocrine manner on distant tissues and organs. They have been suggested to influence 
reproductive function due to their effect on hypothalamic function and direct effects on the 
ovary and endometrium (Kershaw and Flier, 2004; Bohler et al., 2010). Serum levels of 
adipokines could therefore be used to assess the metabolic activity and effect of different 
adipose tissue compartments on female reproduction. Further studies are needed to assess 
whether serum adipokine levels correlate with the volume of IAF and SAF, and whether the 
serum adipokine levels can be used to measure the metabolic activity and effect of IAF and 




























 Figure 2.  CT scan showing intra-abdominal fat (IAF) and subcutaneous abdominal fat (SAF). With 







Weight loss for resumption of ovulation 
The management of obesity should include measures to help patients lose weight and 
maintain appropriate body weight, thus lowering their cardiovascular and metabolic risks 
and putatively enhance their chances of conception. Weight loss programmes in women 
with anovulation have shown that 5‒10% loss of initial body weight leads to resumption of 
ovulation in about 60% of women by reducing circulating insulin levels and reducing 
hyperandrogenaemia (Kiddy et al., 1992; Guzick et al., 1994; Clark et al., 1995). In women 
with PCOS, 5% loss of abdominal fat is associated with resumption of ovulation (Huber-
Buchholz et al., 1999). During modest weight loss in women with obesity, loss of IAF had 
a greater beneficial effect on IR than loss of SAF (Park and Lee, 2005). It is important to 
investigate whether it is the loss of IAF and not SAF that contributes to resumption of 
ovulation in anovulatory women with obesity. The results of such studies can facilitate 
future lifestyle intervention programmes targeting the loss of IAF.  
 
Medication as an adjunct to lifestyle intervention 
Lifestyle intervention programmes aiming at achieving and maintaining weight loss are 
usually modestly successful due to poor adherence to dietary and exercise measures and 
high drop-out rates (Finley et al., 2007). Drop-outs tend to have less weight loss (Finley et 
al., 2007), and therefore drop-out is an important limiting factor in the success of lifestyle 
intervention programmes (Messier et al., 2010). Weight loss medication as an adjunct to 
lifestyle invention has been shown to achieve more weight loss than lifestyle intervention 
alone, and up to 10% loss of initial body weight has been reported over a 1 year period 
(Vetter et al., 2010). Orlistat, a Food and Drug Administration approved weight loss drug, 
cannot be used in women who anticipate conception because of lack of safety data during 
its use in early pregnancy. Sibutramine, a second weight loss drug has been withdrawn 
from the American and European markets out of safety concerns. Insulin-sensitizing drugs 
are not considered weight loss drugs, even though some studies indicate that metformin 
might contribute to weight loss (Knowler et al., 2002). In anovulatory women with PCOS, 
metformin was studied extensively and may contribute to resumption of ovulation in a 
subset of patients (Tang et al., 2012). If insulin-sensitizing drugs can be shown to 
contribute to weight loss in women of reproductive age, they should be considered to be 
used as an adjunct to lifestyle intervention. 
 
Aims and outline of the thesis  
The studies in this thesis are undertaken to assess various aspects of obesity and female 
infertility with the main focus on the role and influence of body-fat distribution and 






There is a need to assess the costs and effects of overweight and obesity on female 
infertility and pregnancy outcome, in order to aid further research on the cost-effectiveness 
of lifestyle intervention and to formulate evidence based guidelines for the treatment of 
these women. In Chapter 2, the consequences of overweight and obesity with respect to 
fecundity, costs of fertility treatment and pregnancy outcome was studied in women with 
infertility.    
Studies on the role IAF and SAF in female infertility are very limited. In Chapter 3, we 
measured body-fat distribution and compared the contribution of IAF and SAF to 
anovulation in obese women with infertility. 
CT is the gold standard for the measurement of IAF and SAF, but US could be an ideal 
alternative due to the absence of radiation exposure, low cost and its general availability in 
most fertility and antenatal clinics. In Chapter 4, we investigated the correlation between 
the measurements of IAF and SAF by US and CT scan in women with obesity and 
infertility. 
Studies are needed to assess whether serum adipokine levels can reflect the differences in 
body-fat distribution and the differences in the volume and metabolic activity of IAF and 
SAF. In Chapter 5, we assessed whether PCOS status is a determining factor in the 
correlation between body-fat distribution parameters and serum adipokine levels in women 
with obesity and infertility. 
Loss of abdominal fat is required for the resumption of ovulation in obese women with 
PCOS. The question remains, whether differential loss of IAF and SAF contributes to 
resumption of ovulation. In Chapter 6, we compared the changes in body-fat distribution 
and specifically IAF and SAF in a group of anovulatory women with PCOS and obesity 
who resumed ovulating to those who remained anovulatory during a lifestyle programme.  
Obese individuals have great difficulty in losing weight and insulin-sensitizing agents may 
help to achieve more weight loss. In Chapter 7, we performed a systematic review in 
women of reproductive age who are overweight or obese to assess whether treatment with 
insulin-sensitizing drugs contributes to weight loss, compared to diet or a lifestyle 
modification programme. 
In Chapter 8, the main findings of this thesis are summarised and recommendations for 
clinical practice and future research are provided. 
 
Patients and methods  
The data presented in Chapters 3 to 6 are based on a prospective cohort of 60 women with 
obesity and infertility who participated in a lifestyle programme at the UMCG between 
2005 and 2009.  
All participants received individualised dietary advice, and an individualised exercise 






participant. Individual guidance by a nurse practitioner consisted of visits to the outpatient 
clinic every 2 weeks, during which body weight was measured and compliance was 
assessed. Motivational counselling techniques were used to address problems of and 
resistance to lifestyle changes and advice on behavior modification was given. Body-fat 
distribution was assessed by anthropometrics, DEXA and CT at intake, after 3 months and 
after 6 months. At these time points, blood samples were also taken. Table 3 gives an 




Table 3.  Overview of 60 women with obesity and infertility participating in a lifestyle programme at 
the University Medical Center Groningen, included in the present analysis 
 
Chapter n Patients Methods 
Three 57 Women with infertility; three women 
excluded because of early drop-out, 




Baseline comparison between 
ovulatory and anovulatory women to 
determine the contribution of 
variables to anovulation 
Four 53 Women for whom US and CT 
measurements were available at 
baseline, month 3 and month 6. 
(BMI 37.0±4.9) 
 
Correlation between the 
measurements of IAF and SAF and 
the changes measured by US and CT 
Five 47 32 women with anovulatory PCOS 
 and 15 ovulatory non-PCOS controls. 
(BMI 36.8±4.9) 
 
Correlation between body-fat 
distribution parameters and serum 
adipokine levels  
Six 32 Anovulatory women with PCOS.  
(BMI 37.5±5.0) 
Changes in anthropometrics and IAF 
and SAF over time comparing 
women who resumed ovulating to 
those who remained anovulatory 
during the lifestyle programme  
 
Abbreviations: Abdominal ultrasound (US); Body mass index (BMI) as kg/m2; Abdominal computerised 
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Background: Overweight and obesity are an epidemic in Western society, and have a 
strong impact on fertility. We studied the consequences of overweight and obesity with 
respect to fecundity, costs of fertility treatment and pregnancy outcome in subfertile 
women.  
Methods: We searched the literature for systematic reviews and large studies reporting on 
the effect of weight on both fecundity and pregnancy outcome in subfertile women. We 
collected data on costs of treatment with ovulation induction, intra-uterine insemination and 
in vitro fertilisation, as well as costs of pregnancy complications. We calculated, for 
ovulatory and anovulatory women separately, the number of expected pregnancies, 
complications and costs in a hypothetical cohort of 1000 normal weight, overweight and 
obese women each.   
Results: In our hypothetical cohort of 1000 women, compared to women with normal 
weight live birth was decreased by 14 and 15% (from 806 live births to 692 and  687 live 
births) in overweight and obese anovulatory women respectively, for ovulatory women it 
was decreased by 22 and 24% (from 698 live births to 546 and 531 live births), 
respectively. These outcomes were associated with an increase in the number of 
complications and associated costs leading to cost per live birth in anovulatory overweight 
and obese women were 54 and 100% higher than their normal-weight counterparts, for 
ovulatory women they were 44 and 70% higher, respectively.  
Interpretation: Overweight and obese subfertile women have a reduced probability of 
successful fertility treatment and their pregnancies are associated with more complications 





The prevalence of overweight and obesity varies in populations and is estimated to range 
from 5% in some developing countries to >30% in developed countries (James et al., 2004). 
The World Health Organisation defines overweight as a body mass index (BMI) ≥25 kg/m2, 
and obesity as a BMI ≥30 kg/m2 (WHO, 2000). Considering the trends in childhood 
obesity, a significant increase in obesity-related subfertility can be anticipated in the future 
(Schokker et al., 2007). Nowadays, the rate of obesity in women of child-bearing age is 
12% in Western Europe and 25% in North America (Butler et al., 2004; Linné et al., 2004; 
Watson et al., 2005; Haslam and James, 2005).  
The strongest obesity-related effect on fertility is anovulation. Polycystic ovarian syndrome 
(PCOS), the most noted cause of anovulation, is furthermore exacerbated by increased 
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insulin resistance and hyperinsulinaemia associated with overweight and obesity (Pasquali 
et al., 2007). In 65% of patients with PCOS, obesity therefore contributes to anovulation 
(Pasquali et al., 2003). On the other hand, even obese women with an ovulatory cycle have 
a lower chance of spontaneous conception (Jensen et al., 1999; Van der Steeg et al., 2007).  
In cases of chronic anovulation, ovulation induction (OI) with clomiphene citrate in 
overweight and obese women results in lower ovulation rates (Imani et al., 1998) and lower 
cumulative live birth rates for women with a BMI >30 kg/m² (Legro et al., 2007). McClure 
et al. (1992) showed that in overweight women ovulation rates are lower due to higher 
cancellation rates, but if OI is successful no difference is found in pregnancy rates in 
different weight categories. Mulders et al. (2003) also found obesity to be associated with 
higher cancellation rates and substantially higher miscarriage rates leading to a lower live 
birth rate per started cycle. This decreased success rate is however not found in all studies 
(Balen et al., 2006).  
The literature on the impact of body weight on the effectiveness of intra-uterine 
insemination (IUI) is just as for OI, inconsistent. Koloszar et al. (2002) showed a negative 
impact of increasing body weight on the success rates of IUI, but Wang et al. (2004) could 
not confirm this finding.  
Furthermore, several retrospective studies have shown a negative impact of overweight and 
obesity in women on the outcome of in vitro fertilisation (IVF) (Lashen et al., 1999; Wang 
et al., 2000; Koloszar et al., 2002; Fedorcsak et al., 2004). The ongoing pregnancy rate and 
live birth rate is however consistently decreased especially due to an increased miscarriage 
rate in women with obesity (Wang et al., 2002; Lintsen et al., 2005; Maheshwari et al., 
2007). 
Apart from these obesity-related fertility problems, there is indisputable evidence that 
pregnancy in overweight and obese women is associated with an increased risk of 
complications, leading to higher maternal and neonatal morbidity and mortality and 
increased costs (Sebire et al., 2001; Cedergren et al., 2004; Linne et al., 2004). Pregnancy 
complications associated with obesity are hypertensive disorders, gestational diabetes, 
prolonged duration of labour, increased need of operative delivery, macrosomia, shoulder 
dystocia and increased blood loss (Garbaciak et al., 1985; Edwards et al., 1996; Weiss et 
al., 2004). Obesity is furthermore associated with an increased risk of adverse pregnancy 
outcomes such as unexplained still birth (Cnattingius et al., 1998; Linne et al., 2004; 
Kristensen et al., 2005) and neonatal admissions (Usha Kiran et al., 2005). 
In view of the issues stated above, it is likely that overweight and obesity have a negative 
impact on the outcome as well as the costs of fertility treatment. The aim of this paper is to 
conceptualise the impact of overweight and obesity on fertility treatment and the resultant 








We developed a framework within which the consequences of fertility treatment and 
outcomes of resultant pregnancy can be evaluated simultaneously for subfertile women in 
different body weight categories. We performed systematic reviews to obtain information 
on outcomes and costs to generate cost-effectiveness estimates for inclusion in decision 
analytic models. To do so, we searched the literature for evidence on the effect of obesity 
on spontaneous pregnancy chances, success of assisted reproduction technologies (ART), 
as well as pregnancy outcome.  
We used the following electronic databases: PubMed, Embase, DARE and the Cochrane 
Library to initially search for systematic reviews on each of the subjects. In absence of 
reviews, we identified large, reliable studies.  
To identify studies that reported on the association between obesity and spontaneous 
pregnancy chances we combined the key words (‘obesity’, ‘overweight’ or ‘body mass 
index’) and (‘pregnancy’ or ‘fertility’). By adding the key words (‘assisted reproduction 
technologies’, ‘intra-uterine insemination’) and (‘ovulation induction’) we looked for 
studies reporting on the effect of obesity on these treatments. To identify studies reporting 
on the association between obesity and pregnancy outcome, we used the key words: 
(‘obesity’, ‘overweight’ or ‘body mass index’) and (‘pregnancy outcome’).  
We included studies reporting on maternal morbidity as well as pregnancy outcome. The 
reported odds ratios (ORs) in the reviews were used, or if not available, calculated by using 
a 2 x 2 table cross-classifying BMI and one of the afore-mentioned outcomes. These ORs 
were used as input for calculating the additional impact of overweight and obesity on both 
fecundity as well as pregnancy. 
The economic analysis was performed from a hospital perspective. Costs of fertility 
treatments were obtained from a series of Dutch studies that reported on the costs of OI, IUI 
and costs of IVF (Goverde et al., 2000; Eijkemans et al., 2005). Furthermore, we looked for 
studies reporting on costs of pregnancy in overweight women and costs of pregnancy 
complications in these women. To do so, we performed a search of several major journals 
in obstetrics and gynaecology for economic evaluations. We looked for studies that 
reported on the costs of each of the complications miscarriage, pre-eclampsia, gestational 
diabetes and caesarean delivery. We assumed no difference in multiple pregnancy rates 
between different weight categories (Esinler et al., 2008). 
 
Next, we assessed the impact of overweight and obesity on the costs and effects of fertility 
treatments. To achieve this, we distinguished between the case of ovulatory women and the 
case of anovulatory women. For each of these situations, we considered women with 
normal weight, overweight, and obese women. According to the WHO normal weight is 
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defined as a BMI between 20 and 25 kg/m², overweight as a BMI between 25 and 30 kg/m² 
and obesity as a BMI over 30 kg/m². Because of differences in definitions of overweight 
and obesity in some studies we used in our review, we could not use the very strict BMI cut 
off points proposed by the WHO for our different weight groups. 
 
We then constructed a theoretical model, simulating the situation where women were 
treated for their subfertility. For each of the six categories, i.e., anovulatory women with 
normal weight, anovulatory overweight women and anovulatory obese women and 
ovulatory women with normal weight, ovulatory overweight women and ovulatory obese 
women, we calculated the expected pregnancy rates, the expected number of fertility 
treatments and the expected number of pregnancy complications for a hypothetical group of 
1000 women. We performed multiple sensitivity analyses on the following variables 
success rate of IVF (range 40% to 60%), success rate of OI (range 70% to 90%) and IUI 
(range 30% to 50%). With these figures we calculated and then plotted in two figures 
different success rates of ART against the costs per live birth in anovulatory and ovulatory 






The search for studies on the association between spontaneous pregnancy chances in 
overweight women revealed two reviews by Jensen and Gesink Law et al. as well as the 
study of Van der Steeg et al. (Jensen et al., 1999; Gesink Law et al., 2007; Van der Steeg et 
al., 2007). The results of these studies are shown in Table 1. Both reviews as well as the 
study of Van der Steeg et al. showed that overweight women take longer to conceive than 
normal-weight women. The reviews were retrospective studies in a cohort of women not 
seeking medical help for any subfertility, whereas Van der Steeg et al. studied women in 
fertility clinics. Based on these results, we assumed that among obese ovulatory women 
spontaneous pregnancy chances were 90% of those in normal weight or overweight 
women. Moreover, we assumed that spontaneous pregnancy chances prior to and in 
between ART cycles were 10% in all groups. 
From the literature no unequivocal conclusion could be drawn about the influence of 
obesity on IUI. Whereas Wang et al. (2004) reported an increased probability of success of 
IUI in women with a BMI >30 kg/m2, Koloszar et al. (2002) reported exactly the opposite, 
i.e. a decrease in success of IUI with increasing BMI. In view of these conflicting results on 



















Spontaneous pregnancy         





OR 0.92  
  (95% CI 0.84‒1.01)  
  for BMI 25‒29.9 
OR 0.82  
  (95% CI 0.75‒0.92) 
  for BMI >30 
OR 0.66  
  (95% CI 0.49‒0.89) 
  for primipari with  
  BMI >30 





OR 0.77  
  (95% CI 0.70‒0.84)  
  for BMI >25 
van de Steeg 2002‒2004 subfertile 
ovulatory 
prospective time to 
pregnancy 
<12 months 
HR 0.95 (CI 0.91‒0.99) 
  per extra kg/m2 from a  
  BMI >29 
 
Intra-uterine insemination        







OR 1.5  
  (95% CI 1.1‒1.9)*  
  for BMI >30 
Koloszar 1992‒1998 infertile 
ovulatory 
prospective pregnancy OR 0.66  
  (95% CI 0.49‒0.88)* 
  for BMI 25‒27 
OR 0.42  
  (95% CI 0.25‒0.73)* 
  for BMI 28‒36 
 
In vitro fertilisation  
    
    






pregnancy OR 0.71  
  (CI 95% 0.62‒0.81) 
  for BMI >25 
OR 0.68  
  (CI 95% 0.55‒0.83)  
   for BMI >30 
 










Maheshwari et al. (2007) published a systematic review of the literature from 1960 until 
2006 on the outcome of IVF for overweight and obese women. They reported an OR for 
pregnancy after IVF of 0.71 (95% CI 0.62‒0.81) for women with a BMI 25 kg/m2 
compared to women with a BMI between 20 and 25 kg/m2, and for women with a BMI >30 
kg/m2 even 0.68 (95% CI 0.55‒0.83) (Table 1). We applied these odds ratios in our model. 
Maheshwari et al. (2007) also found that overweight women require more total units of 
gonadotrophins during hyperstimulation for IVF, but these additional costs were not 
considered in the present analysis. 
We found one meta-analysis and three studies that reported on the impact of BMI on the 
effectiveness of OI in anovulatory women (Table 2) (Imani et al., 2002; Mulders et al., 
2003; Al-Azemi et al., 2004; Balen et al., 2006). The study of Al-Azemi et al. (2004) 
showed a negative impact of obesity on live birth rate after OI with clomiphene citrate. The 
meta-analysis of Mulders et al. (2003) did not show a significant impact of BMI on the 
fecundity after OI with gonadotrophins. However, they found higher cancellation rates per 
cycle (OR 1.9) and higher miscarriage rates in the obese group (OR 3.1), thus leading to 























live birth OR  0.74* (0.39‒1.4) 
  for BMI 25‒29 
OR  0.15* (0.07‒0.30) 
  for BMI >30  
Mulders 1986‒2002 infertile women 
undergoing 
gonadotrophin-OI 
meta analysis pregnancy OR 1.22  
  (95% CI  0.77‒1.93)  
  obese vs lean women 
        cancellation rate  OR 1.86  
  (95% CI 1.13‒3.06) 
        miscarriage rate OR 3.05  
  (95% CI 1.45‒6.44) 
Balen 2002‒2003 after 3 cycles CC 




pregnancy OR 1.3*  
  (0.71‒2.2) for  BMI>25 
OR 0.99* (0.48‒2.0)  
  for BMI >30  




ovulation OR 0.92 (0.88‒0.96) 
  obese vs normal weight 
        live birth OR 1.00 (0.97‒1.04)  
 






Balen et al. (2006) studied anovulatory women with a BMI up to 35 kg/m2 and also did not 
find a significant difference in pregnancy rates after OI with gonadotrophins in overweight 
and obese women compared to women of normal weight. Imani et al. (2002) found among 
anovulatory women a hazard ratio of 0.92 for obese versus lean women for ovulation after 
OI with clomiphene citrate, but they also did not find a difference in live birth chances 
between the weight groups. We therefore assumed in our analysis that there is no influence 
of BMI on pregnancy rates after OI in anovulatory women. 
Table 3 shows the additional risk of obstetric complications due to overweight and obesity. 
We applied meta-analyses conducted by Chu et al. (2007a,b,c) and Cnossen et al. (2007). 
These studies report that there is an additional risk of stillbirth, caesarean delivery, pre-
eclampsia and gestational diabetes with increasing BMI. Fedorcsak et al. (2004) studied the 




Table 3. Odds ratios of maternal and fetal complications in overweight and obese women 
 













OR 2.0* (95% CI 1.1‒3.7)  
  for BMI >25 





stillbirth OR 1.5 (95% CI 1.1‒1.9)  
  for overweight women 
OR 2.1 (95% CI 1.6‒2.7)  
  for obese women 







LRs (95% CI) 1.7 (0.3 ‒11.9) 
  for BMI > or = 25 
  and 0.73 (0.22‒2.45)  
  for BMI <25 (OR 2.3) 
LRs 2.7 (1.0‒7.3)  
  for BMI > or = 35 
  and 0.86 (0.68‒1.07)  
  for BMI <35 (OR 3.7) 







OR 1.5 (95% CI 1.3‒1.6)  
  for overweight women 
OR 2.1 (95% CI 1.9‒2.3)  
  for obese women 
OR 2.9 (95% CI 2.3‒3.8)  
  for severely obese women 







OR 2.1 (95% CI 1.8‒ 4.2)  
  for overweight women 
OR 3.6 (95% CI 3.1‒4.2)  
  for obese women 
OR 8.6 (95% CI 5.1‒16)  
  for severely obese women 
 
BMI, body mass index; OR, odds ratio; LR, likelihood ratio; *, calculated OR. 
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Table 4. Costs of pregnancy complications and ART per pregnancy 
 
Study (year) Complication/treatment Costs per pregnancy  (€) 
Chen (2001) caesarean delivery 3350* 
Barton (2006) hypertensive disorder 8250* 
Moss (2007) gestational diabetes mellitus   345* 
Graziosi (2005) miscarriage   683 
Goverde (2000) IVF 1700* 
Eijkemans (2005) OI   250 
Goverde (2000) IUI   450* 
 
*Calculated from US and AUS dollars and Dutch guilders. 
 
 
Table 4 presents expected costs of fertility treatment and pregnancy complications. We 
used several studies on costs of pregnancy complications and calculated the costs presented 
in euro’s using the current exchange rates (Chen et al., 2001; Graziosi et al., 2005; Barton 
et al., 2006; Moss et al., 2007). Furthermore, we used studies on costs in The Netherlands 
for OI, IUI and IVF treatment (Goverde et al., 2000; Eijkemans et al., 2005). 
 
Expected outcome and costs  
Table 5 shows the result when the model was applied on a hypothetical cohort of 1000 
anovulatory women. Our model represents costs until birth, including the costs of delivery. 
In 1000 normal-weight anovulatory women, treatment with three cycles of OI and, if 
needed, followed by one or two cycles of IVF, would result in 900 pregnancies. Figure 1A 
shows that costs per live birth are higher for overweight and obese anovulatory women with 
different success rates of OI and IVF and these differences in costs are roughly constant 
over a large range of success rates.  
Of these pregnancies 90 are expected to end in miscarriage and 810 women will have an 
ongoing pregnancy. The expected number of pregnancies complicated by pre-eclampsia, 
gestational diabetes and caesarean delivery, will be 81, 41 and 81, respectively, whereas 4 
women will suffer stillbirth. Overall, 806 women are expected to deliver a child, for a total 
cost of € 2430 per woman, resulting in a cost of  € 3016 per live birth.  
From Table 5, it can also be seen that in overweight anovulatory women the effectiveness 
of treatment decreases, resulting in a decrease of the number of pregnancies and live births, 
an increase in costs and a relative increase of the number of complications. This results in a 
decrease in the number of live births of 114 (14%), and an expected increase in costs of 
almost € 800 (32%) per patient. For obese anovulatory women, these figures are slightly 
worse, as the number of live births decrease to 119 (15%), and the expected increase in cost 






Table 5. Hypothetical cohort of 1000 anovulatory women in different weight categories 
 





Cohort 1000 1000 1000 
Impact of overweight on OI (OR) 1 1 1 
Pregnant after 3 cycles OI (baseline rate 80%) 800 800 800 
     
Number of women undergoing IVF 200 200 200 
Impact of weight on effectiveness IVF (OR) 1 0.71 0.68 
Pregnant after 2 cycles IVF (baseline rate 50%) 100 71 68 
     
Expected number of pregnancies 900 871 868 
Impact of weight on miscarriage (OR) 1 2 2 
Expected number of miscarriages (baseline rate 10%) 90 174 174 
Number of women without ongoing pregnancy 190 303 306 
Number of women with ongoing pregnancy 810 697 694 
     
Impact of weight on pre-eclampsia (OR) 1 2.3 3.7 
10% pregnancies complicated by pre-eclampsia  81 160 257 
Impact of weight on gestational diabetes (OR) 1 2.1 3.6 
5% pregnancies complicated by gestational diabetes 41 73 125 
Impact of weight on caesarean deliveries (OR) 1 1.5 2.1 
10% pregnancies caesarean delivery 81 105 146 
Impact of weight on  stillbirth (OR) 1 1.5 2.1 
0.5% pregnancies stillbirth 4 5 7 
    
Total women with live birth 806 692 687 
Total costs complications (€) 1000 1788 2724 
Total expected cost (*€1000) 2430 3218 4154 
Cost per live birth (€) 3016 4653 6045 
Cost per pregnancy (€) 3001 4618 5982 
 
a Applied BMI (kg/m²) threshold differed from study to study (range 25‒27). 




Table 6 shows the results for a theoretical cohort of 1000 ovulatory women. In 1000 
normal-weight ovulatory women, treatment consisted of three cycles of IUI and if this was 
unsuccessful one or two cycles of IVF, added with 10% spontaneous pregnancies that occur 
on waiting lists or in between cycles, would result in 780 pregnancies. Figure 1B shows 
that over a large range of different success rates of IUI and IVF the costs per live birth are 
higher for overweight and obese ovulatory women.  
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Of these pregnancies 78 are expected to suffer a miscarriage and 702 women will have an 
ongoing pregnancy. The expected number of pregnancies complicated by pre-eclampsia, 
gestational diabetes and caesarean delivery, will be 70, 35 and 70, respectively, whereas 4 
women will suffer stillbirth. Overall, 698 women are expected to deliver a child, for a total 




Figure 1 (A). Sensitivity analyses showing the effect of variation of success rates of OI and IVF 
on costs per live birth in anovulatory women. (B). Sensitivity analyses showing the effect of 








Table 6. Hypothetical cohort of 1000 ovulatory women in different weight categories 
 





Cohort 1000 1000 1000 
Impact of overweight on spontaneous pregnancies (OR) 1 1 0.9 
Spontaneous pregnancies (baseline rate 10%) 100 100 90 
     
Number of women undergoing IUI 900 900 910 
Treatment effect of IUI (OR) 0.4 0.4 0.4 
Pregnant after 3 cycles IUI  (baseline rate 40%) 360 360 364 
     
Number of women undergoing IVF 640 640 636 
Impact of overweight on effectiveness IVF 1 0.71 0.68 
Pregnant after 2 cycles IVF (baseline rate 50%) 320 227 216 
     
Expected number of pregnancies 780 687 670 
Impact of weight on miscarriage (OR) 1 2 2 
Expected number of miscarriages (baseline rate 10%) 78 137 134 
Number of women without ongoing pregnancy 298 450 464 
Number of women with ongoing pregnancy 702 550 536 
     
Impact of weight on pre-eclampsia (OR) 1 2.3 3.7 
10% pregnancies complicated by pre-eclampsia 70 126 198 
Impact of weight on gestational diabetes (OR) 1 2.1 3.6 
5% pregnancies complicated by gestational diabetes 35 58 97 
Impact of weight on caesarean deliveries (OR) 1 1.5 2.1 
10% pregnancies caesarean delivery 70 82 113 
Impact of weight on stillbirth (OR) 1 1.5 2.1 
0.5% pregnancies stillbirth 4 4 6 
     
Total women with live birth 698 546 531 
Total costs complications (€) 867 1410 2103 
Total expected cost (*€1000) 4258 4801 5494 
Cost per live birth  (€) 6096 8800 10355 
Cost per pregnancy  (€) 6066 8734 10246 
 
a Applied BMI (kg/m²) threshold differed from study to study (range 25‒27). 
b Applied BMI (kg/m²) threshold differed from study to study (range 29‒35). 
 
Similarly as for anovulatory women, it can be shown that in overweight ovulatory women 
the effectiveness of treatment decreases, resulting in a decrease of the number of 
pregnancies and live births, an increase in costs and a relative increase of the number of 
complications. This results in a decrease in the number of live births of 153 (22%), with the 
expected increase in costs of € 543 (13%), resulting in a cost per live birth of € 8800. For 
obese ovulatory women, these figures are worse with a decrease in live births of 167 (24%), 
with the expected increase in costs of almost € 1250 (29%), resulting in a cost per live birth 
of € 10,355. 
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Overweight and obesity are an increasing problem in Western society. In this review, we 
collected data on the impact of overweight and obesity on fertility care. We found that both 
in ovulatory and in anovulatory subfertile women overweight and obesity resulted in a 
decreased fecundity and in an increase in the number of pregnancy complications and 
associated costs. However, there is no proven cause and effect between overweight and 
subfertility. It remains possible that excessive weight and subfertility are both symptoms of 
an unknown pathology. 
Our results roughly suggest that overweight leads to an additional cost of € 1500 per 
pregnancy and 100 fewer pregnancies per 1000 anovulatory women undergoing fertility 
treatment, where this is € 2500 and 150 pregnancies, respectively, for anovulatory women. 
The validity of our findings depends on the robustness of our methodology. We put forward 
a framework that can be used to encourage development of more advanced models for 
generating cost-effectiveness information through robust economic evaluation. In our 
review of the literature, we found different and occasionally conflicting results on the 
impact of overweight and obesity on the effect of fertility treatment. When this was the 
case, we chose to consider no effect of overweight. Furthermore the success rate of IVF 
decreases with increasing BMI (Maheshwari et al., 2007), thus overweight and obese 
women will have to undergo more cycles compared to normal-weight women.  
As a consequence, our findings may be an underestimation of the impact of overweight and 
obesity. Since the purpose of this review was not to give exact figures on costs but to show 
a trend in costs and cost-effectiveness, we feel this possible inaccuracy does not undermine 
the overall conclusion.  
From our analysis several issues rise. First, as a higher BMI is associated with more 
pregnancy complications, there is the question as to whether women should lose weight 
before fertility treatment is started. A recent retrospective analysis by Maheshwari et al. 
(2009) concludes that cost of  IVF is not different for several weight categories but because 
of obstetric complications associated with higher BMI women with overweight should be 
advised to lose weight prior to IVF. Our analysis concurs with this conclusion and gives 
indicative results that merit consideration in counselling patients and guiding evidence-
based discussions on current practice and policy. 
Weight loss may be achieved by lifestyle modification interventions, incorporating multiple 
approaches (diet, exercise, behaviour). Interventions of this kind are advised as a key 
component for the improvement of reproductive function in overweight women, 
specifically with PCOS (Kiddy et al., 1992; Clark et al., 1995; Huber-Buchholz et al., 
1999; Hoeger et al., 2004; Norman et al., 2004; Balen et al., 2006; Tang et al., 2006), 






cost-effectiveness of losing weight has never been assessed in large groups of subfertile 
women with respect to increasing treatment success for weight-related subfertility, 
prevention of complications during pregnancy and improvement of perinatal outcome. 
Until this has been demonstrated we do not think it should be obligatory for overweight 
subfertile women to undergo a lifestyle intervention programme before starting fertility 
treatment but in counselling patients there should be attention for possible pregnancy 
complications with increasing BMI. It is clear that losing weight takes great effort and we 
feel that overweight should be considered a disease rather than an amenable condition. 
Second, apart from the unproven effectiveness of lifestyle interventions in overweight 
subfertile women, there is the question as to whether there should be upper limits for BMI 
above which couples should not be treated. Some authors have suggested limits for BMI for 
women undergoing fertility treatment, both with the arguments of patient safety concerns, 
as well as a lack of effectiveness of treatment of obese women (Gillett et al., 2006; 
Zachariah et al., 2006; Maheshwari et al., 2007). However, we feel that from the 
perspective of effectiveness of treatment, our data show that there is no reason to withhold 
treatment. Although effectiveness rates decrease with increasing BMI, the same appears 
true for women undergoing assisted reproduction over the age of 40, which is a well 
accepted practice in many countries. Age is however a predictable and amenable factor 
considering the fact that many couples delay conception to for example pursue career 
opportunities. In our opinion, studies on weight loss interventions should show a clear 
increase of effectiveness of fertility treatment and a clear decrease in pregnancy-related 
complications, before BMI thresholds can be implemented. In conclusion, in ovulatory and 
anovulatory subfertile women overweight and obesity is associated with a decrease in the 
number of pregnancies, a sharp increase in the number of complications with an additional 
rise of associated costs per pregnancy. There is not enough evidence however to prove that 
losing weight will improve the outcome of fertility treatment and decrease complications in 
pregnancies, and therefore strict BMI thresholds cannot be recommended yet. However, 
overweight and obese subfertile women should be counselled that overweight is a risk 
factor in pregnancy and is associated with several complications in both mothers and their 
children. 
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Context: Abdominal fat contributes to anovulation.  
Objective: We compared body-fat distribution measurements and their contribution to 
anovulation in obese ovulatory and anovulatory infertile women.  
Design: 17 ovulatory and 40 anovulatory women (age 30±4 years; body mass index (BMI) 
37.7±6.1 kg/m2) participated. Body-fat distribution was measured by anthropometrics, dual-
energy x-ray absorptiometry (DEXA) and single-sliced abdominal CT scan (ssCT). 
Multiple logistic regression analysis was applied to determine which fat compartments 
significantly contributed to anovulation.  
Results: Anovulatory women had a higher waist circumference (113±11 vs 104±9 cm;     
P<0.01), significantly more trunk fat (23.0±5.3 vs 19.1±4.2 kg; P<0.01) and abdominal fat 
(4.4±1.3 kg vs 3.5±0.9 kg; P<0.05) on DEXA scan than ovulatory women in spite of 
similar BMI. The volume intra-abdominal fat (IAF) on ssCT was not significantly different 
between the two groups (203±56 vs 195±71 cm3; P=0.65), but anovulatory women had 
significantly more subcutaneous abdominal fat (SAF) (992±198 vs 864±146 cm3; P<0.05). 
After multiple logistic regression analysis, only trunk fat, abdominal fat and SAF were 
associated with anovulation.  
Conclusions: Abdominal fat is increased in anovulatory women due to a significant 
increase in SAF and not in IAF. SAF and especially abdominal and trunk fat accumulation 





The prevalence of obesity in women of child-bearing age ranges from 3% in Africa to 
almost 25% in Northern America (Haslam and James, 2005) and is expected to increase 
further. Overweight (BMI 25‒29.9 kg/m2) and obesity (BMI≥30 kg/m2) in women have 
deleterious effects on ovulation frequency with an exponential increase in anovulation with 
increased body weight (Green et al., 1988; Grodstein et al., 1994).   
Independent of body weight, body-fat distribution, expressed by waist/hip ratio (WHR), has 
also been shown to influence the reproductive potential. Conception rates, both in 
spontaneous cycles and in assisted reproduction cycles, decline with accumulation of fat 
around the waist and trunk, called upper-body obesity (WHR >0.8 in women), independent 
of body weight (Zaadstra et al., 1993; Wass et al., 1997). The differential role and 
contribution of intra-abdominal fat (IAF) and subcutaneous abdominal fat (SAF) 
compartments to anovulation are not clear. Increased IAF is associated with insulin 
resistance and the resulting hyperinsulinaemia contributes to anovulation by increased 
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ovarian androgen secretion (Poretsky, 1991; Dunaif, 1997) leading to lower sex hormone 
binding globulin (SHBG) concentrations (Pasquali et al., 1994; Pasquali et al., 2003) and 
consequently higher free androgen levels. Insulin directly influences intra-ovarian 
steroidogenesis which may lead to arrest of follicle growth, as has been shown in women 
with polycystic ovary syndrome (PCOS) (Franks et al., 1996; Willis et al., 1996). 
Increased androgens in turn contribute to upper-body obesity (Escobar-Morreale and San 
Millan, 2007), thus a vicious circle evolves where androgens favour abdominal fat 
accumulation and upper-body obesity which in turn facilitates insulin resistance and 
androgen production (Garg, 2004; Escobar-Morreale and San Millan, 2007). However, 
many women with upper-body obesity have ovulatory cycles and little or no insulin 
resistance. The differential role and contribution of the IAF and SAF compartments to 
insulin resistance and anovulation has not previously been investigated. 
There is an ongoing controversy on the relative contribution of the SAF and IAF to insulin 
resistance and the metabolic syndrome (Lebovitz and Banerji, 2005; Miles and Jensen, 
2005).  Some studies (Guo et al., 1999; Garg, 2004; Miles and Jensen, 2005) indicate that 
SAF contributes to insulin resistance while others (Lebovitz and Banerji, 2005; Weiss, 
2007) to the contrary report that IAF is associated with insulin resistance and the metabolic 
complications of obesity.  
 
Some studies have shown more trunk- and abdominal fat on DEXA scan in women with 
PCOS (Hoeger et al., 2004; Carmina et al., 2007). A study using abdominal ultra-
sonography to measure the IAF and SAF showed that non-obese women with PCOS have 
more IAF compared to a group of lean ovulatory women (Yildirim et al., 2003). Another 
study, using single-slice abdominal CT (ssCT) scan in obese women with PCOS, showed 
that IAF correlates stronger with insulin resistance than SAF (Lord et al., 2006).  A cross-
sectional study comparing 50 women with PCOS with 28 controls, showed that women 
with PCOS had significantly more SAF and gluteal subcutaneous fat. However, after 
adjusting for the differences in BMI and total fat mass, there were no significant differences 
in IAF and SAF between women with PCOS and controls (Barber et al., 2008). 
Considering the above-mentioned controversy, the question arises whether the IAF and 
SAF compartments are different in ovulatory and anovulatory infertile women with obesity, 
and which compartment, IAF or SAF, is associated with anovulation.  
The aim of this study was to assess the contribution of different body-fat distribution 










SUBJECTS AND METHODS  
 
Study subjects 
The study was carried out between 2005 and 2008 at the Fertility clinic of the University 
Medical Center Groningen (UMCG). All infertile women with a BMI>29 kg/m2  who met 
the following inclusion criteria (infertility >1 year, age <38 years, partner with total 
concentration motile sperm/ejaculate >10 million) were approached to participate in a 
lifestyle intervention programme (Women of Weight with Infertility) in order to achieve 
weight loss. Of the 60 eligible women that agreed to participate, two did not undergo the 
baseline assessment due to early drop-out and pregnancy. One anovulatory woman with a 
BMI of 58 kg/m2 was excluded from the analysis because the ssCT could not be performed 
accurately due to physical constraints. Except for one anovulatory woman with type 1 
diabetes mellitus, no other study subjects were known to have impaired glucose tolerance 
or type 2 diabetes mellitus. Except for the one subject with type 1 diabetes mellitus 
receiving insulin therapy, no other study subject received hormonal preparations or 
metformin in the 3 months preceding inclusion. All women were caucasian, except for one 
women of asian origin. 
 
Ovulatory status of study subjects was defined as follows:  
• women with amenorrhea (cycle interval ≥6 months) were considered anovulatory. 
• women with regular cycles ≤42 days underwent an ultrasound monitoring of the 
menstrual cycle and women were considered ovulatory because follicle development 
was seen and ovulation was confirmed by a well-timed midluteal progesterone rise >15 
nmol/l.  
• women with cycles ≤42 days where ovulation could not be identified during ultrasound 
monitoring as well as women with menstrual cycles between 42 days and 6 months 
kept a basal body-temperature chart. A midluteal progesterone rise of >15 nmol/l 1 
week after a maintained temperature rise was considered indicative of ovulation.  
 
Hyperprolactinaemia, abnormal thyroid function, non-classical 21-hydroxylase deficiency 
and androgen secreting tumours were excluded in all anovulatory patients. 
In all study subjects, the Rotterdam consensus diagnostic criteria for PCOS were 
considered and subjects were diagnosed as PCOS if two of the following criteria were 
present: anovulation, hyperandrogenaemia (clinically or biochemically) or polycystic ovary 
morphology on ultrasound after the exclusion of other endocrine causes of anovulation 
(Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004). 
Hirsutism was used a clinical marker of hyperandrogenaemia, and a serum testosterone 
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level >3.5 nmol/l and a free testosterone level >62 pmol/l was considered as biochemical 
hyperandrogenaemia.  
Informed written consent was obtained from all women, and the study was approved by the 
Medical Ethical Committee of the UMCG. 
 
Anthropometric assessment  
The following anthropometric measurements were determined at intake: body weight (kg), 
height (cm), BMI (= weight (kg) divided by height in meters2), waist circumference (Wc = 
waist measured at the narrowest part of the torso located between the lower rib and the iliac 
crest) and WHR. The WHR was calculated by dividing Wc by hip circumference 
(measured at the level of the greatest gluteal protuberance in a horizontal plane parallel to 
the floor). All measurements were carried out by the same observer.  
A whole body scan was performed by dual-energy x-ray absorptiometry (DEXA), using a 
Hologic A Discovery Bone Densitometer (Hologic Inc., Bedford, MA, USA). Total fat 
mass and total fat percentage was determined for the whole body and two regions (trunk 
and abdominal slice) were specified by computer programming and measured as mentioned 
in previous studies (Carmina et al., 2007).  
All participants, positioned supine, underwent a ssCT at the level of the umbilicus 
(corresponding well with lumbar vertebrae 4-5) at 120-kV exposure. Initially the Siemens 
Somatom Sensation 16 was used with a total slice thickness of 18 mm (4 subslices x 0.45 
cm). During the study a more advanced CT-scan, the Siemens Somatom Sensation 64 was 
used with a slice thickness of 18 mm (3 subslices x 0.6 cm). Syngo Volume (Siemens, 
Berlin, Germany) was the software used for both apparatus. To assess the total abdominal 
fat (TAF) area, each subslice was edited by delineating the total slice with a graph pen, then 
the adipose tissue volume was computed with an attenuation range of -150 to -50 
Hounsfield units. The area for measuring IAF was delineated by drawing a line within de 
muscle wall surrounding the abdominal cavity en letting the computer program calculate 
the adipose tissue within this area. SAF area was calculated by subtracting IAF from TAF. 
These measurements were performed by a single observer. By multiplying the IAF and 
SAF area (cm2) with each sub-slice (cm) of the ssCT, the IAF and SAF volume (cm3) was 
calculated and the mean of the subslices recorded for analysis. The edited data were 
archived in Rogan. 
 
Biochemical assessment 
All blood samples were taken at intake after an overnight fast of 10 hours. Serum total 
testosterone was measured by radioimmunoassay, using [1,2,6,7-3H]testosterone as tracer 
(Amersham Biosciences, Buckinghamshire, UK) and antiserum developed by Pratt (Pratt et 






(Amersham, Buckinghamshire, UK) and [1H]dihydrotestosterone (Sigma-Aldrich, St. 
Louis, MO, USA). The coefficients of intra-assay variations were 4.9‒7.1% for total 
testosterone and 8.8‒10% for SHBG. The interassay variation was 14‒19% for total 
testosterone and 14‒17% for SHBG. Reference values for women were 0‒3.5 nmol/l for 
total testosterone and 20−100 nmol/l for SHBG. 
Free testosterone was calculated with the formula according to Vermeulen (Vermeulen et 
al., 1999). In the UMCG, the normal range for free testosterone has been estimated at 9–62 
pmol/l and values >62 pmol/l are defined as hyperandrogenaemia. For insulin measurement 
a DSL-1600 Insulin Radioimmunoassay (Diagnostic Systems Laboratories, Inc., Webster, 
TX, USA) was used. Radio-activity was measured by a gamma-counter. Fasting glucose 
was determined with a clinical chemistry analyzer. Homeostasis model assessment score 
for insulin resistance (HOMA-IR), was calculated as [fasting serum insulin (mU/l) x fasting 
plasma glucose (mmol/l)] / 22.5 by using the digital HOMA calculator which corrects for 
insulin measurement techniques (Manley et al., 2008; Muniyappa et al., 2008).  
 
Statistical analysis 
For comparison between groups, subjects were stratified by ovulatory status into an 
anovulatory and ovulatory group. Inter-group comparisons were made by using a unpaired 
Student’s t-tests for normally distributed continuous variables or a Mann-Whitney U-test 
when the distribution was skewed. Normal distribution was tested using the Kolmogorov-
Smirnov test. Multiple logistic regression analyses were /used to determine the contribution 
of various variables to anovulation after correction for BMI, testosterone and fasting 
insulin. The goodness of fit of the multiple logistic regression analyses was presented as the 
Nagelkerke R-square and P-value of the model Chi-square test. All results were considered 





Clinical characteristics of study subjects 
The clinical characteristics of the anovulatory (n=40) and ovulatory women (n=17) are 
shown in Table 1. The women ranged in age from 20‒38 years. The BMI ranged from 
29.2–7.4 kg/m2 in the anovulatory women and 29.4‒46.3 kg/m2 in the ovulatory women. In 
14 of the 17 ovulatory patients, PCOS could be excluded. Three ovulatory patients had a 
free testosterone level >62 pmol/l; however, due to morbid obesity, the ovaries could not be 
visualised by transvaginal ultrasonography to exclude polycystic ovary morphology. 
In 33 of the 40 anovulatory women PCOS could be diagnosed and in 3 women PCOS could 
be excluded. In 4 anovulatory women without clinical or biochemical hyperandrogenaemia, 
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PCOS could not be excluded, because the ovaries could not be visualised by transvaginal 
ultrasonography due to morbid obesity. 
In spite of a non-significant difference in BMI, age and total fat mass on DEXA scan, 
anovulatory obese women had a significantly higher Wc, WHR, abdominal and trunk fat on 
DEXA scan and SAF on ssCT compared to the ovulatory obese women. The IAF on ssCT 
was not significantly different between anovulatory and ovulatory obese women. 
Fasting insulin was significantly increased in anovulatory women but the HOMA-IR was 
not significantly different. Free testosterone was significantly higher in the anovulatory 






Table 1. Clinical characteristics comparing anovulatory to ovulatory obese women with infertility 
 
a Data expressed as mean±SD; or as median, range. 
b Significant at level P≤0.05. 
c  Significant at level P≤0.01. 
Parameter Anovulatory 
(n = 40) 
Ovulatory 
(n = 17) 
P value 
Age (years)  29.1±4.3  31.1±4.1 0.09 
BMI (kg/m2)  37.6±4.8  35.6±4.9 0.15 
Waist circumference (cm)   113±11   104±9 0.007 c 
Waist/hip ratio    0.9±0.1    0.8±0.1 0.02 b 
    
Total fat DEXA (kg)  46.0±10.4  42.0±10.0 0.19 
Total % fat DEXA   41.3±4.6  39.9±4.7 0.29 
Trunk fat DEXA (kg)  23.0±5.3  19.1±4.2 0.009 c 
Abdomen fat DEXA (kg)    4.4±1.3    3.5±0.9 0.02 b 
    
TAF ssCT (cm3) 1199±213 1059±187 0.02 b 
IAF ssCT (cm3)   203±56   195±71 0.65 
SAF ssCT (cm3)   992±198   864±146 0.02 b 
    
Testosterone (pmol/l) a   3.9 (1.6‒6.5)     3.1 (1.6‒5.4) 0.09 
SHBG (nmol/l) a 23 (8–43)   32 (9–93) 0.02 b 
Free testosterone (pmol/l) a 87 (28–217)   46 (25–131) 0.009 c 
    
Fasting glucose (nmol/l)    4.9±1.2     5.1±0.6 0.52 
Fasting insulin (pmol/l) a 175.8 (25.8–602.7) 120.1 (43.8–222.4) 0.046 b 






Table 2. Results of multivariate logistic regression analyses of contribution to anovulatory status by 
different fat measurements in obese women with infertility 
 
Fat measurements OR a 95% CI R-square/P b    P c 
Wc (cm) 0.90 0.79 – 1.03 0.34 / 0.014 0.12 
IAF ssCT/100 (cm3) 1.89 0.46 – 7.68 0.33 / 0.012 0.38 
SAF ssCT/100 (cm3) 0.56 0.31 – 1.03 0.39 / 0.003 0.06 
Total body-fat DEXA (kg) 0.94 0.81 – 1.09 0.32 / 0.017 0.40 
Abdominal fat DEXA (kg) 0.21 0.05 – 0.78 0.46 / 0.001 0.01 
Trunk fat DEXA (kg) 0.73 0.54 – 0.99 0.42 / 0.002 0.04 
 
a After correction for BMI, fasting insulin and testosterone. 
b Nagelkerke R-square and P value of model Chi-square test. 






Contributors of anovulatory status  
To find contributors to the anovulatory status, we performed multivariate logistic regression 
analysis correcting for BMI, testosterone and fasting insulin (Table 2). Abdominal slice fat 
and trunk fat on DEXA scan were significant contributors to anovulation, while the 
contribution of SAF on ssCT to anovulation was of borderline significance (OR 0.56, 95% 
CI 0.31‒1.03, P=0.06). The Nagelkerke R-square on these analyses ranged from 0.33 to 
0.4, indicating a reasonable goodness of fit for the prediction of anovulation. The IAF on 
ssCT, showed no contribution to anovulatory status. Wc as a clinical tool did not 





This study indicates that the SAF and not the IAF compartment is significantly increased in 
anovulatory women with obesity and infertility compared to ovulatory counterparts with 
similar BMI. Fat accumulation around the trunk and abdomen and the SAF are associated 
with anovulation, while the IAF compartment is not associated with anovulation.  
Previous studies comparing fat distribution in women with PCOS with ovulatory controls 
also showed more trunk and abdominal fat on DEXA scan in PCOS women even in cases 
with normal BMI (Puder et al., 2005). One study differentiating SAF from the IAF using 
abdominal ultrasound indicated that women of normal weight with PCOS have more IAF 
than normal-weight women with regular menstrual cycles (Yildirim et al., 2003). After 
adjusting for the differences in BMI and total fat mass in a study comparing 50 women with 
PCOS with 28 controls, no significant differences in IAF and SAF were found between the 
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two groups (Barber et al., 2008). Using ssCT in obese women with infertility, our study 
showed that the IAF is not different between anovulatory and ovulatory women of similar 
BMI. Considering the difference in mean BMI (36.5 vs <25.0 kg/m2 and 36.5 vs 28.3 
kg/m2) between the study populations of the two mentioned studies (Yildirim et al., 2003; 
Barber et al., 2008) and the findings of the present study, a possible explanation for the 
discrepancy in the findings could be the critical intra-abdominal fat threshold hypothesis. 
According to this hypothesis, with increase in body weight the intra-abdominal fat 
compartment reaches a point of saturation after which fat is shunted to the subcutaneous fat 
compartments (Freedland, 2004). This hypothesis could therefore account for increased 
SAF with increasing BMI. The ratio of the volume of IAF and SAF on ssCT in the present 
study population was however unchanged across different BMI ranges. On the other hand, 
the discrepancy of the findings of the present study and previous studies, can also be 
attributed to the hypothesis of dysregulated upper-body subcutaneous fat (Danforth, 2000; 
Jensen, 2008). Dysregulated adipocytes of upper-body subcutaneous fat are resistant to the 
antilipolytical effects of insulin, resulting in the shunting of post-prandial FFAs to the liver 
and skeletal muscles. This might be mediated by inflammatory changes, increase in 
adipocyte size and decreased adiponectine synthesis by the subcutaneous fat (Koska et al., 
2008). Fat storage in the liver and skeletal muscles furthermore contributes to insulin 
resistance (Guo et al., 1999). 
Insulin resistance and hyperandrogenaemia are pivotal mechanisms through which obesity 
and fat distribution leads to anovulation (Dunaif, 1997; Pasquali et al., 2003). The finding 
of significantly higher free testosterone and insulin levels in anovulatory women in the 
present study supports the findings of previous studies. In the present study, in spite of 
significantly higher fasting insulin levels, increased insulin resistance in anovulatory 
women expressed by the HOMA-IR did not reach statistical significance possibly due a 
small sample size. 
 
The present study supports an association of accumulation of subcutaneous fat around the 
abdomen and trunk with anovulation and insulin resistance. Increased free fatty acid (FFA) 
delivery to skeletal muscles seems to be the main mediator of insulin resistance (Boden, 
2008). Studies assessing the FFA from different fat compartments show that the 
subcutaneous fat of the abdomen and trunk (upper body) contribute almost 75% of the total 
FFAs to the systemic circulation (Guo et al., 1999). A simple explanation for the SAF to be 
the primary cause of insulin resistance is that it is on average 5 times greater in volume than 
the IAF which only contributes approximately 15% of the total systemic FFAs.  
The finding of the present study does however not necessarily exclude functional 
mechanisms of IAF contributing to anovulation. In spite of a much smaller volume of IAF 






using multivariate analysis, various studies showed a significant correlation of the IAF with 
insulin resistance and the metabolic complications of obesity (Lebovitz and Banerji, 2005). 
IAF has higher lipolytical activity per unit fat mass and direct drainage into the portal vein 
results in increased delivery of FFAs to the liver (Garg, 2004).  
The differential secretion of adipokines and cytokines by the IAF and SAF compartments 
might also play a contributory role in obesity-related infertility and anovulation. In view of 
a significantly greater amount of SAF, a different obesity-related mechanism contributing 
to anovulation could also be considered. Leptin, an adipokine mainly produced by SAF, 
induces anovulation by direct ovarian effects in animal models (Duggal et al., 2000). IAF 
and SAF compartments are interlinked and changes in the one compartment lead to 
adaptations in the other (Weiss, 2007). The IAF may contribute more to the pro-
inflammatory component of the metabolic syndrome by the secretion of adipokines and 
cytokines with a different profile compared to subcutaneous fat (ntuna-Puente et al., 2008). 
In women with PCOS and a mean BMI of 35 kg/m2, the IAF showed a stronger correlation 
with metabolic dysfunction than the SAF (Lord et al., 2006). The contributory role of the 
pro-inflammatory IAF and the voluminous SAF on infertility and anovulation needs further 
elucidation. The finding of this study only shows an association of the volumes of IAF and 
SAF with anovulation and no conclusions can be drawn on a cause and effect relationship.  
A limitation of this study was the small sample size. Larger studies are needed to confirm 
our data in obese infertile ovulatory and anovulatory women with respect to body-fat 
distribution and the role of these different fat compartments in insulin resistance and 
anovulation. This study was limited to obese women, and cannot be extrapolated to women 
of normal weight.  In 7 of the 57 study subjects PCOS could not be diagnosed or excluded 
because the ovaries could not be visualised by transvaginal ultrasonography, therefore 
limiting the comparison of the findings with previous studies on women with PCOS. 
Excluding the one anovulatory women with type 1 diabetes mellitus would not have 
changed the outcome of the analysis. Because 56 of the 57 study subjects were from 
caucasian origin, the presented data cannot be extrapolated to non-caucasian populations. 
 
In conclusion, in anovulatory women with obesity and infertility, the total amount of 
abdominal and trunk fat is significantly increased, with an significant increase in the 
volume of SAF and no difference in the volume of IAF compared to ovulatory women with 
obesity and infertility. Abdominal and trunk fat accumulation and SAF accumulation but 
not the IAF are associated with anovulation. This association is however only based on the 
volume of these fat compartments and does not necessarily reflect the consequences of their 
metabolic activity.  
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The aim of the study was to investigate the correlation between the measurements of intra-
abdominal fat (IAF) and subcutaneous abdominal fat (SAF) by abdominal ultrasound (US) 
and Computerised Tomography (CT) in women with obesity and infertility. In 53 
participants undergoing a lifestyle programme, the Pearson’s correlation coefficients were 
calculated of the measurements of IAF and SAF by CT and US at fixed time points 
(baseline, month 3 and month 6) and of the changes of IAF and SAF. A method comparison 
analysis was performed for the IAF measurements. The correlation between the IAF 
measurement by US and CT was good at all time points (all r>0.71). The correlation 
between the SAF measurement by US and CT was reasonable at baseline (r=0.54) and poor 
at month 3 and month 6 (all r≤0.39). The correlation between the measurement of the 
changes of IAF by US and CT was only significant between baseline and month 6 (all 
r>0.48). The correlation of the measurement of the changes of SAF between US and CT 
was poor (all r<0.23). The method comparison analyses for the IAF measurements showed 
good agreement. In conclusion, in women with obesity and infertility, the measurement of 
IAF by US correlates strongly with the measurement of IAF by CT scan. US can measure 
the changes of IAF over time only with when sufficient loss of IAF has occurred. The 






Increased accumulation of fat around the abdomen, called abdominal obesity, contributes 
strongly to the metabolic consequences of obesity on health and it plays a role in female 
infertility and pregnancy complications (Despres et al., 2001; McCarthy et al., 2004; 
Haslam and James 2005; Nelson and Fleming, 2007; Brisson et al., 2010;). Waist 
circumference (Wc) measurement is used to identify individuals with abdominal obesity 
(Janssen et al., 2002; Zhang et al., 2008); however, it cannot differentiate between intra-
abdominal fat (IAF) and subcutaneous abdominal fat (SAF) accumulation (Despres, 2006; 
Jensen, 2008; Weiss, 2007). The reliable measurement of IAF and SAF is not only 
important as a tool to predict cardiovascular and metabolic disease risk, but it is also 
essential to evaluate the effect of these fat compartments on female reproductive function. 
IAF accumulation is related to insulin resistance in women with Polycystic Ovary 
Syndrome (PCOS) (Lord et al., 2006) and in these women the resulting hyperinsulinaemia 
contributes to anovulation (Pasquali et al., 2006). Obese anovulatory women with PCOS 
who resume ovulation during a 6-month lifestyle programme lose more IAF with no 
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difference in the change of SAF compared to the women who did not resume ovulation 
(Kuchenbecker et al., 2011). On the other hand, in women with obesity and infertility, SAF 
and not IAF was associated with anovulation after correcting for BMI, insulin and 
testosterone (Kuchenbecker et al., 2010). Increased IAF during early pregnancy is 
associated with insulin resistance and increased diastolic blood pressure (Bartha et al., 
2007) and it can predict glucose intolerance in later pregnancy (Martin et al., 2009).  
Considering the worldwide obesity epidemic and its consequence on female reproduction, 
more studies are needed on the influence of the changes of IAF and SAF on female 
reproduction. Abdominal ultrasound (US) might be a good tool for the measurement of IAF 
and SAF due to the absence of radiation exposure, low cost and its general availability in 
fertility and antenatal clinics.  
Several studies in various populations have confirmed that US is a reliable tool for the 
measurement of IAF and SAF when compared to the gold standard of Abdominal 
Computerised Tomography scan (CT) or Magnetic Resonance Imaging (MRI) (Armellini et 
al., 1993; Stolk et al., 2001; De Lucia Rolfe et al., 2010; Gradmark et al., 2010). However, 
these validation studies were mostly conducted in older populations and have not been 
performed in women of reproductive age before. It is relevant to do so, since body 
composition and abdominal fat distribution change with age, potentially affecting the 
reliability of the US measurement technique. Furthermore, only one study tried to validate 
the measurement of the changes of IAF and SAF between US and CT in study subjects 
undergoing weight loss (Armellini et al., 1991). Before introducing US as a tool for 
studying the effect of the changes of IAF and SAF on the reproductive outcome in women 
undergoing lifestyle intervention, validation of the US technique by comparing CT and US 
measurement is required in obese women of reproductive age. 
 
The first aim of this methodological study was to investigate the correlation and agreement 
of the measurement of IAF and SAF between US and CT in women with obesity and 
infertility at fixed time points (baseline, month 3 and month 6) of a lifestyle programme to 
achieve weight loss. The second aim of the study was to evaluate the correlation of the 
measurement of the changes of IAF and SAF between US and CT between baseline and 







METHODS AND PROCEDURES 
 
Subjects 
Participants were women with obesity and infertility attending the Fertility clinic of the 
University Medical Center Groningen (UMCG) between 2005 and 2008. All women with a 
BMI >29 kg/m2 who met the inclusion criteria (infertility >1 year, age <38 years, partner 
with total motile sperm concentration/ejaculate ≥10 million) were approached to participate 
in a lifestyle programme. Informed written consent was obtained and the study was 
approved by the Medical Ethics Committee of the UMCG. The lifestyle programme 
comprised dietary intervention, increased physical activity and behaviour modification as 
described before (National Heart, Lung and Blood Institute/National Institutes of Diabetes 
and Digestive and Kidney diseases, 1998; Kuchenbecker et al., 2011).  
 
Anthropometric measurements and US and CT measurements of IAF and SAF were 
performed at baseline, at month 3 and month 6 of the lifestyle programme. At these three 
respective time points all measurements of each patient were performed on the same day. 
Pregnancy was excluded before each CT. For this analysis, 53 participants for whom both 
the US and CT data were available were selected from the total cohort of 57 women 
undergoing the lifestyle programme as published previously in (Kuchenbecker et al., 2010).  
 
Anthropometric measurements 
Body weight (up to nearest 0.1 kg) and height (up to nearest 1 cm) were measured using a 
calibrated scale and stadiometer (SECA model 764, Seca, Birmingham, UK) with 
participants wearing light indoor clothes and no shoes. BMI was calculated as weight in kg 
divided by height in square meters (m2). Waist circumference (Wc) was measured (up to 
the nearest 0.5 cm) at the narrowest part of the torso located between the lower rib and the 
iliac crest using a CEFES®-CONTROL tape measure (HOECHTMASS Balzer GmBH, 
Sulzbach, Germany).  
Using a Harpenden Skinfold Caliper (Baty International, Burgess Hill,  West Sussex , UK), 
four skinfold thickness (SFT) measurements were performed in duplicate on the right side 
of the body with all subjects in a standing position. The SFT measurements were performed 
according to the Anthropometric Standardization Reference Manual (Lohman and Roche, 
1991) and included the triceps, biceps, subscapular and supra-iliac measurements and the 
total sum of the four skinfolds was calculated. 
 
Abdominal Ultrasound (US) 
US was performed using a ALOKA SSD-1000 (Aloka, Tokyo, Japan) ultrasound machine 
with a 3.5 MHz convex-array abdominal transducer to measure IAF and SAF. A validated 
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protocol was followed to perform the measurements (Stolk et al., 2001). In short, all 
measurements were performed at the level of the Wc.  To avoid distorting of the abdominal 
cavity, all measurements were taken at the end of a quiet expiration. IAF measurements 
were performed in the midline and the right and left longitudinal lines (10 cm to the left and 
right of the midline, respectively) in a longitudinal plane. IAF was measured as the distance 
in cm from the anterior boundary of the lumbar vertebra and the peritoneal boundary of the 
anterior abdominal wall. SAF was measured in the midline, in a transversal plane at the 
































Figure 1. Example of an ultrasound (US) showing the intra-abdominal fat (IAF) and the 



































The image was captured when the transducer just had contact with the skin to avoid 
compression of the subcutaneous adipose tissue. See Figure 1 for an illustration of the US 
measurements of IAF and SAF. All measurements were obtained by a single trained 
observer, blinded to the measurements by CT. The data are presented in cm (to the nearest 
0.1 cm) as SAF midline, IAF midline, IAF midline and right and IAF mean (mean of 
midline, right and left). The left measurement of IAF was often difficult to obtain due to 
reflection by gas in the descending colon. We therefore evaluated IAF by US with and 
without the measurement of the left longitudinal plane separately. The intra-observer 
variability was previously shown to be 1.8‒2.9% for IAF and 0.6‒3.0% for SAF (De Lucia 
Rolfe et al., 2010) 
 
Figure 2. Example of a CT scan showing the intra-abdominal fat (IAF) and the subcutaneous 
abdominal fat (SAF). The lines 1, 2 and 3 indicate the location of the distance measurement of IAF 









CT scan  
A single-sliced abdominal CT scan with a total slice thickness of 18 mm (consisting of 3‒4 
subslices) was performed at the level of the umbilicus (corresponding with lumbar 
vertebrae 4-5) and the measurement of the IAF and the SAF volume (cm3) was calculated 
as published previously by us (Kuchenbecker et al., 2010). For the method comparison 
analysis, IAF was measured on the most cranial subslice of  the CT scan as a distance in cm 
from the anterior boundary of the lumbar vertebra and the peritoneal boundary of the 
anterior abdominal wall in the midline and 10 cm to the left and right of the midline, 
respectively. The data are presented in cm (to the nearest 0.1 cm) as IAF midline, IAF 
midline and right and IAF mean (mean of midline, right and left). Distance measurement of 
the SAF was not possible due the distortion of SAF by the umbilicus in the midline of the 
CT scans. See Figure 2 for an illustration of the distance measurements of IAF.  Although 
distance measurement of IAF on the CT scan is inferior to volume measurement, the 
distance measurement was necessary for the Blant-Altman plot which requires similar units 
of measurement for both methods. All measurements were performed by a single observer 
blinded for the results of the US measurements. The edited data were archived in Rogan. 
 
Statistical analysis 
Data were expressed as mean±standard deviation. Pearson’s correlation coefficients were 
used for comparison of the methods. Cross-sectional comparisons were made at fixed time 
points (baseline, month 3 and month 6) of the lifestyle programme. For longitudinal 
comparison, the changes between baseline and month 3 and baseline and month 6 as well as 
the percentage of change were calculated. Method comparison analysis was performed by 
constructing Bland-Altman plots to evaluate the extent to which the IAF measurement by 
US and CT agreed. All analyses were performed using SPSS, versions 17 and 18 (SPSS 





The baseline data of the 53 included women (mean BMI 37.0±4.9 kg/m2) are presented in 
Table 1. At month 3 and month 6 of the lifestyle programme, 35 and 27 participants 
remained for analysis due to pregnancy and drop-out (11 pregnant and seven drop-outs at 
month 3; one pregnant and seven additional drop-outs at month 6). The 6-month lifestyle 









Table 1.   Measurements in women with obesity and infertility undergoing a lifestyle programme 
 
Method Baseline Month 3 Month 6 Month 3 Month 6 
 (n=53) (n=35) (n=27) (n=24) (n=24) 
    Completers data 
Age (years)   29.7±4.3    
BMI (kg/m2)   37.0±4.9   36.6±4.9   35.2±5.5 -1.1% -4.9% 
Body weight (kg) 106.2±15.5 106.7±14.5 102.9±16.2 -3.3% -6.0% 
Waist circumference (cm)    110±11    109±13    107±14 -0.9% -2.6% 
      
US n=53 n=33 n=24   
SAF (cm) midline     5.4±1.2     5.3±1.0     5.2±1.0   -0.6%   -1.6% 
IAF (cm) midline     7.4±2.0     7.1±1.9     6.4±1.9 -10.0% -14.7% 
IAF (cm) midline and right     7.9±2.0     7.6±1.9     6.9±1.8   - 9.9% - 12.6% 
IAF (cm) mean     7.8±1.9     7.7±2.0     6.9±1.9 - 10.1% - 13.0% 
      
CT n=53 n=35 n=27   
SAF CT scan (cm3)     956±198    929±158    896±208    -2.8%   -6.3% 
IAF CT scan (cm3)     202±62    197±56    182±69    -2.5%   -9.8% 
IAF midline (cm)        8.2±2.2     8.3±2.2     7.4±2.0    -0.3%   -9.2% 
IAF  midline and right (cm)        8.9±2.1     9.0±2.0     8.3±1.8    -0.2%   -8.6% 
IAF  mean (cm)        9.1±2.0     9.2±2.0     8.5±1.7    -0.2%   -6.1% 
      
SFT n=53 n=35 n=27   
Biceps (mm)    29.3±5.8   27.8±6.5   27.0±7.4    -5.7%   -6.9% 
Triceps (mm)      32.9±6.3   32.9±6.2   31.5±6.3    -0.6%   -1.1% 
Subscapular (mm)     38.9±5.4   37.2±7.0   34.2±9.1    -6.9% -13.9% 
Supra-iliacal (mm)    37.7±6.9   36.9±6.9   33.7±6.0    -4.7% -10.7% 
Sum of total (mm)  138.7±16.9 134.0±20.3 128.7±26.6    -6.2%   -9.8% 
 
Data are presented as mean±SD and % change from baseline; percentages presented are based on completers data. 
BMI, body mass index; CT, abdominal CT scan; IAF, intra-abdominal fat; SAF, subcutaneous abdominal fat; SFT, 





The mean loss of SAF measured by US between baseline and month 6 was small (mean      
-1.6%; range 23.7% to -28.1%) compared to the mean loss of SAF measured by CT (mean   
-6.3%; range 32.9% to -26.2%). Measurement of the loss of IAF by US between baseline 
and month 6 (mean -13.2%; range 15.3% to -36.5%) was in agreement with the volume 
measurement by CT (mean -9.8%; range 18.6% to -20.9%).  
Table 2 shows that the US measurements of IAF and SAF correlated well with the CT 
measurements of IAF (range r=0.739 to r=0.797) and SAF (r=0.538) at baseline. At month 
3 and month 6 the correlation between the US and CT measurement of SAF was poor 
(r=0.390 and r=0.328, respectively). The correlations between the measurement of IAF by 
US and CT remained strong (range r=0.716 to r=0.898) at 3 and 6 months. The median 
BMI of the total group (36.5 kg/m2) was chosen to select two BMI groups for a sub-
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analysis. The correlation of the IAF measurements between US and CT at baseline were 
comparable in participants with a BMI ≥36.5 kg/m2 (range r=0.659 to r=0.758) as compared 
to a BMI <36.5 kg/m2 (range r=0.738 to r=0.753). The correlation of the SAF measurement 
between US and CT was however less accurate (r=0.242) in participants with a BMI ≥ 36.5 
kg/m2 compared to those with a BMI <36.5 kg/m2 (r=0.590). The comparison of method 
analysis between the measurement of IAF by US and CT in distance at baseline showed a 
mean negative bias for IAF of -1.1 (95% limits of agreement: -3.9 to 1.6) (Figure 3). 
Changes in IAF and SAF were recorded between baseline and month 3, and baseline and 
month 6, using US and CT. The change in SAF over time measured by US did not correlate 
with the change measured by CT (Table 3). To exclude the possibility that loss of SAF was 
too little to measure the change of SAF accurately, skin-fold thickness (SFT) measurement 
was added. The sum of the SFT measurement showed comparable loss of SAF between 
SFT and CT (Table 1) and a significant correlation between the CT and SFT measurements 
of SAF at month 3 (r=0.347) and month 6 (r=0.432).   
The correlation between the changes of IAF measured by US and CT was poor between 
baseline and month 3 (range r=0.238 to r=0.298) and significant (range r=0.486 to r=0.580) 
between baseline and month 6 (Table 3). The comparison of method analysis between the 
measurement of the changes of IAF by US and CT in distance between baseline and month 





















Figure 3. Bland-Altman plot representing the mean intra-abdominal fat (IAF) thickness in cm by 
ultrasound (US) and CT scan (CT) on the x-axis and the difference between the IAF measurement 















































































































































































































Table 3.  Correlations of the measurements of changes in SAF and IAF during a lifestyle programme 
 
 Month 3 vs Baseline (n=33)  Month 6 vs Baseline (n=24) 
 r R2 P value  r R2 P value 
SAF by US in cm                                           SAF by CT cm3 
SAF midline 0.215 0.046 0.221  0.229 0.052 0.305 
 
Subcutaneous fat by SFT in mm                               SAF by CT cm3 
Biceps  0.274 0.075 0.106  0.256 0.066 0.197 
Triceps  0.030 0.000 0.860  0.531 0.282 0.004 
Subscapular 0.297 0.088 0.083  0.190 0.036 0.342 
Supra-iliacal 0.121 0.015 0.481  0.077 0.006 0.704 
Sum of total 0.347 0.12 0.041  0.432 0.187 0.024 
 
IAF by US in cm 
 
IAF by CT in cm3 
IAF  midline 0.298 0.089 0.087  0.486 0.216 0.022 
IAF  midline and right 0.238 0.057 0.231  0.538 0.177 0.012 
IAF  mean 0.240 0.057 0.187  0.580 0.252 0.007 
 
IAF by CT in cm 
 
IAF by CT in cm3 
IAF  midline 0.566 0.321 <0.001  0.509 0.259 0.008 
IAF  midline and right 0.587 0.345 <0.001  0.480 0.231 0.013 
IAF  mean 0.593 0.352 <0.001  0.493 0.243 0.010 
r, Pearson correlation coefficient; R2, adjusted R square; significant at level P<0.05. CT, abdominal CT scan; IAF, 





















Figure 4.  Bland-Altman plot representing the mean change intra-abdominal fat (IAF) thickness in 
cm between baseline and month 6 by ultrasound (US) and CT scan (CT) on the x-axis and the 




































Figure 5 summarises the most important correlations presented in the Tables 2 and 3. 
Figure 5B in particular, illustrates that the measurement of IAF by US correlated well with 
the measurement by CT. As shown in Figure 5C and D, the correlation of the changes over 
time measured by US and CT between baseline and month 6, were stronger for IAF than 






Figure 5. (A) Correlation between subcutaneous abdominal fat (SAF) by CT scan (CT) and 
ultrasound (US) at baseline of a lifestyle program. (B) Correlation between intra-abdominal fat 
(IAF) by CT and US at baseline of a lifestyle program. (C) Correlation between the changes in SAF 
measured by CT and US after 6 months. (D) Correlation between the changes in IAF measured by 
CT and US after 6 months. Negative numbers indicate a decrease. 
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The most important finding of the present study is that in women with obesity and 
infertility, the measurement of IAF by US is accurate and comparable to the measurement 
of IAF by CT. Considering the detrimental role of IAF accumulation on female 
reproductive function and pregnancy outcome, the measurement of IAF by US can be a 
valuable tool in reproductive research on IAF.  
The correlation found in our study between the measurement of IAF by US and CT at the 
three fixed time points of the lifestyle programme is comparable to the findings of previous 
validation studies in different patient populations and different BMI and age groups  
(Armellini et al., 1993; Stolk et al., 2001; De Lucia Rolfe et al., 2010; Gradmark et al., 
2010). In agreement with the previous validation studies, we have also shown that the 
correlation of the measurement of SAF by US and CT is weaker than the measurement of 
IAF by these two methods (all r≤0.54 versus all r>0.71). A sub-analysis in participants with 
different BMI levels (BMI ≥36.5 kg/m2 versus BMI <36.5 kg/m2) revealed that the findings 
remained unchanged for the measurement of IAF, but that the correlation of the 
measurement of SAF by US and CT was less accurate in the higher BMI group. 
The detection of changes in IAF over time by US compared to the CT measurements, were 
not as strong as the correlation of the measurements at the fixed time points. An important 
observation was that the detection of changes in IAF was poor at month 3 and significant at 
month 6 with 2.5% and 9.8% loss of IAF measured by CT, respectively. This suggests that 
the use of US for the measurement of the changes in IAF is only reliable when the change 
in IAF over time is large enough. The comparison of method analysis at baseline, showed a 
mean negative bias of -1.1 cm of the measurement of IAF by US compared to CT in 
distance (as a surrogate for the volume measurement) (Figure 3). The limits of agreement 
were wide and tend to increase with an increase in the distance of IAF. The comparison of 
method analysis of the measurement of the changes of IAF between baseline and month 6 
showed a good agreement between US and CT (Figure 4). Considering the wide range of 
the limits of agreement between the measurement of IAF by US and CT (Figures 3 and 4), 
the accuracy of US is not sufficient to be used for diagnostic purposes in individual 
patients, but may perform well in a cohort-based analysis or in an epidemiological setting 
to investigate the role of IAF in female reproduction. 
In contrast with the findings for IAF, the changes over time in SAF as detected by CT could 
not be reproduced by US. This could be explained by the fact that US only showed -1.6% 
loss of SAF compared to -6.1% loss of SAF measured by CT. A sub-analysis (data not 
presented) of 10 women who lost a mean of 12.7 kg of body weight, also showed that even 
with greater weight loss, US is not able to detect the changes in SAF reliably. This raises 






the present study, is suitable in obese women of reproductive age. Subcutaneous fat depots 
are heterogeneous and changes in one depot might not reflect changes in the other depots. 
Too little loss of SAF as one explanation for the poor performance of US for the 
measurement of SAF is unlikely, because the sum of SFT measurements also showed 
comparable loss of subcutaneous fat as measured by CT. We recommend that future studies 
should investigate whether measurement of SAF by US at multiple locations improves the 
accuracy of the measurement of the changes of SAF. 
Our study confirms the findings of the only previous validation study showing that US can 
measure changes in IAF but not in SAF compared to CT (Armellini et al., 1991). In this 
study subjects lost on average 1.9 cm of IAF on US compared to 1 cm (over 6 months) of 
IAF on US in our study. The changes in IAF in this study was measured by CT as change in 
surface (cm2) compared to change in volume (cm3) as measured in our study. Therefore, the 
changes in IAF and SAF on CT cannot be compared between these two studies. 
The following limitations of this study should be considered. IAF and SAF distribution 
were captured by a single-sliced abdominal CT scan at the level of L4-L5, whilst the 
outcome depends on the individual variation of IAF and SAF distribution which can be 
measured more accurately by whole abdominal CT or MRI scan (Lee et al., 2004, Thomas 
and Bell 2003). Future validation studies should therefore use multiple slices of abdominal 
CT or MRI to calculate the volume of IAF and SAF. A study published after the present 
study was launched (Kuk et al., 2010), indicates that in women the measurement of IAF by 
single-sliced CT scan at the level of L2-L3 shows better correlation with whole abdomen 
CT scan (r=0.95) than single-sliced CT scan at the level of L4-L5 (r=0.89).  
It was noted that the left IAF measurement by US was often disturbed and difficult to 
perform due to gas in the descending colon.  This study shows that the left measurement of 
IAF can be omitted, because the medial, and the mean of the medial and right measurements 
of IAF still show good correlation with the CT measurement (Tables 2 and 3).   
In conclusion, in women with obesity and infertility, there is a strong correlation between 
the measurements of IAF by US and CT. Furthermore, US can only measure the changes of 
IAF over time if sufficient loss of IAF has occurred. Considering the safety and general 
availability of abdominal US machines at fertility clinics and antenatal clinics, the use of 
US is an affordable tool for further research on the role of IAF on female reproductive 
function. Measurement of SAF by US proved not to be reliable enough for implementation 
in its present form and further studies are required to investigate whether measurement of 
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Objective: Body-fat distribution and the adipose tissue function and morphology is 
different in anovulatory obese women with polycystic ovary syndrome (PCOS) compared 
to ovulatory non-PCOS controls. The aim of this study was to assess whether PCOS status 
(i.e., defined as anovulation and polycystic ovaries on ultrasound and/or hyper-
androgenaemia) is a determining factor in the association between body-fat distribution 
parameters and serum adipokine levels in women with obesity and infertility. 
Design: Prospective cohort study 
Methods: The differences in body mass index (BMI), waist circumference, total-, trunk- 
and abdominal fat on DEXA scan and intra-abdominal fat (IAF) and subcutaneous fat 
(SAF) on single-sliced CT scan and serum adipokine levels (leptin, adiponectin, 
interleukin-6 and tumour necrosis factor α) were assessed in 32 women with anovulatory 
PCOS and 15 ovulatory non-PCOS controls (mean BMI of total group  36.8±4.9 kg/m2). 
The correlation between body-fat distribution parameters and serum adipokine levels was 
assessed followed by linear regression analysis correcting for PCOS status, BMI and age. 
Liver-fat accumulation was assessed by abdominal ultrasound. 
Results: Women with anovulatory PCOS had significantly more abdominal obesity (waist 
circumference, trunk fat – and abdominal fat on DEXA scan) and significantly more SAF. 
Abdominal ultrasound revealed a trend of more moderate to severe liver-fat accumulation 
in anovulatory PCOS women compared to ovulatory non-PCOS controls. Leptin showed a 
significant positive correlation with SAF, trunk, abdominal fat and total fat on DEXA scan 
and interleukin-6 showed a significant positive correlation with total fat on DEXA scan. 
Linear regression analysis of the adipokines with body-fat distribution parameters revealed 
that PCOS status had no association between the adipokines and body-fat distribution 
parameters.  
Conclusion: PCOS status (i.e., defined as anovulation and polycystic ovaries on ultrasound 
and/or hyperandrogenaemia) is a not a determining factor in the association between body-






Polycystic ovary syndrome (PCOS) affects 5‒10% of women of reproductive age and is the 
most common cause of anovulation. PCOS is associated with a different body-fat 
distribution and the adipose tissue function and morphology may also be different 
compared to ovulatory controls (Norman et al., 2007). PCOS is defined by two of the 
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following three criteria: anovulation, polycystic ovary morphology on ultrasound and 
clinical or biochemical hyperandrogenaemia (Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2004). Overweight/obesity and abdominal obesity 
independently contribute to anovulation in women with PCOS by contributing to insulin 
resistance (IR), which is considered to play a pivotal role in the pathogenesis of PCOS and 
anovulation (Pasquali et al., 2006; Carmina et al., 2007). Abdominal fat can be divided into 
subcutaneous abdominal fat (SAF) and intra-abdominal fat (IAF). IAF is considered a 
marker of IR in women with PCOS (Lord et al., 2006; Cascella et al., 2008) and IAF is 
associated with IR in premenopausal women even after correcting for SAF (Ross et al., 
2002). The results of studies assessing the differences between IAF and SAF between 
women with PCOS and ovulatory controls are inconsistent (Yildirim et al., 2003; Barber et 
al., 2008a; Dolfing et al., 2011; Manneras-Holm et al., 2011) and may be related to the 
difference in BMI of the study populations. The predictive value of IAF on the risk of IR 
seems to decrease with increasing BMI as a result of the so-called ‘critical intra-abdominal 
fat threshold’ hypothesis (Freedland, 2004). It is postulated that, with increase in body 
weight, IAF reaches a point of saturation after which fat is shunted to SAF. When the 
ability of SAF to store excess fat is exhausted, fat is shunted as free fatty acids (FFA) to 
ectopic sites like the liver, skeletal muscles and pancreas (Weiss, 2007; Koska et al., 2008; 
Stefan et al., 2008; Arsenault et al., 2011). This accumulation of fat in ectopic sites is 
strongly associated with IR (Weiss, 2007; Stefan et al., 2008). The above-mentioned 
findings support the notion that with increasing BMI, the measurement of the volumes of 
IAF and SAF can no longer be used to predict IR due to fat redistribution and accumulation 
of fat in ectopic sites.  
Adipose tissue is not only a site of lipid storage, but a complex endocrine organ expressing 
and secreting many bioactive peptides, collectively called adipokines. Previous studies 
suggest that the morphology and function of adipose tissue in PCOS women differs from 
that of ovulatory controls. In women with PCOS, subcutaneous adipose tissue is 
characterised by enlarged adipocytes and low-grade inflammation (increased macrophage 
density), although the latter is not supported by all studies (Escobar-Morreale et al., 2011; 
Lindholm et al., 2011; Manneras-Holm et al., 2011).  In women with PCOS, fat cells of 
IAF and SAF have different lipolytical activity compared to ovulatory controls (Ek et al., 
2002; Faulds et al., 2003). The hyperlipolytic state of the IAF contributes to drainage of 
FFA, glycerol and adipokines to the liver contributing to IR.  
Adipokines, like leptin, adiponectin, interleukin-6 (IL-6) and tumour necrosis factor α 
(TNFα) act in an autocrine and paracrine fashion on adipose tissue and in an endocrine 
manner on distant tissues and organs and they may influence female reproduction by an 
effect on the hypothalamus, the ovary and the endometrium (Mitchell et al., 2005; Robker 







It can be hypothesised that the difference in the body-fat distribution in combination with 
differences in the morphology and function of the adipose tissue in women with PCOS 
compared to ovulatory controls could lead to a difference in the secretion of adipokines 
(Bohler et al., 2010). However, leptin levels in obese women with PCOS do not differ 
significantly from those of age- and weight-matched ovulatory controls (Remsberg et al., 
2002; Sepilian et al., 2006; Carmina et al., 2009,).  The positive correlation between BMI 
and leptin is similar in PCOS and ovulatory controls (Brzechffa et al., 1996). According to 
a meta-analysis there are no significant differences in the serum levels of IL-6 and TNFα 
between PCOS and ovulatory controls even after excluding BMI mismatched studies 
(Escobar-Morreale et al., 2011).  Initial studies did not consistently show that serum levels 
of adiponectin are decreased in women with PCOS but a meta-analysis and more recent 
studies have shown that after controlling for BMI-related effects, adiponectin levels are 
lower in women with PCOS compared to ovulatory controls (O'Connor et al., 2010; Toulis 
et al., 2009 Manneras-Holm et al., 2011). The discrepancy of the findings of previous 
studies could be explained by the fact that initial studies did not correct for differences in 
BMI and did not measure the high molecular weight (HMW) adiponectin, which is 
specifically reduced in women with PCOS (O'Connor et al., 2010; Wickham et al., 2011).  
In a study comparing 48 women with PCOS (BMI 27.1±5.6 kg/m2) to 20 BMI (BMI 
26.8±3.9 kg/m2) matched ovulatory controls, PCOS women had significantly more 
abdominal fat on DEXA, no difference in serum leptin levels, but significantly lower 
adiponectin levels. Serum leptin showed a positive and adiponectin a negative correlation 
with all parameters of body-fat distribution (Carmina et al., 2009). In other study 
populations, leptin secretion correlates with fat mass and the secretion is greater from SAF 
than from IAF (Kershaw and Flier, 2004), while adiponectin shows a negative correlation 
with IAF and SAF (Jain et al., 2009). The release of TNFα is not different between IAF 
and SAF while IL-6 is preferentially released by IAF (Fain et al., 2004). Most studies show 
a BMI-related difference in the secretion of adipokines by IAF and SAF (Fain, 2010; 
Kershaw and Flier, 2004), but the redistribution of fat from IAF to SAF and ultimately to 
ectopic fat sites like the liver, skeletal muscles and pancreas were not measured in these 
studies. The contribution of IAF and SAF compartments to the serum adipokines in women 
with anovulatory PCOS needs further assessment. We investigated in women with obesity 
and infertility, whether PCOS status (i.e., anovulation and polycystic ovaries on ultrasound 
and/or hyperandrogenaemia) determines the association between the body-fat distribution 











MATERIALS AND METHODS  
 
Subjects  
All participants were recruited from women with obesity and infertility attending the 
Fertility clinic of the University Medical Center Groningen (UMCG), The Netherlands with 
the aim to follow a 6-month lifestyle programme. For the present analysis the participants 
were selected from a total cohort of 57 participants, published previously as a comparison 
of body-fat distribution characteristics between ovulatory and anovulatory infertile women 
with obesity as well as the contribution of IAF and SAF to anovulation (Kuchenbecker et 
al., 2010). Thirty two anovulatory women with PCOS and 15 ovulatory non-PCOS controls 
were included in the present analysis. After the fertility work-up, the 15 ovulatory non-
PCOS controls were diagnosed as unexplained or mild male factor infertility, whilst 
anovulation was the cause of infertility in the 32 PCOS women. Participants were 
diagnosed as PCOS according to the Rotterdam consensus diagnostic criteria (Rotterdam 
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) if two of the 
following criteria were identified: anovulation (in all 32 women), hyperandrogenemia 
(clinically or biochemically) (in 30 women) or polycystic ovary morphology on ultrasound 
[≥12 follicles 2‒9 mm and/or increased ovarian volume (>10 ml) in at least one ovary] (in 
19 women). Hyperandrogenaemia was defined by a serum testosterone level >3.5 nmol/l or 
a free testosterone level >62 pmol/l or when clinical hirsutism was present. PCOS is a 
heterogeneous condition and we therefore focussed on the specific subgroup of anovulatory 
PCOS because of its association with obesity. Of the 15 ovulatory non-PCOS controls, 13 
did not show PCO morphology on ultrasound and had no clinical or biochemical 
hyperandrogenaemia, whilst two women had PCO morphology on ultrasound without 
clinical of biochemical hyperandrogenaemia. No study subject received hormonal 
preparations or metformin in the 3 months preceding inclusion. All women were Caucasian, 
except for one women of Asian origin. The study was approved by the Medical Ethical 
Committee of the UMCG and informed written consent was obtained from all women. 
 
Anthropometric assessment  
The following anthropometric measurements were determined at intake: body weight (up to 
nearest 0.1 kg), BMI, waist circumference (Wc) (up to the nearest 1 cm). A whole body 
scan by DEXA assessed the total and trunk fat mass as well as the abdominal fat mass.  All 
participants underwent a single-sliced abdominal CT scan (ssCT) at the level of the 
umbilicus for the measurement of the IAF and the SAF. A detailed description of the 
protocol of anthropometric assessments in this study population was published previously 








Abdominal ultrasound (US) was performed using a ALOKA SSD-1000 (Aloka, Tokyo, 
Japan) ultrasound machine with a 3.5 MHz convex-array abdominal transducer to measure 
liver-fat accumulation according to a qualitative scoring method (Joseph et al., 1991, 
Mendler et al., 1998). Liver-fat accumulation was categorised in four groups: severe, 




All blood samples were taken after an overnight fast of 10 hours. The following blood tests 
were performed on all samples: total testosterone, sex hormone-binding globulin (SHBG), 
insulin, glucose, leptin, adiponectin, TNF-α and IL-6. A detailed description of the 
measurement techniques of total testosterone, SHBG, insulin and glucose in this study 
population was published previously (Kuchenbecker et al., 2010). Homeostasis model 
assessment score for insulin resistance (HOMA-IR), was calculated as [fasting serum 
insulin (mU/l) x fasting plasma glucose (mmol/l)] / 22.5 by using the digital HOMA 
calculator which corrects for insulin measurement techniques (Manley et al., 2008; 
Muniyappa et al., 2008).  Free testosterone was calculated with the formula according to 
Vermeulen (Vermeulen et al., 1999). In the UMCG, a free testosterone level >62 pmol/l is 
defined as hyperandrogenemia. Serum levels of leptin were quantified by Enzyme-linked 
immunosorbent assay (ELISA), (Linco Reasearch, St. Charles, MN, USA) and showed a 
limit of sensitivity of 0.135 ng/ml with an intra-assay variation of 2.6‒4.6% and an inter-
assay variation of 2.6‒6.2%. The serum adiponectin was also measured by ELISA 
(Millipore, St. Charles, MN, USA), showing a limit of sensitivity of 0.78 ng/ml with an 
intra-assay variation of 0.9‒7.4% and an inter assay variation of 2.4‒8.4%. TNFα and IL-6 
were measured by a quantitative sandwich enzyme immunoassay technique (Quantikine HS 
Immunoassay kit, R&D Systems, McKinley Place, MN, USA) with a limit of sensitivity for 
TNFα of 0.106 pg/ml with an intra-assay variation of 3.1‒8.5% and an inter-assay variation 
of 7.3‒10.6%. Measurement of IL-6 showed a limit of sensitivity of 0.039 pg/ml with an 
intra-assay variation of 6.9‒7.8% and an inter-assay variation of 6.5‒9.6%. 
 
Statistical analysis 
For comparison between groups, subjects were stratified by PCOS status into an 
anovulatory PCOS group and an ovulatory non-PCOS control group. Inter-group 
comparisons were made by using a χ2 test for ordinal variables and an unpaired Student’s   
t-test for normally distributed continuous variables or a Mann-Whitney U-test when the 
distribution was skewed. Normal distribution was tested using the Kolmogorov-Smirnov-
test. The relationship between body-fat distribution parameters and adipokine levels in the 
total group of participants were examined using bivariate correlation (Pearson). Linear 
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regression analysis was performed with the adipokines as dependant variable and the body- 
fat distribution parameters as covariates correcting for PCOS and in a separate analysis 
correcting for BMI and age. All analyses were performed using SPSS, version 18 (SPSS 






In the total group of 47 women with obesity and infertility, the BMI ranged from 29.2–47.4 
kg/m2 and the age ranged from 20‒38 years. There was no significant difference in BMI 
and age between the 32 anovulatory PCOS women and the 15 ovulatory non-PCOS 






Table 1. Characteristics of obese women with infertility comparing women with anovulatory PCOS 
to ovulatory non-PCOS controls 
 
Parameter Total  
(n = 47) 
PCOS  
(n = 32) 
Controls  
(n = 15) 
P 
Age (years)a 29.2±4.0 28.4±3.8 30.8±4.2 0.061 
BMI (kg/m2)a 36.8±4.9 37.5±4.9 35.2±4.7 0.150 
Waist circumference (cm)a 110±12 113±12 104±9 0.014* 
Total fat DEXA (kg)a 44.7±10.3 46.1±10.1 41.9±10.4 0.194 
Trunk fat DEXA (kg)a 21.8±5.5 23.1±5.5 18.9±4.4 0.013* 
Abdomen fat DEXA (kg)a 4.1±1.3 4.5±1.3 3.4±0.9 0.008* 
IAF ssCT (cm3)a 194±62 196±57 188±74 0.692 
SAF ssCT (cm3)a 951±190 992±196 864±148 0.030* 
Testosterone (nmol/l)b 3.7 (1.6–6.5) 4.0 (1.6–6.5) 3.1 (1.6–5.4) 0.034* 
SHBGb 26 (8–93) 21 (8–43) 37 (9–93) 0.007* 
Fasting insulin (pmol/l)b 146.2 (25.8–400.0) 164.5 (25.8–400.0) 125.9 (43.8–301.1) 0.045* 
HOMA-IRb 2.6 (0.5–6.2) 2.8 (0.5–6.2) 2.1 (0.8–4.0) 0.081 
Leptin (ng/ml)a 47.2±14.4 48.5±14.1 43.7±15.8 0.276 
Adiponectin (ng/ml)b 6.4 (1.7–12.0) 6.4 (3.4–12.0) 6.7 (1.7–11.1) 0.603 
IL-6 (pg/ml)b 2.4 (0.6–6.2) 2.4 (0.6–6.2) 2.4 (0.7–5.5) 0.423 
TNF-α (pg/ml)b 2.2 (0.6–3.9) 2.4 (0.6–3.8) 1.9 (0.6–3.9) 0.133 
 
Data expressed as a mean±SD using an independent sample Student’s t-test or as  b median, minimum and 
maximum using a Mann-Whitney U-test. 








Table 2.  Liver-fat accumulation in obese women with infertility comparing women with anovulatory 
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Differences by χ2 test; P=0.236. 
 
 
The difference in anthropometric parameters between the anovulatory PCOS and ovulatory 
non-PCOS controls are shown in Table 1. Anovulatory PCOS women had a significantly 
higher Wc, abdominal and trunk fat on DEXA scan, significantly more SAF on ssCT, and a 
non-significant difference in BMI and total fat mass on DEXA scan compared to the 
ovulatory non-PCOS controls. The IAF on ssCT was not significantly different between 
anovulatory PCOS women and ovulatory non-PCOS controls. The present study shows 
more liver-fat accumulation on US in women with anovulatory PCOS compared to the 
ovulatory non-PCOS group, with moderate and severe liver-fat accumulation in 58.6% and 
33.3% of women in the anovulatory PCOS and ovulatory non-PCOS group, respectively 
(Table 2). These differences were not statistically significant.  
The 32 anovulatory PCOS women had significant higher levels of fasting insulin, 
testosterone and SHBG compared to the 15 ovulatory non-PCOS controls. The HOMA-IR 
was higher in women with anovulatory PCOS compared to ovulatory non-PCOS controls, 
but the difference did not reach significance (P=0.081) (Table 1). There was no significant 
difference in serum levels of leptin, adiponectin, TNF-α  and IL-6, between the anovulatory 
PCOS women and the ovulatory non-PCOS controls (Table 1).  
In the total group of 47 women (anovulatory PCOS and ovulatory non-PCOS controls), 
leptin showed a significant positive correlation with SAF on ssCT, and with trunk fat, 
abdominal fat and total fat on DEXA scan (r=0.488–0.681; P<0.001). IL-6 showed a 
significant positive correlation with total fat on DEXA scan (r=0.314; P=0.043) (Table 3). 
Linear regression analysis of the adipokines with body-fat distribution parameters revealed 
that PCOS status had no influence on the association. After correcting for BMI and age, 
PCOS status still had no influence on the association between the adipokines and body-fat 
distribution parameters.  
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Table 3.  Correlation of body-fat distribution parameters, fasting insulin and adipokines in obese 
women with infertility (total groups of anovulatory PCOS and ovulatory non-PCOS controls) 
    
  Insuline Leptin Adiponectin IL-6 TNFα 
IAF (cm3)  Pearson    0.170  0.094 -0.082 0.027   0.071 
 P   0.260  0.552  0.604 0.865   0.653 
SAF (cm3)  Pearson -0.067  0.523**  0.209 0.262   0.061 
 P   0.660 <0.001  0.184 0.093   0.701 
AbdDexa (kg) Pearson    0.072    0.488*  0.076 0.230   0.120 
 P   0.636 <0.001  0.630 0.143   0.448 
TrunkDexa (kg) Pearson    0.195  0.535**  0.019 0.265   0.088 
 P   0.195 <0.001  0.905 0.090   0.578 
TotFat (kg) Pearson    0.001 0.681**  0.161 0.314* -0.029 
 P   0.997 <0.001  0.307 0.043   0.855 
   
* Correlation is significant at the 0.05 level. 






This study shows that, in spite of significant differences in body-fat distribution parameters 
between anovulatory PCOS women and ovulatory non-PCOS controls, PCOS status (i.e., 
defined as anovulation and polycystic ovaries on ultrasound and/or hyperandrogenaemia) is 
not a determining factor in the association between serum adipokine levels and body-fat 
distribution parameters in the total group of women with obesity (mean BMI 36.8±4.9 
kg/m2) and infertility.  
In accordance with previous studies, the present study confirms that women with 
anovulatory PCOS who are overweight and obese have abdominal obesity compared to 
ovulatory non-PCOS controls (Carmina et al., 2007). Furthermore, the present study shows 
that obese women with anovulatory PCOS have significantly more SAF and no difference 
in IAF compared to obese ovulatory non-PCOS controls. The results of previous studies 
evaluating the differences in IAF and SAF between women with PCOS and ovulatory 
controls were inconsistent (Yildirim et al., 2003; Barber et al., 2008a; Cascella et al., 2008; 
Dolfing et al., 2011; Hutchison et al., 2011). These study populations had different mean 
BMI levels and the inclusion criteria for PCOS and the control groups were different 
between the studies. Two studies used US to measure IAF in stead of the gold standard of  
Abdominal Computerised Tomography scan or Magnetic Resonance Imaging (Yildirim et 
al., 2003; Cascella et al., 2008), whilst US measurement of IAF was not validated in 







The correlation of the body-fat distribution parameters and serum leptin, IL-6 and TNFα  
levels in women with obesity and infertility (total group) in the present study are in 
accordance with previous reports (Kershaw and Flier, 2004; Carmina et al., 2009; Jain et 
al., 2009). Except for a non-significant negative correlation of adiponectin with IAF, this 
study did not show a negative correlation of adiponectin with other body-fat distribution 
parameters. The present study could not confirm the finding of a meta-analysis showing a 
decrease in serum adiponectin levels in women with PCOS compared to ovulatory controls 
(Toulis et al., 2009). However, more recent studies correcting for differences in BMI and 
fat mass do not consistently show lower adiponectin and lower high molecular weight 
(HMW) adiponectin levels in women with PCOS compared to ovulatory controls (Barber 
et al., 2008b; O'Connor et al., 2010; Wickham et al., 2011). Adiponectin levels follow a 
circadian pattern and can be influenced by high-carbohydrate meals, dietary supplements 
and oxidative stress (Bohler et al., 2010), factors which have not been reported in the 
abovementioned meta-analysis. Future studies on adiponectin levels should attempt to 
eliminate and correct for these influences and should attempt to measure the HMW 
adiponectin because it most closely correlates with the measures of insulin sensitivity 
(Fisher et al., 2005; Nakashima et al., 2006). 
In spite of a significant increase in abdominal obesity measures and SAF and the known 
difference in the morphology and function of adipose tissue in obese women with 
anovulatory PCOS compared to obese anovulatory non-PCOS controls, linear regression 
analysis correcting for BMI and age, did not reveal that PCOS status is a determining factor 
in the correlation between body-fat distribution and serum adipokine levels. Two possible 
explanations for this finding should be considered.  
The first explanation is based on the process of body-fat redistribution as described in the 
introduction. During chronic exposure to energy dens diets, subcutaneous adipose tissue 
needs to regulate the recruitment, differentiation and proliferation of preadipocytes to 
mature adipocytes (adipogenesis), leading to more adipocytes and an increased storage 
capacity of excess fat (hyperplastic obesity) (Danforth, 2000; Rodriguez-Acebes et al., 
2010). In many obese patients adipogenesis may become dysregulated, resulting in 
dysfunctional subcutaneous adipose tissue in many obese patients, leading to adipocyte 
hypertrophy and decreased fat-storage capacity (hypertrophic obesity) (Danforth, 2000; 
Villa and Pratley, 2011). Hypertrophic obesity is associated with increased fat cell size, 
necrosis and an inflammatory response (Weiss, 2007; Rasouli and Kern, 2008), resulting in 
a decreased ability to store additional fat and the secretion of a different adipokine profile. 
Dysfunctional subcutaneous adipose tissue contributes to the process of body-fat 
redistribution with shunting of excess fat from subcutaneous adipose tissue to ectopic sites 
like the liver, skeletal muscles and pancreas. Accumulation of fat in these ectopic sites is 
strongly associated with IR and an adverse metabolic profile (Weiss, 2007; Koska et al., 
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2008; Arsenault et al., 2011). Individuals with hyperplastic obesity on the other hand can 
store increased amount of fat in the subcutaneous adipose tissue without shunting of fat to 
ectopic sites. Individuals with hyperplastic obesity have limited IR and a favourable 
metabolic profile and are described as having a metabolically healthy obese phenotype 
(Stefan et al., 2008; Hayes et al., 2010).  In Figure 1 adipose tissue dysfunction and the 
consequences of body-fat redistribution is schematically presented.  
We hypothesize that in women with infertility and high BMI levels, adipose tissue 
dysfunction occurs resulting in body-fat redistribution with fat shunted from IAF to SAF 
and later to ectopic sites. This explains the findings of the present study that in women with 
anovulatory PCOS and obesity, SAF and not IAF volume is increased, as well as the non-
significant increase of moderate and severe liver-fat accumulation in anovulatory PCOS 
women compared to ovulatory non-PCOS controls. In anovulatory PCOS women with 
lower BMI levels and no adipose tissue dysfunction, body-fat distribution parameters may 
be different compared to women with higher BMI levels, because body-fat redistribution 
may not have been initiated in the anovulatory PCOS women with low BMI. 
Recent data indicate that the adipogenesis in PCOS women may be altered due to decreased 
expression of genes involved in the proliferation of omental fat (Corton et al., 2007). Some 
studies indicate that androgen excess in women with PCOS may also contribute to impaired 
adipogenesis. Dihydrotestosterone decreases the differentiation and lipid accumulation in 
human preadipocytes and adipocytes in culture (Gupta et al., 2008). Prenatal exposure to 
androgens in animal models induces increased adipocyte cell size accompanied by IR 
(Roland et al., 2010).  It might be hypothesised, that androgen excess in women with PCOS 
may initiate the process of adipose tissue dysfunction at a lower BMI level compared to 
non-PCOS controls.  
The second explanation of the main finding of the present study is that adipokine serum 
levels may not accurately reflect the function of adipose tissue compartments. Some 
adipokines are exclusively secreted by adipocytes (like adiponectin) while others (like 
leptin) are also expressed by other tissues (Rasouli and Kern, 2008; Bohler et al., 2010). 
Only one-third of circulating IL-6 originates from adipocytes and like TNFα, it acts mostly 
in an autocrine and paracrine manner (Bohler et al., 2010). The release of adipokines and 
FFA by IAF into the portal venous system to the liver contributes to significant metabolic 
changes, which will not accurately be reflected by their serum levels (Weiss, 2007). 
Furthermore, the contribution of ectopic fat depots, like the liver, skeletal muscle and 
pancreas, to serum adipokine levels needs further assessment in women with PCOS. 
The following limitations of our study should be considered. Due to the limited number of 
participants, a sub-analysis of different BMI groups was not possible and subtle differences 
in the serum adipokine levels and findings of the correlations between body-fat distribution 


















































































































































































































































Another limitation of our study is that IAF and SAF were measured by ssCT scan at the 
level of L4-L5, and that the outcome depends on the individual variation of IAF and SAF 
distribution. A study published after initiation of ours, indicates that in women the 
measurement of IAF by single-sliced CT scan at the level of L2-L3 shows better correlation 
with whole abdomen CT scan (Kuk et al., 2010). In the present study we did not measure 
the HMW adiponectin levels, which might give a better reflection of the level of IR. 
In conclusion, in women with obesity and infertility and a mean BMI of 36.8±4.9 kg/m2, 
PCOS (i.e., defined as anovulation and polycystic ovaries on ultrasound and/or hyper-
androgenaemia) is not a determining factor in the association between the body-fat 
distribution parameters and serum adipokine levels. The explanation of the discrepancy of 
our results with previous studies in women with PCOS and lower BMI levels may be that 
with high BMI levels, adipose tissue dysfunction occurs leading to body-fat redistribution 
and altered adipokine secretion. With increasing BMI, the differences in body-fat 
distribution between women with anovulatory PCOS and ovulatory non-PCOS controls are 
therefore overruled by body-fat redistribution. Future studies should aim to analyse adipose 
tissue (including omental fat and ectopic fat mass) features in women with PCOS over a 
wide range of BMI levels, in order to evaluate the difference in adipogenesis and the effect 
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Background: It is not clear why some anovulatory women with polycystic ovary syndrome 
(PCOS) and obesity resume ovulation and others remain anovulatory after weight loss. The 
objective of this study was to compare the changes in body-fat distribution and specifically 
intra-abdominal fat (IAF) and subcutaneous abdominal fat (SAF) between a group of 
anovulatory women with PCOS and obesity who resume ovulation (RO+) to those who 
remain anovulatory (RO-) during a lifestyle programme.  
Methods: In a prospective pilot cohort study, anovulatory women with PCOS underwent a 
6-month lifestyle programme in a tertiary fertility clinic. Body-fat distribution was assessed 
by anthropometrics, dual-energy x-ray absorptiometry (DEXA), single-slice abdominal CT 
scan (ssCT) at intake, after 3 months and after 6 months. Baseline-corrected changes over 
time were analysed using Generalised Estimating Equations (GEE) longitudinal regression 
analysis.  
Results: In 32 anovulatory women with PCOS (age 28±4 years; BMI 37.5±5.0 kg/m²), there 
were no significant baseline differences in anthropometrics and biochemical assessment 
between 14 RO+ participants and 18 RO- participants. RO+ women lost more weight (6.3% 
versus 3.0%) and abdominal fat on DEXA (15.0% versus 4.3%) compared to RO- women. 
Resumption of ovulation was associated with early and consistent loss of IAF (12.4% 
versus 5.0% at 3 months and 18.5% versus 8.6% at 6 months). Loss of SAF between the 
RO+ women and the RO- women was similar at 3 months (6.2% versus 6.1%) but did not 
change any further in RO- women (6.1 %) as it did in RO+ women (11.4 %) at 6 months. 
Conclusions: In anovulatory women with PCOS and obesity undergoing a lifestyle 
programme, RO+ women lose more body weight and abdominal fat on DEXA than RO- 
women. In addition, this study shows that early and consistent loss of IAF is associated 
with resumption of ovulation. Future studies should address the mechanisms behind these 






The high prevalence of overweight (body mass index (BMI) 25‒29.9 kg/m2) and obesity 
(BMI ≥30 kg/m2)  is significantly contributing to the overall burden of disease worldwide, 
and the effect on female reproduction is a growing additional concern (Haslam and James, 
2005; Nelson and Fleming, 2007). Overweight and obesity in women is a main contributor 
to anovulation, with an exponential increase in anovulation with increasing body weight 
(Green et al., 1988; Rich-Edwards et al., 1994). 
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Increased abdominal fat accumulation (waist hip ratio >0.8 in women) contributes to 
reproductive dysfunction (Zaadstra et al., 1993; Wass et al., 1997; Pasquali et al., 2006)  
and these findings are unchanged after correcting for BMI. Abdominal fat accumulation is 
an indicator of higher metabolic risk profile because it is associated with insulin resistance 
(IR) (Despres et al., 2001). Hyperinsulinaemia in women with obesity contributes to 
anovulation by increased ovarian androgen secretion (Pasquali et al., 2006; Bohler et al., 
2010), leading to arrest of follicle growth (Willis et al., 1996).  
Loss of abdominal fat, on the other hand, is associated with resumption of menstruation and 
ovulation in obese women with polycystic ovary syndrome (PCOS) undergoing a weight 
loss programme (Huber-Buchholz et al., 1999; Thomson et al., 2008). It has been shown 
that resumption of ovulation in anovulatory women with obesity undergoing weight loss is 
mediated by improvement of IR and decrease in free androgen levels (Guzick et al., 1994; 
Holte et al., 1995; Pasquali et al., 2006). Abdominal fat consists of intra-abdominal fat 
(IAF) and subcutaneous abdominal fat (SAF). In study subjects with obesity who lost 
weight, loss of IAF had a greater beneficial effect on IR than loss of SAF (Park and Lee 
2005). The independent contribution of exercise to the improvement of IR and loss of IAF 
is not clear because only few studies tried to correct for diet and weight loss (Carroll and 
Dudfield, 2004; Christiansen et al., 2009; Hutchison et al., 2011).  
It remains unexplained why some women remain anovulatory and others resume ovulation 
after weight loss. It can be hypothesised that specifically loss of IAF is required for 
improvement of IR, decease in androgen levels and resumption of ovulation. We tested this 
hypothesis by comparing the changes in body-fat distribution, and especially IAF and SAF, 
in a group of obese anovulatory women with PCOS who resumed ovulation to those who 
remained anovulatory during a 6-month lifestyle programme. 
 
 
MATERIALS AND METHODS 
 
Population 
In a pilot prospective cohort study, participants were recruited from women with obesity 
and infertility attending the Fertility Clinic of the University Medical Center Groningen 
(UMCG) between 2005 and 2008. All women with a BMI >29 kg/m2 who met the inclusion 
criteria (infertility >1 year, age <38 years, partner with total motile sperm 
concentration/ejaculate >10 million) were asked to participate in a 6-month lifestyle 
programme. The baseline data of this cohort of women before start of the lifestyle 
programme were published previously as a comparison of body-fat distribution 







2010). In the present study, assessing changes during the lifestyle programme, only 
anovulatory women with PCOS were included in the analysis.  
Participants were diagnosed as PCOS according to the Rotterdam consensus diagnostic 
criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) 
if two of the following criteria were identified: anovulation, hyperandrogenaemia (clinically 
or biochemically) or polycystic ovary morphology on ultrasound and after other endocrine 
causes of anovulation were excluded. Hyperandrogenaemia was defined by a serum 
testosterone level >3.5 nmol/l or a free testosterone level >62 pmol/l or when clinical 
hirsutism was present. No participant received hormonal medications or metformin in the 3 
months preceding inclusion. All participants were Caucasian, except for one participant of 
Asian origin.  
 
Women with amenorrhea (cycle interval  ≥6 months) were considered anovulatory. Women 
with cycles ≤42 days in whom ovulation could not be confirmed by ultrasound monitoring, 
as well as women with menstrual cycles between 42 days and 6 months kept a basal body 
temperature (BBT) chart. Women with no BBT rise or a midluteal progesterone level     
≤15 nmol/l, 1 week after a BBT rise, were considered anovulatory. In all study subjects, 
hyperprolactinaemia, abnormal thyroid function, non-classical 21-hydroxylase deficiency 
and an androgen secreting tumour was excluded. 
During the lifestyle programme, all women kept a BBT chart and a midluteal progesterone 
level was assessed 1 week after a maintained temperature rise. Resumption of ovulation 
was defined as a midluteal progesterone level >15 nmol/l at least once, or by the occurrence 
of conception.  
Participants who did not resume ovulation (RO-) and those who resumed ovulation (RO+) 
but did not conceive remained in the 6-month lifestyle programme. Women who conceived 
did not continue the lifestyle programme. Women who stopped the lifestyle programme 
before the 6th month were considered to be drop-outs. All drop-outs were contacted by 
telephone 6 months after drop-out to inquire about self-reported weight loss and 
conception.  
The study was approved by the Medical Ethical Committee of the UMCG and informed 
written consent was obtained from all subjects. 
The lifestyle programme of 6 months was based on the National Institute of Health 
evidence report of the treatment of obesity (National Heart, Lung and Blood 
Institute/National Institutes of Diabetes and Digestive and Kidney diseases, 1998) and 
consisted of a combination of dietary advice, increased physical activity and behaviour 










Body weight (kg), height (cm), BMI (weight (kg) divided by height in meters2), waist 
circumference (Wc, waist measured at the narrowest part of the torso located between the 
lower rib and the iliac crest), a whole body DEXA scan (DEXA) and a single-slice 
abdominal CT scan (ssCT) were measured at baseline. All measurements were carried out 
by the same observer. Bodyweight was recorded every 2 weeks and the Wc, DEXA and the 
ssCT were measured again at month 3 and month 6 of the lifestyle programme.  
Total, trunk and abdominal fat mass was measured by DEXA, using a Hologic A Discovery 
Bone Densitometer (Hologic Inc., Bedford, MA, USA).  Total fat mass was determined for 
the whole body, and by using computer programming, two regions (trunk and abdominal 
slice) were specified and measured as mentioned in previous studies (Carmina et al., 2007).  
The ssCT consisting of three to four subslices was performed at the level of the umbilicus 
for the measurement of the IAF and the SAF (Seidell et al., 1990). The technique used to 
measure IAF and SAF was published previously (Kuchenbecker et al., 2010).  In short, the 
IAF and SAF volume (cm3) was calculated by multiplying the IAF and SAF area (cm2) of 
each subslice with the subslice thickness (cm), and the mean volume (cm3) of the subslices 
was recorded for analysis. All measurements were performed by a single observer.  
Pregnancy was excluded before each DEXA and ssCT scan by a urine pregnancy test. 
 
Biochemical assessment 
Total testosterone, sex hormone binding globulin (SHBG) and insulin were measured after 
an overnight fast of 10 hours at intake, after 3 months and after 6 months of the lifestyle 
programme. The formula according to Vermeulen (Vermeulen et al., 1999) was used to 
calculate free testosterone. The exact measurement techniques used for the biochemical 
assessments were published previously (Kuchenbecker et al., 2010).  
 
Lifestyle programme 
All participants received individualised dietary advice aiming for reduction in calorie intake 
of at least 500 kcal/day, but avoiding a total calorie intake <1200 kcal/day. An 
individualised exercise programme was tailored to the ability and personal and social 
circumstances of each participant. Each participant kept a diet record and carried a 
pedometer SW-200 (New Lifestyles, Lee's Summit, MO, USA) to record the amount of 
steps over 2-week periods during the 6-month programme. Individual guidance by a nurse 
practitioner consisted of visits every 2 weeks, during which body weight was measured and 
compliance was assessed by evaluating the diet and pedometer records completed at home. 
In addition, the BBT chart was evaluated and a serum midluteal progesterone level 







problems of and resistance to lifestyle changes and behaviour modification were addressed 
and advice was given (Levensky et al., 2007). 
 
Statistical analysis 
At the end of the lifestyle programme, the participants were divided into those who had 
resumed ovulation (RO+) and those who had not resumed ovulation (RO-) and post-hoc 
comparison was performed between the two groups at baseline. The drop-outs were 
contacted by telephone 6 months after drop-out. If no further weight loss or conception 
after drop-out was reported, the drop-outs were analysed as part of the RO- group until the 
time of drop-out.  
Between-group comparisons were performed using an independent samples Student’s t-test 
for normally distributed continuous variables or a Mann-Whitney U-test when the 
distribution was skewed. Normal distribution was tested using the Kolmogorov-Smirnov-
test. Changes over time were analysed using Generalised Estimating Equations (GEE) 
longitudinal regression analysis with time, ovulatory status, and an interaction term of 
ovulatory status and time as the predictors. GEE makes maximum use of the available 
measurements in a longitudinal design without the limitations of complete case analysis. 
For interventions such as this lifestyle programme, complete case analysis does not reflect a 
real-life scenario and poses the risk of negative selection since only those who do not 
conceive or resume ovulation remain in the programme. Baseline correction was performed 
by including the measurement at T=0 of the respective parameter as a covariate in the GEE 
analysis. Participants remained in the GEE analysis until conception or drop-out. For this 
pilot study, no sample-size calculation could be performed. All analyses were performed 
using SPSS, versions 16 and 17 (SPSS Inc., Chicago, IL, USA). Differences or effects were 





Clinical characteristics of participants  
Thirty two anovulatory women with PCOS and obesity were included in the lifestyle 
programme and their baseline data were recorded. During the first 3 months, the four 
women that conceived and four drop-outs left the programme, while another five women 
who resumed ovulation continued the lifestyle programme, therefore leaving 24 participants 
to measure and record the data at 3 months. Out of the 24 participants continuing the 
second 3 months of the lifestyle programme, the three women who conceived and six drop-
outs left the programme, leaving 15 participants to measure and record the data at 6 months. 
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Table 1. Baseline characteristics of anovulatory women with PCOS and obesity undergoing a 6-
month lifestyle programme: comparison of the 10 drop-outs with the participants who completed the 
lifestyle programme 
 
Parameter Completed (n = 22) Drop-out (n = 10) P value 
Age (years)a 28.9 ± 4.1   27.5 ± 2.9 0.35 
BMI (kg/m2)a 37.8 ± 5.2   36.7 ± 4.3 0.56 
Waist circumference (cm)a 114 ± 13 110 ± 9 0.36 
Total fat DEXA (kg)a   47.6 ± 10.1   42.7 ± 9.7 0.21 
Trunk fat DEXA (kg)a 23.8 ± 5.8   21.7 ± 4.9 0.34 
Abdomen fat DEXA (kg)a   4.7 ± 1.3     3.9 ± 1.3 0.14 
IAF ssCT (cm3)a 197 ± 61   195 ± 51 0.96 
SAF ssCT (cm3)a 1023 ± 183     971 ± 223 0.50 
Testosterone (pmol/l)b        3.7 (1.6 – 6.1)         4.7 (1.6 – 6.5) 0.04* 
SHBG (nmol/l)b          22 (10 – 38)   20 (8 – 36) 0.72 
Free testosterone (pmol/l)b 87 (32 – 169) 116 (32 – 217) 0.04* 
Fasting insulin (pmol/l)b  170.3 (25.8 – 602.7)   193.0 (25.8 – 595.2) 0.80 
 
Data expressed as a mean ±SD using an independent sample Student’s t-test or as b median, minimum and 
maximum using a Mann-Whitney U-test. 





None of the 10 drop-outs reported any further weight loss or conception until 6 months 
after drop-out. They were therefore analysed as part of the RO- group. To ensure that the 
anthropometric and biochemical measurements of the drop-outs did not differ from the 
participants that completed the study, we performed a comparison of the baseline 
characteristics between both groups (Table 1). There was no difference in age, BMI and 
anthropometric assessment between the drop-outs and the participants that completed the 
study. Except for significantly higher free testosterone and total testosterone level in the 
drop-outs (P=0.04), there were no baseline differences in the biochemical assessments 
between the drop-outs and the participants who completed the study.  
The baseline data of the RO+ (n=14) and RO- (n=18) women are shown in Table 2. There 
was no difference in age, BMI, anthropometric- and biochemical assessment at baseline 
between the RO+ and RO- women.  
 
Changes during the lifestyle programme 
At the end of the lifestyle programme, the participants were divided into those who had 
resumed ovulation (RO+) and those who had not resumed ovulation (RO-) and GEE 
analysis was performed on the two groups. The unadjusted results of the measurements of 


















































































































































































































































































































The results of the GEE analyses of changes over time in body weight and abdominal fat on 
DEXA are presented in Figure 1. Since GEE was performed with correction for baseline the 
values differ from those in Table 2. The total group of RO+ women lost more weight (6.3% 
versus 3.0% at 6 months, P=0.018, Figure 1a) and abdominal fat on DEXA (15.0% versus 
4.3% at 6 months, P=0.025, Figure 1b) compared to the total group of RO- women. Figure 2 
shows that the RO+ women lost more IAF on ssCT between baseline and month 3 (12.4% 
versus 5.0%, P=0.002, Figure 2a) and baseline and month 6 (18.5% versus 8.6%, P=0.005, 
Figure 2a) compared to the RO- women. For SAF on ssCT, on the other hand, changes for 
RO+ women and RO- women were similar between baseline and month 3 (6.2% versus 
6.1%, P=0.946, Figure 2b). Due to continued loss of SAF after 3 months in RO+ women, 
there was a difference in loss of SAF between baseline and 6 months (11.4% versus 6.1%, 
P=0.031, Figure 2b) compared to RO- women.  
GEE analysis showed a non-significant decrease of fasting insulin (P=0.194) and free 
testosterone (P=0.086) in the RO+ women compared to the RO- women. The increase in 


























Figure 1. Baseline corrected GEE 
analysis of 32 anovulatory 
women with PCOS and obesity 
undergoing a lifestyle program 
with post hoc allocation of 
participants into those who 
resumed ovulation (RO+) and 
those who remained anovulatory 
(RO‒) at the end of 6 months 
shows a difference in loss of 
body weight (P ¼ 0.018) (a) and 
abdominal fat on DEXA (P¼ 
0.025) and (b) between RO+ 
(solid line) and RO‒ (dashed 
line) participants. Error bars 

































This study shows that in anovulatory women with PCOS and obesity participating in a 
lifestyle programme, resumption of ovulation was associated with more weight loss and 
loss of abdominal fat on DEXA. Resumption of ovulation was associated with early and 
consistent loss of IAF.  
In anovulatory women, >5% loss of body weight is required for resumption of ovulation ( 
Kiddy et al., 1992; Guzick et al., 1994; Clark et al., 1995; Holte et al., 1995; Huber-
Buchholz et al., 1999). Previous studies using DEXA to quantify the changes in abdominal 
fat in women with PCOS undergoing a weight loss programme, indicated that loss of 
abdominal fat is associated with resumption of ovulation (Huber-Buchholz et al., 1999; 
Thomson et al., 2008). The present study confirms these findings, since the RO+ women 
lost 6.3% of their body weight and 15.0% abdominal fat on DEXA during the lifestyle 
 
 
Fig 2. Baseline-corrected GEE 
analysis of 32 anovulatory 
women with PCOS and obesity 
undergoing a lifestyle program 
with post hoc allocation of 
participants into those who 
resumed ovulation (RO+) and 
those who remained anovulatory 
(RO‒) at the end of 6 months 
show a difference in loss of IAF 
from month 0 to month 3 (P¼ 
0.002) (a) and from month 0 to 
month 6 (P¼ 0.005) (a), and 
difference in loss of SAF from 
month 0 to month 3 (P¼ 0.946) 
(b) and from month 0 to month 
6 (P¼ 0.031) and (b) between 
RO+ (solid line) and RO‒ 
(dashed line) participants. Error 










programme, as compared to 3.0% loss of body weight and 4.3% loss of abdominal fat on 
DEXA in RO- women. Compared to RO- women, RO+ women lost on average 4.0 kg more 
body weight and 0.5 kg more abdominal fat on DEXA.   
Moreover, our study shows that early and consistent loss of IAF over a 6-month period is 
associated with resumption of ovulation. Only after more than 3 months of lifestyle 
intervention, RO+ women started losing more SAF than RO- women.  Previous studies in 
different patient populations have shown that during the initial period of calorie restriction, 
preferential loss of IAF occurs which correlates significantly with improvement in IR 
(Goodpaster et al., 1999; Park and Lee, 2005). Loss of IAF and not SAF during initial 
calorie restriction can be explained by increased lipolysis of IAF due to its higher metabolic 
activity (Smith and Zachwieja, 1999). After surgical removal of IAF, IR has been shown to 
improve (Thorne et al., 2002), while removal of SAF by liposuction does not significantly 
alter IR (Klein et al., 2004). Based on the above-mentioned mechanism, the early and 
consistent loss of IAF in RO+ women might have contributed to improvement in IR and 
resumption of ovulation. We could not confirm the expected difference in fasting insulin 
levels between RO+ and RO- women in our study, which may be due to the high average 
BMI in our population. Moderate weight loss in women with BMI >35 kg/m2 does not 
always lead to the same decrease in fasting insulin levels as in women with lower BMI, as 
shown in a previous study in women with PCOS and obesity (Tang et al., 2006).  
We have previously shown that in women with obesity and infertility, anovulatory women 
have significantly more SAF and higher fasting insulin levels and the same amount of IAF 
compared to ovulatory women with the same BMI (Kuchenbecker et al., 2010).  A possible 
explanation for an increased volume of SAF in anovulatory women with obesity could be 
provided by the concept of a critical IAF threshold. This concept suggests that during 
constant high calorie food consumption, storage of fat in IAF reaches a point of saturation, 
after which fat is shunted to the subcutaneous fat compartments (Freedland, 2004). With 
increased accumulation of SAF, inflammatory changes and increase in adipocyte size 
occur, limiting the SAF storage capacity and contributing to the antilipolytical effects of 
insulin.  Fat is then shunted from SAF to the liver and skeletal muscle which contributes to 
increased insulin resistance (Weiss, 2007; Koska et al., 2008). IAF, liverfat and skeletal 
muscle fat due to the higher lipolytical activity of these fat compartments compared to 
SAF. This mobilization of fat from IAF, liver fat and skeletal muscle fat leads to improved 
IR (Goodpaster et al., 1999; Freedland, 2004). This mechanism could also explain the 
findings of the present study that early and consistent loss of IAF and not SAF was 
associated with resumption of ovulation. 
Previous studies suggest that exercise contributes to loss of IAF (Kay and Fiatarone Singh, 
2006; Ohkawara et al., 2007) while another study could not show an independent effect of 







structured exercise programme showed higher ovulation rates and improvement in IR 
compared to a diet programme alone (Palomba et al., 2008). A more recent study showed 
that exercise was associated with loss of IAF and improvement in IR in PCOS women, 
despite weight maintenance. Using the euglycemic hyperinsulinemic clamp technique, no 
significant correlation was found; however, between improvement in IR and loss of IAF 
(Hutchison et al., 2011). Exercise might also improve insulin resistance by increasing 
muscle mass and enhancing glucose disposal in skeletal muscle (Carroll and Dudfield, 
2004; Thomson et al., 2008). In the present study, we cannot exclude that the non-
significant increase in pedometer steps might have contributed to increased loss of IAF and 
resumption of ovulation in the RO+ women compared to RO- women. 
As shown in previous studies, resumption of ovulation during weight loss is associated with 
a decrease in fasting insulin and free testosterone levels (Guzick et al., 1994; Pasquali et 
al., 2006). In addition, weight loss with improvement in IR and therefore lower insulin 
levels, leads to less androgen production by the ovarian theca cells and more SHBG 
production in the liver (Poretsky, 1991). Lower free androgen levels in the long term, in 
turn limits the amount of abdominal fat accumulation (Bohler et al., 2010; Pasquali et al., 
2006). In our study, we found a decrease in free testosterone in the RO+ women that was 
not statistically significant compared to RO- women. This might be due to small numbers 
in our study.  
This study shows that in anovulatory women with PCOS and obesity, participating in a 
lifestyle programme, resumption of ovulation is associated with early and consistent loss of 
IAF. The most likely mechanism of resumption of ovulation after loss of IAF during a 
lifestyle programme is improvement of IR and lower free androgen levels but other 
mechanisms should also be considered. Women with anovulatory PCOS have altered 
adipocytokine secretion (Carmina et al., 2009) and changes in the adipocytokine secretion 
due to loss of IAF can also be considered as a mechanism of resumption of ovulation, as 
these substances also have direct effects on the ovary (Mitchell et al., 2005). Future studies 
should try to evaluate interventions aimed at loss of IAF and should try to explore the 
mechanism involved in resumption of ovulation due to loss of IAF. 
The present study was a pilot to investigate the feasibility of a lifestyle programme in a 
tertiary fertility centre. In spite of personal guidance by a nurse practitioner using 
motivational interviewing techniques, there was a high drop-out rate of 31.3%. Our drop-
out rate is in agreement with the rates of 27‒35% reported in previous studies on lifestyle 
intervention in comparable patient populations (Clark et al., 1995; Hoeger et al., 2004; 
Palomba et al., 2008). Based on follow-up data until 6 months after drop-out, we decided to 
allocate the drop-outs to the RO- group until the moment of drop-out. This decision was 
based on the fact that resumption of ovulation is highly unlikely in anovulatory women 
with obesity who do not lose weight (Clark et al., 1995). We can however not exclude the 
6





possibility that women in the drop-out group had occasional ovulation in spite of no further 
weight loss. The high drop-out rate deserves further evaluation in order to improve the 
effectiveness of lifestyle programmes. If predictive factors for drop-out in this patient 
population could be indentified (Teixeira et al., 2005), specific personal guidance and 
intervention should be developed to improve motivation and adherence to diet – and 
exercise programmes to achieve weight loss.  
In conclusion, this study indicates that anovulatory women with PCOS and obesity who 
resume ovulation during a lifestyle programme lose 4 kg (3.3%) more weight and 0.5 kg 
(10.7%) more abdominal fat on DEXA than the women who remain anovulatory. 
Moreover, early and consistent loss of IAF is associated with resumption of ovulation.  
Future larger studies on lifestyle interventions in anovulatory women with PCOS should 
aim to confirm our findings and to evaluate the mechanisms of resumption of ovulation. 
Trials should be designed to assess the combination of diet and structured exercise 
programmes aimed at loss of IAF and improvement of IR for resumption of ovulation, 
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Background: Women of reproductive age who are overweight or obese are prone to 
suffering from infertility. Weight loss in these women leads to increased fecundity, higher 
chances of conception after infertility treatment and improved pregnancy outcome. In spite 
of the advantageous effects of weight loss, most patients have difficulty losing weight and 
often regain lost weight over time. The objective of this review was to assess whether 
treatment with insulin-sensitizing drugs contributes to weight loss, compared to diet or a 
lifestyle modification programme.  
Methods: After a systematic search and analysis of the literature, only randomised 
controlled trials (RCTs), which investigated the effect of insulin-sensitizing drugs on 
weight loss in comparison to placebo and diet and/or a lifestyle modification programme, 
were included. Subjects were restricted to women of reproductive age. The main outcome 
measure was weight loss reported in change in body mass index (BMI).  
Results: Thirty-one trials performing the comparisons of interest were identified. Using 
strict selection criteria, only fourteen trials, unintentionally all but two on women with 
polycystic ovarian syndrome (PCOS) only, were included in the analysis. Treatment with 
metformin showed a statistically significant decrease in BMI compared to placebo (WMD  
-0.68, 95% CI -1.13 to -0.24).  
Conclusion: This review showed that treating women of reproductive age with PCOS who 
are overweight or obese with metformin leads to a significant decrease in BMI, independent 





The rising prevalence of obesity in women worldwide has implications for their 
reproductive outcome. Obesity is associated with menstrual disorders and anovulation 
(Hartz et al., 1979; Green et al., 1988; Grodstein et al., 1994; Lake et al., 1997) but  
fertility is also decreased in women with regular menstrual cycles who are overweight 
(Jensen et al., 1999; van der Steeg et al., 2008). Furthermore, women who are overweight 
or obese while undergoing assisted reproduction have lower pregnancy rates and higher 
miscarriage rates (Wang et al., 2000; Lintsen et al., 2005; Maheshwari et al., 2007). During 
pregnancy, obesity leads to a significant increase in pregnancy complications (Cedergen, 
2004; Weiss et al., 2004) and difficulties during labour (Sebire et al., 2001). Infants are at 
greater risk of congenital abnormalities (Waller et al., 1994; Werler et al., 1996) and intra-
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uterine demise (Stephansson et al., 2001; Nohr et al., 2005) contributing to an increase in 
perinatal morbidity and -mortality. 
Obesity is characterised by insulin resistance and consequent hyperinsulinaemia. 
Hyperinsulinaemia contributes to anovulatory infertility by increased ovarian androgen 
secretion (Poretsky, 1991; Dunaif, 1997). In women with PCOS, insulin enhances intra-
ovarian steroidogenesis by interacting with luteinising hormone (LH) leading to 
inappropriate advancement of granulosa cell differentiation and arrest of follicle growth 
(Franks, Robinson et al., 1996;Willis, Mason et al., 1996). 
 
The cornerstone of the treatment of obesity should be based on lifestyle changes by diet, 
exercise and behavioural modification (NIH, 1998). In obese women with anovulatory 
infertility, weight loss leads to spontaneous ovulation and improves the chances of 
spontaneous conception (Kiddy et al., 1992; Guzick et al., 1994; Clark et al., 1995; 
Hollman et al., 1996). In obese women with PCOS, a minimum of 5% loss of abdominal fat 
is essential for the resumption of spontaneous ovulation (Huber-Buchholz et al., 1999). An 
intensive lifestyle modification programme improves the chances of spontaneous 
conception and conception during fertility treatment (Clark et al., 1998). Pre-pregnancy 
weight loss can reduce the incidence of gestational diabetes (Glazer et al., 2004). 
 
In view of the low success rate in achieving weight loss and even lower success rate for 
maintaining this weight loss, drug therapy for obesity in conjunction with the continuation 
of lifestyle changes is advised according to obesity guidelines (NIH, 1998). According to a 
randomised controlled trial, the combination of a lifestyle modification programme with 
drug therapy, achieves more weight loss than a lifestyle programme alone (Wadden et al., 
2005). Orlistat and sibutramine, two approved anti-obesity drugs, should however not be 
used in women who anticipate conception because of lack of safety data on their use during 
early pregnancy. 
 
Insulin-sensitizing drugs are not considered anti-obesity drugs even though some evidence 
indicates that metformin therapy might contribute to weight loss (Knowler et al., 2002). A 
systematic review confirming the effectiveness of metformin for ovulation induction in 
women with PCOS, could not demonstrate that metformin contributes to weight loss (Lord 
et al., 2003). Another review on the same topic did however demonstrate a contribution of 
metformin to weight loss (Harborne et al., 2003). A recent RCT comparing three ovulation 
induction modalities (metformin and placebo, metformin and clomiphene, clomiphene and 
placebo) in women with PCOS also showed more weight loss in women treated with 







If metformin treatment does contribute to weight loss, treatment of women of reproductive 
age with obesity and infertility could improve the chances of conception. Data on the safety 
of metformin use in the first trimester are re-assuring (Gilbert et al., 2006; Lilja and 
Mathiesen, 2006). 
The objective of this review was to assess whether treatment of women, of reproductive age 
who are overweight or obese, with insulin-sensitizing agents contributes to weight loss in 





The aim of this review was to assess the effect of insulin-sensitizing drugs on weight loss in 
women of reproductive age who are overweight or obese. The following clinical 
comparisons were assessed: (1) The effectiveness of insulin-sensitizing drugs for losing 
weight compared to placebo, with or without a diet/lifestyle programme. (2) The side-
effects and drop-out rate reported by women taking these drugs. (3) The most effective 
insulin-sensitizing drug for losing weight, compared to each other, with or without a 
diet/lifestyle modification programme.  
 
Data sources 
The following databases were searched for this review: Cochrane Central Register of 
Controlled Trials (CENTRAL), MEDLINE, and EmBASE were searched up to and 
including August 2007. Only randomised controlled trials were included. 
Main keywords used for this search were: Body weight, BMI, obesity, RCT, diet, insulin-
sensitizing drugs and weight loss (See Appendix for the full list of keywords). 
Hand-searching was performed on the references used in the included studies and relevant 
review articles were meticulously searched for related articles. Authors were contacted for 
missing data or questions regarding the methodology. 
 
Study selection 
Titles and abstracts identified through the search strategies were independently screened by 
two reviewers (A. Nieuwenhuis-Ruifrok, W. Kuchenbecker). Articles were discarded if 
they did not meet the inclusion criteria. Full text articles were obtained of studies for 
potential inclusion. Independent review of the trials was undertaken by the same two 
reviewers to assess the quality and characteristics of the studies. Differences in opinion 
between the reviewers on selected articles were settled by consensus. 
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The subjects were women of reproductive age who are overweight (BMI 25‒29.9 kg/m²) or 
obese (BMI ≥30 kg/m²) according to accepted diagnostic criteria (NIH, 1998) and who 
were deemed eligible for weight loss measures. Studies that included prepubertal and 
postmenopausal women were excluded.  
 
Main intervention: Treatment with insulin-sensitizing drugs: metformin, pioglitazone, 
rosiglitazone or D-chiro-inositol. Treatment with metformin was assessed in two 
subanalyses according to the daily dosage of <1500 mg or >1500 mg. This dosage cut-off 
for metformin was used because most initial studies used the dosage of 500 mg tablets 3 
times daily (low dose) and later studies using 1000 mg twice daily or 850 mg tablets 2‒3 
times daily (high dose). 
Comparison interventions: One or more of the following: Placebo only or placebo with diet 
advice or a lifestyle modification programme. The primary outcome measure was change in 
BMI in kg/m2.  
Secondary outcomes were drop-out rates and side effects caused by the drugs. 
 
Data synthesis and analysis 
Using RevMan for the analysis, measuring the effect in WMD and 95% confidence 
intervals (CI), data from the fourteen trials were stratified over two main interventions and 
subanalysis was performed on four co-interventions while still maintaining adequate 
numbers of patients for analysis. 
For statistical analysis standard deviations (SDs) were required. Hence for all trials in 
which 95% CI or standard error of the means (SEM) were given, these values were 
converted into SDs. In two trials (Fleming et al., 2002; Kjotrod et al., 2004) more expanded 
calculations were needed to derive the SDs. 
 
Quality assessment 
Trial quality was assessed on minimisation of selection bias, performance bias, attrition 
bias and detection bias. Assessment of the quality of allocation concealment was graded in 
four categories: adequate (A), unclear (B), inadequate (C) or not given (D). Other trial 
characteristics assessed were differences in baseline values, non-compliance, standardised 
outcome measures, drop-out rate, the extent of losses to follow-up, side effects, blinding 
methods, and whether analysis was by intention to treat. 
 
In the statistical analysis the weighted mean difference (WMD) was used to express the 
effect of each continuous outcome. Heterogeneity in the data was noted and cautiously 
explored using certain characteristics of the study, particularly assessments of quality. In 







analyses were performed. These analyses included quality of allocation concealment, 







The search strategy revealed thirty-one trials eligible for inclusion in this review. After 
studying these publications, seventeen trials were excluded (see separate reference list) and 
the data of the remaining fourteen trials were analysed. See Table 1 of included studies for 
full details of the fourteen included trials (extended version of Table 1 hosted on website of 
Human Reproduction Update). 
The fourteen included studies randomised 649 women with 20 subjects in the smallest trials 
(Pasquali et al., 2000; Gambineri et al., 2004) and 143 in the largest trial (Tang et al., 
2006). 
Eleven of these trials were stated to be double-blind and two single-blind. One did not state 
the blinding method (Mitkov et al., 2006). 
 
In three trials randomisation was performed by centre (Nestler and Jukubowicz, 1996; 
Kjotrod et al., 2004; Tang et al., 2006) and in three trials the randomisation was computer 
generated (Fleming et al., 2002; Vandermolen et al., 2001; Yarali et al., 2002). 
Pasquali et al. (2000), packaged drug and placebo and labelled according to subject 
number. Then randomisation was performed in blocks of four. 
One trial stated that it ‘randomly placed’ its subjects (Gambineri et al., 2004), two trials 
numbered the participants sequentially (Jakubowicz et al., 2001; Kocak et al., 2002). 
However, Kocak et al. (2002), randomised patients by order of admission, resulting in a 
quasi-randomised study. Two studies used random number tables (Kilicdag et al., 2005; 
Ortega-Gonzalez et al., 2005) and two (Crave et al., 1995; Mitkov et al., 2005) did not state 
the method of randomisation. 
 
In four studies a power calculation was performed (Fleming et al., 2002; Kjotrod et al., 
2004; Kilicdag et al., 2005; Tang et al., 2006), while the other nine did not mention a 
sample-size calculation. In three trials an analysis by intention-to-treat was stated to have 




































































































































































































The analysis of metformin versus thiazolidinediones was included even though these three 
trials tested two different thiazolidinediones; rosiglitazone and pioglitazone.  
 
The analysis comparing the duration of trials was included as the effectiveness of the drugs 
involved might be correlated with the duration of its use. 
Five trials were included in the ‘duration <8 weeks’ arm (Nestler and Jukubowicz, 1996; 
Jakubowicz et al., 2001; Vandermolen et al., 2001; Kocak et al., 2002; Yarali et al., 2002), 
lasting 35 days to 7‒8 weeks. Six trials were included in the ‘duration >8 weeks’ arm 
(Crave et al., 1995; Pasquali et al., 2000; Fleming et al., 2002; Gambineri et al., 2004; 
Kjotrod et al., 2004; Tang et al., 2006), lasting from 16 weeks to 6 months. 
 
The criteria for diet or no-diet were not very strict. When mention was made of diet or 
lifestyle adaptations, the trial was coded as diet, even if compliance to diet was not 
assessed. In seven of the included studies no mention was made of a diet (Nestler and 
Jukubowicz, 1996; Jakubowicz, 2001; Vandermolen et al., 2001; Kocak et al., 2002; Yarali 
et al., 2002; Kilicdag et al., 2005; Mitkov et al., 2006). In two trials (Gambineri et al., 
2004; Ortega-Gonzalez, 2005) the women were instructed not to modify their usual eating 
or exercise patterns during the study period, these trials were coded as ‘no diet’. 
In the other five trials, diet as co-intervention was implemented with a variety of criteria 
(Crave et al., 1995; Gambineri et al., 2004; Kjotrod et al., 2004; Pasquali et al., 2000; Tang 
et al., 2006). Pasquali et al. (2000) and Gambineri et al. (2004) placed the women on a 
standardised hypo caloric diet (1200‒1400 kcal daily) for the 1st month, and continuing 
dietary treatment for the rest of the study period. Crave et al. (1995) placed the women on a 
low fat low caloric diet (1500 kcal daily with 30% fat). Kjotrod et al. (2004) mentioned diet 
and lifestyle modification without specifying the intervention. The patients in the trial of 
Tang et al. (2006) received standardised dietary advice from a research dietician aiming for 
a calorie reduction of 500 kcal per day. 
 
In one of the twelve trials clomiphene citrate (CC) was used as a co-intervention 
(Vandermolen et al., 2001). In this trial all participants received CC for the first 5 days of 
the first cycle. With ovulation, the CC dose did not change, but with persistent anovulation, 
the dosage of CC was increased by 50 mg/day for the next cycle. 
 
All studies used for this review were fully published in peer-reviewed journals. Ten of the 
included trials were single-centre studies (Crave et al., 1995; Pasquali et al., 2000; 
Jakubowicz et al., 2001; Fleming et al., 2002; Kocak et al., 2002; Gambineri et al., 2004; 
Kjotrod et al., 2004; Kilicdag et al., 2005; Ortega-Gonzalez et al., 2005; Mitkov et al., 
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2006) and four trials were multicentre (Nestler and Jukubowicz, 1996; Vandermolen et al., 
2001; Yarali et al., 2002; Tang et al., 2006). 
 
Unintentionally all studies, except two (Crave et al., 1995; Pasquali et al., 2000), were 
found to be on women with PCOS. The diagnostic criteria for PCOS broadly followed the 
National Institute of Health consensus criteria (anovulation and hyperandrogenaemia with 
exclusion of other endocrinopathies) or the diagnostic criteria of the Rotterdam consensus 
meeting (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004). 
The following criteria were used to define overweight/obesity: In three trials all women 
required a BMI >28 kg/m² (Gambineri et al., 2004; Kjotrod et al., 2004; Mitkov et al., 
2006) and in one trial (Nestler and Jukubowicz, 1996) all participants required a BMI ≥27.5 
kg/m2. The remaining trials (Crave et al., 1995; Pasquali et al., 2000; Jakubowicz et al., 
2001; Fleming et al., 2002; Kocak et al., 2002; Yarali et al., 2002; Kilicdag et al., 2005; 
Mitkov et al., 2006; Tang et al., 2006) did not specify their criteria; seven of these trials had 
an average BMI at baseline >28 kg/m2 in both treatment arms and in three (Crave et al., 
1995; Kilicdag et al., 2005; Mitkov et al., 2006) the average BMI in both treatment arms at 
baseline was >25 kg/m2. 
 
The included trials were performed on different ethnic groups and geographical locations. 
Trials were performed in Europe, United States of America, Turkey, Mexico, Bulgaria and 
Venezuela, and one study was spread over Venezuela, USA and Europe.  
 
The mean baseline characteristics for BMI can be found in Table 2. 
All women included in the trials were of reproductive age. The duration of the trials varied 
between 35 days and 6 months.  
Heterogeneity in this review was assessed for each analysis. Performance bias (blinding) 
was explored; for each trial blinding methods are stated in Table 1. 
 
Analyses 
The analysis was structured to address three relevant clinical comparisons as mentioned in 
the Methods section: 
(1) The effectiveness of insulin-sensitizing drugs for losing weight compared to placebo, 
with or without a diet/lifestyle programme.  
























































(A) Metformin versus placebo (BMI) (Figure 1): Eleven trials with a total of 537 women 
compared metformin treatment with placebo (Crave et al., 1995; Nestler and Jakubowicz, 
1996; Pasquali et al., 2000; Jakubowicz et al., 2001; Vandermolen et al., 2001; Fleming et 
al., 2002; Kocak et al., 2002; Yarali et al., 2002; Gambineri et al., 2004; Kjotrod et al., 
2004; Tang et al., 2006). Of these 537 women, only the 469 women who completed the 
trials were included in the analysis. 
Metformin treatment contributed to a significant decrease in BMI (WMD -0.68, 95% 
confidence interval (CI) -1.13 to -0.24, P=0.003). 
Test for heterogeneity: Chi2=9.35, df=10 (P=0.50). I2=0% 
 
(B) High-dose metformin (>1500 mg/day) versus placebo (BMI) (Figure 1, upper part): 
Eight trials with a total of 429 women compared high-dose metformin (>1500 mg/day) 
versus placebo (Crave et al., 1995; Pasquali et al., 2000; Fleming et al., 2002; Kocak et al., 
2002; Yarali et al., 2002; Gambineri et al., 2004; Kjotrod et al., 2004; Tang et al., 2006). 
Fifty-seven women did not complete the trial and were not included in the analysis, leaving 


















































High-dose metformin treatment contributed to a significant decrease in BMI (WMD -0.98, 
95% CI -1.51 to -0.45, P=0.003).  
Test for heterogeneity: Chi2=4.29, df=7 (P=0.75), I2=0%. 
 
(C) Low-dose metformin (<1500 mg/day) versus placebo (BMI) (Figure 1, lower part): 
Three trials compared low-dose metformin (<1500 mg/day) versus placebo, with a total of 
98 women (Nestler and Jakubowicz, 1996; Jakubowicz et al., 2001; Vandermolen et al., 
2001). In this analysis 97 women were included for analysis, as one did not complete the 
trial.  
There was no evidence of effect on BMI (WMD 0.02, 95% CI -0.79 to 0.84, P=0.96). 
Test for heterogeneity: Chi2=0.94, df=2 (P=0.62), I2=0%. 
 
(D) High-dose metformin versus placebo, diet/no diet (BMI) (Figure 2): The same trials 
were used as in analysis 3. Five trials included diet as a co-intervention (Crave et al., 1995; 
Pasquali et al., 2000; Gambineri et al., 2004; Kjotrod et al., 2004; Tang et al., 2006) 
randomising 247 women, of which 222 were included in the analyses, since 25 women did 
not complete the trials. Three trials in which 182 women were randomised did not include 
diet as a co-intervention (Fleming et al., 2002; Kocak et al., 2002; Yarali et al., 2002). 
Thirty women did not complete the trial, hence 143 were left to be analysed. 
Figure 2. High-dose metformin versus placebo, diet versus no diet. 
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There was no evidence of effect on BMI in the ‘diet’ group, five trials of 220 women 
(WMD -0.84, 95% CI -2.20 to 0.51, P=0.22). In the ‘no diet’, three trials of 152 women, 
there was however a significant decrease in BMI (WMD -1.01, 95% CI -1.59 to -0.43, 
P=0.0006).  
Test for heterogeneity (diet): Chi2=3.86, df=4 (p=0.43), I2=0%.  
Test for heterogeneity (no diet): Chi2=0.38, df=2 (p=0.83), I2=0%. 
 
(E) Metformin versus placebo, duration <8 weeks/duration >8 weeks (BMI) (Figure 3): 
The same trials as in analysis 1 were used; in the duration of <8 weeks arm five trials were 
included (Nestler and Jukubowicz, 1996; Jakubowicz et al., 2001; Vandermolen et al., 
2001; Kocak et al., 2002; Yarali et al., 2002). In this arm 186 were randomised, of which 
184 women completed the trials and were included in the analysis. In the arm of duration of 
>8 weeks, six trials were included (Crave et al., 1995; Pasquali et al., 2000; Fleming et al., 
2002; Gambineri et al., 2004; Kjotrod et al., 2004; Tang et al., 2006), 341 women were 
randomised and 287 completed the trials. 
There was no evidence of effect on BMI in the ‘duration <8 weeks’, but there was evidence 
of effect in the ‘duration >8 weeks’ sub-analyses.  
 
 




















































Duration ≤8 weeks: WMD -0.16, 95% CI -0.90 to 0.58, P=0.67, duration >8 weeks: WMD 
-0.97, 95% CI -1.53 to -0.42, P=0.0006. Test for heterogeneity (≤8 weeks): Chi2=2.50, df=4 
(p=0.65), I2=0%. Test for heterogeneity (>8 weeks): Chi2=3.90, df=5 (p=0.56), I2=0%. 
 
 
(2) The side-effects and drop out rates reported by women taking these drugs. 
Due to the heterogeneous description of side-effects and drop outs in the various studies we 
could not perform an analysis on percentages of drop outs and side-effects in the 
abovementioned comparisons. An overview of the side-effects and drop outs is presented in 
Table 3.  
 
(3) The most effective insulin-sensitizing drug for losing weight compared to each other.  
High-dose metformin versus thiazolidinedione (BMI): 
Three trials with a total of 112 women compared high-dose metformin (>1500 mg/day) 
versus thiazolidinedione (Kilicdag et al., 2005; Ortega-Gonzalez et al., 2005; Mitkov et al., 
2006). Ninety-five women completed the trials, only these were included in the analysis. 
These three trials were the only trials assessing the effect of thiazolidinedione. Therefore 
they were included in the analysis in spite of no placebo group. 
There was no evidence of a differential effect on BMI (WMD -1.61, 95% CI -3.84 to 0.62, 
P=0.16).  
Test for heterogeneity: Chi2=0.31, df=2 (p=0.86), I2=0% 
 
Sensitivity analyses 
Sensitivity analyses were performed on the metformin intervention arm to test whether 
there was an influence from allocation concealment and blinding. Excluding the three trials 
that were graded ‘B’ (Gambineri et al., 2004; Mitkov et al., 2006) or ‘C’ (Kocak et al., 
2002) for allocation concealment did not change the analyses for BMI. When excluding the  
trials that were single blinded (Nestler and Jukubowicz, 1996; Gambineri et al., 2004) or 
did not state the blinding method (Crave et al., 1995; Mitkov et al., 2006), no change in the 






The fourteen selected RCTs randomised a total of 649 women but only the 554 women who 
completed the trials were included for analysis. All except two of the studies analysed were 







This review indicates that metformin treatment of reproductive aged women with PCOS 
who are overweight or obese, leads to a significant decrease in BMI when compared to 
placebo.  
Studies assessing the treatment with high-dose metformin (>1500 mg/day) revealed a more 
pronounced decrease in BMI when compared to the low-dose metformin (≤1500 mg/day) 
studies. The fact that no significant decrease in BMI was seen in the three trials on low-
dose metformin (Nestler and Jukubowicz, 1996; Jakubowicz et al., 2001; Vandermolen et 
al., 2001) could be attributed to shorter duration of treatment and with only 97 women 
analysed, this sub-analyses was potentially underpowered to show a significant effect. 
Duration of the treatment for ≤ 8 weeks did not show a significant decrease in BMI even 
after excluding the three trials on low-dose metformin (Nestler and Jukubowicz, 1996; 
Jakubowicz et al., 2001; Vandermolen et al., 2001). 
The group with ‘diet’ as a co-intervention did not a show a significant decrease in BMI. 
The poor reporting and implementation of diets or a lifestyle programme in the analysed 
trials could explain this unexpected finding. On the other hand, this finding could also 
indicate that metformin treatment does not have an additional effect on weight loss in 
patients who undergo a diet or lifestyle programme.  
Due to inconsistent reporting of the gastrointestinal side-effects of metformin(nausea, 
abdominal cramps and diarrhoea) in the trials, this review could not assess whether the 
significant decrease in BMI in the metformin group can be attributed to gastrointestinal 
side-effects. A RCT comparing different doses of metformin in obese women with PCOS 
(Harborne et al., 2005), showed that high-dose metformin (2550 mg/day) had a more 
consistent effect on weight loss compared to low-dose metformin (1500 mg/day) without 
increased drop outs rates due to gastrointestinal side effects.  
Treatment with metformin did not significantly contribute to a decreased BMI when 
compared to thiazolidinedione. This finding was unexpected because treatment with 
thiazolidinedione is known to contribute to weight gain (Kahn et al., 2006; Balas et al., 
2007). With only 95 women completing the trials, this analysis was potentially under-
powered to show more weight loss in the metformin group. 
 
The most important limitation of this review is that the analysis was only performed on the 
study subjects completing the trial period. Because only three trials (Fleming et al., 2002; 
Kjotrod et al., 2004; Vandermolen et al., 2001) used intention to treat analysis and the other 
trials inconsistently reported baseline BMI values and withdrawal after randomisation, 
sound statistical analysis was not possible using all included patients and a sensitivity 
analysis including and excluding the withdrawals after randomisation and the drop outs was 
not possible. The second limitation of this review is that most of the fourteen included trials 
7





were designed for a different primary outcome and clinical question.  Heterogeneity of the 
study populations is another limitation of this review. 
What would the clinical relevance be of minimal additional weight loss due to high-dose 
metformin treatment? With the  average women analysed in this review having a BMI of 35 
kg/m2 and assuming an average length of 1.64 m, treatment with high-dose metformin 
would have contributed to reach a final BMI of 34.02 kg/m2 (WMD -0.98) and a decrease in 
weight from 94.2 kg to 91.5 kg. This decrease of 2.7 kg corresponds to a 2.9% decrease in 
initial bodyweight. 
Orlistat and sibutramine, two of the registered anti-obesity agents, taken for a period of one 
year, contribute to 2.9% and 4.6% additional weight loss respectively (Padwal et al., 2003; 
(Padwal and Makumbar, 2007). Considering the lack of safety data, both of these 
medications should not be taken during conception and early pregnancy while data on the 
use of metformin during conception and early pregnancy are extensive and reassuring 
(Gilbert et al., 2006; Lilja and Mathiesen, 2006; Legro et al., 2007).  
In overweight or obese women with PCOS a minimum of 5% weight loss is required for 
resumption of ovulation and spontaneous conception (Kiddy et al., 1992; Hollman et al., 
1996). In obese women with PCOS, a minimum of 5% loss of abdominal fat is essential for 
the resumption of spontaneous ovulation (Huber-Buchholz et al., 1999). Minimal weight 
loss improves the chances of spontaneous conception and conception after fertility 
treatment in obese women undergoing a lifestyle modification programme (Clark et al.. 
1998). Modest pre-pregnancy weight loss decreases the incidence of gestational diabetes 
(Glazer et al., 2004) and prevention of minimal weight gain between pregnancies decreases 
the chance of pregnancy complications (Villamor and Cnattingius, 2006). 
With the above-mentioned evidence in mind, the 2.9% additional weight loss achieved 
when treating women with PCOS who are overweight or obese with high-dose metformin 
therapy (with a maximum intervention period in this review being 6 months) can be 
compared to the additional weight loss achieved with orlistat and sibutramine (with an 
intervention period of 1 year). High-dose metformin therapy can therefore be considered a 
safe and possibly relevant intervention in women with PCOS who are overweight or obese 
to achieve additional weight loss.  
 
In conclusion, this review shows that treating women of reproductive age with PCOS who 
are overweight or obese with metformin leads to a significant decrease in BMI. Considering 
the limitations of this review, this conclusion should be interpreted with caution. There is 
some indication of greater effect with high-dose metformin (>1500 mg/day) and longer 
duration of therapy (>8 weeks) leading to 2.9% additional weight loss. This is however 







duration subgroups. According to this review, the addition of a diet or lifestyle programme 
does not contribute to further weight loss.  
A structured lifestyle modification programme to achieve weight loss should still be the 
first line treatment in obese women with or without PCOS. Adequately powered RCTs are 
required to confirm the findings of this review and to assess whether the addition of high-
dose metformin therapy to a structured lifestyle modification programme might contribute 
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The aim of this thesis was to assess various aspects of obesity and female infertility with 
the main focus on studying the role and influence of body-fat distribution, especially IAF 
and SAF and serum adipokines in women with obesity and infertility undergoing a lifestyle 
programme.  
Baseline assessment of 57 women with obesity and infertility revealed that trunk fat, 
abdominal fat and SAF but not IAF were associated with anovulation. On the other hand, in 
32 women with PCOS, early and consistent loss of IAF and not SAF was associated with 
resumption of ovulation. In spite of significantly more abdominal obesity and significantly 
more SAF and no difference in IAF in the PCOS women compared to non PCOS controls 
at baseline, PCOS status had no influence on the correlation of the body-fat distribution 
parameters with the serum adipokine levels. In women with obesity and infertility, the 
measurement of IAF by US and not SAF correlates strongly with the measurement by CT 
scan and US can measure the changes of IAF over time only with when sufficient loss of 
IAF has occurred.  
A systematic review showed that metformin treatment of reproductive aged women with 
PCOS who are overweight or obese, leads to a significant decrease in BMI when compared 
to placebo. We have shown that the costs of fertility treatment and of pregnancy 
complications in obese women compared to women of normal weight, were  € 6045 and  € 
3016 in anovulatory women and € 10,355  and € 6096  in ovulatory women per live birth, 
respectively. 
  
Obesity, adipose tissue dysfunction and body-fat redistribution 
In women of reproductive age with obesity and infertility, it is essential to identify women 
with abdominal obesity because of its association with infertility and pregnancy 
complications (Wass et al., 1997; Sattar et al., 2001; Zaadstra et al., 1993; Brisson et al. 
2010). In women with abdominal obesity a further risk assessment can be performed by 
identifying individuals with predominantly IAF accumulation compared to those with more 
SAF accumulation. Little controversy exists that an excess of IAF is associated with a high 
cardiometabolic risk (Jensen, 2008). Subcutaneous fat on the other hand can have a 
protective effect against developing cardiometabolic disease by buffering postprandial free 
fatty acid (FFA) and lipid fluxes (Koska et al., 2008; Weiss, 2007). In premenopausal 
women with abdominal obesity, IAF is associated with IR even after correcting for SAF 
(Ross et al., 2002). In women with PCOS limited evidence indicates that an excess of IAF 







pressure during pregnancy (Bartha et al., 2007, Martin et al., 2009). We have shown that in 
women with obesity (BMI 37.7±6.1 kg/m2) and infertility anovulatory women have a 
significantly higher volume of SAF and fasting insulin levels and no difference in the 
volume of IAF compared to ovulatory women, and after multiple logistic regression 
analysis, SAF and not IAF was associated with anovulation (Chapter 3).  When limiting the 
baseline comparison of the body-fat distribution parameters to women with PCOS 
compared to ovulatory controls (BMI 36.8±4.9 kg/m2), PCOS women had significantly 
more abdominal obesity (waist circumference and abdominal fat on DEXA scan) and SAF, 
but no difference in IAF (Chapter 5). Barber et al.  showed that women with PCOS (BMI 
28.2 kg/m2)  had equal amounts of IAF and significantly more SAF than ovulatory controls, 
but after adjusting for the differences in BMI and total fat mass, there were no significant 
differences  in IAF and SAF anymore (Barber et al., 2008a). Previous studies comparing 
the body-fat distribution and volumes of IAF and SAF between non-obese women with 
PCOS to lean ovulatory controls, did not consistently show a difference in abdominal 
obesity and IAF (Yildirim et al., 2003; Dolfing et al., 2011; Manneras-Holm et al., 2011). 
The discrepancy of the findings in the abovementioned studies on the volumes of IAF and 
SAF in women with infertility and PCOS can be attributed to the differences in BMI of the 
various study populations. According to the so-called ‘critical intra-abdominal fat threshold’ 
hypothesis (Freedland, 2004), with further increasing BMI and continuous excess calorie 
intake, IAF reaches a point of saturation after which fat is shunted to SAF. When 
subcutaneous adipose tissue can not store further excess fat due to adipose tissue 
dysfunction, a process of body-fat redistribution is initiated.  
In order to increase its storage capacity of excess fat, subcutaneous adipose tissue regulates 
the recruitment and differentiation of preadipocytes to mature adipocytes (adipogenesis), 
leading to more adipocytes that can store excess fat (hyperplastic obesity) (Danforth, 2000, 
Rodriguez-Acebes et al., 2010). In many obese patients, after chronic exposure to energy 
dense diets and increasing BMI, adipogenesis becomes dysregulated, leading to adipocyte 
hypertrophy and decreased fat storage capacity of the subcutaneous adipose tissue 
(hypertrophic obesity) (Danforth, 2000; Villa and Pratley, 2011). Hypertrophic obesity is 
associated with increased fat cell size, necrosis and an inflammatory response (Rasouli and 
Kern, 2008; Weiss, 2007), resulting in a decreased ability to store additional fat leading to 
dysfunctional subcutaneous adipose tissue. Due to the dysfunctional subcutaneous adipose 
tissue, a process of body-fat redistribution occurs, leading to shunting of excess fat from 
SAF to ectopic sites like the liver, skeletal muscles and pancreas. Accumulation of fat in 
these ectopic sites is strongly associated with IR and an adverse metabolic profile (Weiss 
2007; Koska et al., 2008; Arsenault et al., 2011) . We hypothesize that with increasing BMI 
initially more fat is shunted from IAF to SAF, explaining that in women with obesity and 







not be the case in women with lower BMI levels, in whom body-fat redistribution has not 
been initiated.  
Some studies indicate that androgen excess in women with PCOS contribute to impaired 
adipogenesis. Dihydrotestosterone decreases the differentiation and lipid accumulation in 
human preadipocytes and adipocytes in culture (Gupta et al., 2008). Prenatal exposure to 
androgens in animal models induces increased adipocyte cell size accompanied by IR 
(Roland et al., 2010).  We therefore hypothesize, that androgen excess in women with 
PCOS may contribute to impaired adipogenesis and initiate the process of adipose tissue 
dysfunction at a lower BMI level compared to non-PCOS women.  
Based on Chapter 3 in which we show that SAF is associated with anovulation, it can not 
be excluded that functional mechanisms of IAF contribute to anovulation. In spite of a 
much smaller volume of IAF compared to SAF, and a much lower contribution of IAF to 
the systemic FFA concentration, various studies showed a significant correlation of IAF 
with IR and metabolic complications of obesity (Arsenault et al., 2011; Lebovitz and 
Banerji, 2005). IAF has higher lipolytical activity per unit fat mass, and direct drainage into 
the portal vein results in increased delivery of FFAs and adipokines to the liver (Weiss, 
2007; Arsenault et al., 2011). The functional contribution of IAF to anovulation is 
supported by the fact that anovulatory women with obesity and PCOS need to lose IAF and 
not SAF for resumption of ovulation (Chapter 6) mediated by improvement of IR. It is 
likely that with increasing BMI and adipose tissue dysfunction in women with obesity and 
infertility, the redistribution of fat from IAF to SAF and ultimately to ectopic fat sites 
contributes to anovulation due to increased IR. In Chapter 5, women with PCOS had 
significantly more SAF, higher fasting insulin levels and a trend of more moderate and 
severe liver-fat accumulation in spite of no difference in the amount of IAF compared to 
non-PCOS controls. With increasing BMI and associated adipose tissue dysfunction and 
body-fat redistribution, it becomes even more difficult to evaluate the individual 
contribution of IAF and SAF to female reproduction. Future studies on the role of IAF and 
SAF in female reproduction should also evaluate deposition of fat in ectopic sites like liver, 
skeletal muscles and the pancreas.  
 
The role of adipokines 
Adipose tissue is a complex and highly active endocrine organ involved in the metabolism 
of steroid hormones and expression and secretion of various proteins and peptides, 
collectively called adipokines (Ahima, 2006). Apart form IR, the secretion of various 
adipokines by the IAF and SAF compartments may also play a role in obesity-related 
infertility and anovulation (Bohler et al., 2010; Mitchell et al., 2005). In view of a 
significantly greater amount of SAF in anovulatory women (Chapter 3), an adipokine 







models leptin, an adipokine mainly produced by SAF, induces anovulation by direct 
ovarian effects (Duggal et al., 2000). Adipose tissue dysfunction due to hypertrophic 
obesity leads to a change in the profile of adipokine secretion by IAF and SAF, ectopic fat 
sites and other body-fat compartments, which may have an adverse effect on female 
reproduction (Rasouli and Kern, 2008; Villa and Pratley, 2011). Adipokines, like leptin, 
adiponectin, interleukin-6 (IL-6) and tumour necrosis factor α (TNFα) have been shown to 
influence reproductive function due to their effects on hypothalamic function and direct 
effects on the ovary and endometrium (Mitchell et al., 2005; Robker et al., 2009; Bohler et 
al., 2010).  
Women with PCOS and obesity are known to have abdominal obesity (Pasquali et al., 
2006; Carmina et al., 2009). The increase in abdominal obesity in women with PCOS 
compared to weight matched ovulatory controls has however not consistently been shown 
in women with PCOS of normal weight (Yildirim et al., 2003; Dolfing et al., 2011; 
Manneras-Holm et al., 2011). In women with PCOS, the morphology of the adipose tissue 
is characterised by enlarged adipocytes and low-grade inflammation of subcutaneous 
adipose tissue (Escobar-Morreale et al., 2011; Manneras-Holm et al., 2011). Increased gene 
expression of inflammatory markers of adipose tissue has been shown in obese compared to 
normal-weight women with PCOS (Lindholm et al., 2011). In obese women (BMI 34.4±4.6 
kg/m2) however, Lindholm et al. (2011) could not show a difference in the gene expression 
of inflammatory markers of adipose tissue between PCOS women compared to non-PCOS 
controls.  In women with PCOS, fat cells of IAF and SAF have different lipolytical activity 
(Ek et al., 2002; Faulds et al., 2003) and dysregulated gene expression for insulin signalling 
of omental fat compared to ovulatory controls (Corton et al., 2007).  
Based on the differences in body-fat distribution and the differences in morphology and 
function of adipose tissue in women with PCOS, a difference may be expected in their 
serum adipokine levels compared to ovulatory controls. However, in women with PCOS, 
leptin levels do not differ significantly from those in age and weight-matched ovulatory 
controls (Remsberg et al., 2002; Sepilian et al., 2006; Carmina et al., 2009). The positive 
correlation between BMI and leptin is comparable in PCOS and ovulatory women 
(Brzechffa et al., 1996). In a meta-analysis, no significant differences in the serum levels of 
IL-6 and TNFα between women with PCOS and ovulatory women could be shown 
(Escobar-Morreale et al., 2011). Another meta-analysis showed lower levels of adiponectin 
in women with PCOS compared to ovulatory controls after correcting for BMI (Toulis et 
al., 2009). Adiponectin consists of three multimers, i.e. low, medium and high molecular 
weight (HMW) adiponectin, of which the HMW adiponectin is specifically associated with 
insulin sensitivity. More recent studies did not consistently show lower HMW adiponectin 
levels in women with PCOS compared to ovulatory controls after correcting for differences 







We tested the hypothesis whether PCOS status is a determining factor in the correlation 
between body-fat distribution parameters and serum adipokine levels. Women with PCOS 
revealed significant  differences in body-fat distribution parameters compared to non-PCOS 
controls (Chapter 5) and the correlation of serum adipokine levels with body-fat 
distribution parameters were in agreement with previous publications (Kershaw and Flier 
2004; Carmina et al., 2009; Jain et al., 2009). Logistic regression analysis correcting for 
BMI and age however, revealed that PCOS status had no influence on the correlation 
(Chapter 5).  
Redistribution of fat and altered function of all body-fat compartments (including ectopic 
sites) is reflected in a changing profile of adipokine secretion (Freedland, 2004; Weiss, 
2007; Despres et al., 2008; Rasouli and Kern, 2008). With increasing BMI and adipose 
tissue dysfunction, redistribution of fat occurs including deposition of fat in ectopic sites 
like the liver, skeletal muscles and pancreas. With increasing BMI therefore, the total fat 
mass and not the individual fat compartments is predominant, explaining why PCOS status 
at higher BMI levels is not a determining factor in the correlation between body-fat 
distribution and serum adipokine levels. 
On the other hand, serum adipokine levels may not accurately reflect the morphology and 
function of adipose tissue compartments for the following reasons. Some adipokines (like 
adiponectin) are exclusively secreted by adipocytes, while only one third of circulating IL-6 
originates from adipocytes. Leptin on the other hand is also expressed by other cells within 
the fat depots and by other tissues. TNFα acts primarily in an autocrine and paracrine 
manner and its serum levels therefore may not reflect its biological activity (Rasouli and 
Kern, 2008; Bohler et al., 2010). Serum levels of adipokines do not accurately reflect the 
release of adipokines by IAF into the portal venous system in spite of the known metabolic 
consequences of hepatic fat accumulation (Weiss, 2007; Arsenault et al., 2011). At present 
it is not possible to define the contribution of ectopic fat depots to serum adipokine levels. 
The mere measurement of the volumes of IAF and SAF and serum adipokine levels will not 
accurately reflect the metabolic activity of the different fat compartments, let alone their 
effect on female reproduction. Studies on the effect of obesity on female reproduction by 
analysing serum adipokine levels should take these limitations into consideration. The 
measurement of serum adipokine levels should not be used in the clinical management of 
women with obesity and infertility. 
In Figure 1 an overview is presented of the concept of adipose tissue dysfunction and of the 
proposed mechanisms by which accumulation and dysfunction of intra-abdominal adipose 
tissue and subcutaneous adipose tissue can be linked to the metabolic and female 
reproductive consequences of obesity. In Figure 1 it is also explained why women with 


























































Figure 1. Proposed mechanisms by which accumulation of intra-abdominal and subcutaneous adipose 
tissue can cause dysfunctional and functional obesity, and be linked to metabolic and female 
reproductive consequences of obesity. (Adapted with permission from (Despres et al., 2008.) 
FFA, free fatty acids; IL-6, interleukin-6; TG, triglycerides; PAI-1, plasminogen activator inhibitor-1; 




Weight loss for the improvement of female reproductive outcome 
Weight loss and exercise in women who are overweight or obese improve the chances of 
spontaneous conception in anovulatory and ovulatory women (Clark et al., 1998; Norman 
et al., 2004) and a decrease in BMI before conception leads to the improvement of 
pregnancy outcomes (Glazer et al., 2004; Villamor and Cnattingius, 2006; Paramsothy et 
al., 2009). According to a recent systematic review and meta-analysis, dietary and lifestyle 
intervention even during pregnancy can improve perinatal and obstetric outcomes 
(Thangaratinam et al., 2012). Weight loss interventions for the improvement of 
reproductive outcome in women with obesity and infertility are based on retrospective and 
small cohort studies, and have not yet been evaluated in randomised controlled trials.    
Previous studies have shown that 5‒10% loss of body weight leads to resumption of 
ovulation in about 60% of anovulatory women who are overweight or obese (Kiddy et al., 
1992; Guzick et al., 1994; Clark et al., 1995), and that 5% loss of abdominal fat on DEXA 
is associated with resumption of ovulation in overweight women with PCOS (Huber-
Buchholz et al., 1999). We have shown that obese anovulatory women with PCOS who 
resume ovulation during a 6-month lifestyle programme lose 15% abdominal fat on DEXA 
compared to 4.3% in women who did not resume ovulation. Furthermore, women with 
PCOS who resume ovulation lost significantly more IAF, with no difference in the loss of 
SAF compared to women who did not resume ovulation (Chapter 6). As shown in different 
patient populations during the initial period of calorie restriction preferential loss of IAF 
occurs, which significantly correlates with an improvement in IR (Goodpaster et al., 1999). 
Surgical removal of IAF leads to improvement in IR (Thorne et al., 2002), while 
liposuction does not alter IR significantly (Klein et al., 2004). In anovulatory women with 
obesity achieving weight loss, resumption of ovulation is mediated by improvement in IR 
and a decrease in free androgen levels (Guzick et al., 1994; Holte et al. 1995; Pasquali et al. 
2006). Improvement in IR and the resulting lower insulin levels lead to less androgen 
production by the ovarian theca cells and more SHBG production in the liver (Poretsky, 
1991), and the lower free androgen levels further contribute to the resumption of ovulation 
(Pasquali et al., 2003; Guzick et al., 1994).  
In Chapter 6, there was a non-significant increase in pedometer steps (an indication of 
increased physical activity) in the women that resumed ovulation compared to those that 







assess whether increased physical activity may contribute to increased loss of IAF and 
resumption of ovulation. Some studies suggest that exercise contributes to loss of IAF (Kay 
and Fiatarone Singh, 2006; Ohkawara et al., 2007). A study controlling for calorie intake 
and diet could not show an independent effect of exercise on loss of IAF (Christiansen et 
al., 2009), but a more recent study indicated that exercise was associated with loss of IAF 
and improvement in IR in PCOS women, despite weight maintenance (Hutchison et al., 
2011). A structured exercise programme in anovulatory women with PCOS showed higher 
ovulation rates and improvement in IR compared to a diet programme alone (Palomba et 
al., 2008). Data prospectively collected from the Nurses’ Health Study II reveal that for 
every hour of vigorous physical activity per week, there was a 5% reduction in the relative 
risk of ovulatory infertility after correcting for BMI (Rich-Edwards et al., 2002). In a recent 
prospective cohort study of physical activity and time to pregnancy, moderate physical 
activity was associated with a small increase in fecundability regardless of BMI (Wise et 
al., 2012). In women of normal weight, a decrease in fecundability with vigorous physical 
activity was seen in a dose-response relationship (Wise et al., 2012). In women with 
overweight or obesity however, a weak positive association was seen between vigorous 
activity and fecundability (Wise et al., 2012). Overweight or obese women are more IR and 
vigorous physical activity may improve glucose disposal and IR by increasing the muscle 
mass (Carroll and Dudfield, 2004; Thomson et al., 2008), while in normal-weight women 
vigorous physical activity alters the GnRH pulse activity contributing to avulatory 
dysfunction. 
Most individuals who are overweight or obese experience great difficulty to achieve and 
maintain weight loss, and a multi-factorial approach based on diet, exercise and behaviour 
modification is advised to help patients lose weight (Anonymous, 1998). Dietary 
interventions should be tailored to individual preferences aimed at achieving a 600 kcal/day 
deficit. Generally, obese individuals achieve maximal weight loss after the first 6 months of 
weight loss intervention irrespective of the dietary composition (Sacks et al., 2009). 
According to a meta-analysis, exercise in combination with dietary intervention achieves 
more weight loss than diet alone (Wu et al., 2009), and it has a favorable effect on general 
well-being and health-related quality of life (Lemoine et al., 2007). Obese individuals have 
an intrinsic resistance to changing behaviour, and low self-esteem and low self-efficacy are 
a limiting factor in achieving weight loss. Individual or group support and cognitive-
behavioural guidance are advised and will contribute to more and sustained weight loss 
(Wadden and Butryn, 2003; Shaw et al., 2005; Sacks et al., 2009). It is essential to try to 
achieve adequate weight loss soon after the start of a lifestyle programme, because too little 
weight loss increases the risk of drop-out (Messier et al., 2010). In our study, in spite of 
personal guidance by a nurse practitioner using motivational interviewing techniques, the 







This is in agreement with the rates of 27‒35% reported in previous studies on lifestyle 
intervention in comparable patient populations (Clark et al., 1995; Hoeger et al., 2004; 
Palomba et al., 2008). Drop-out in women with obesity and infertility undergoing a lifestyle 
programme is a major limiting factor in achieving the maximal benefit of weight loss on 
female reproductive outcome. More studies should be performed to elucidate the patient-
related factors that lead to high chances of drop-out. 
According to several international guidelines, women with overweight and obesity are 
required to lose weight before conception. Some fertility clinics even expect women with 
severe obesity to reduce their BMI to <35 kg/m2 in order to limit serious obesity-related 
pregnancy complications (Balen et al., 2006; Nelson and Fleming, 2007). Women with 
severe obesity who are unable to reduce their weight sufficiently are faced with not being 
accepted for fertility treatment (Farquhar and Gillett, 2006; Pandey et al., 2010). A national 
survey in the US indicated that in spite of the absence of firm guidelines on BMI 
restrictions, most fertility specialists believe that BMI guidelines or cutoffs should exist 
(Harris et al., 2011).  In  women with infertility and severe obesity who have failed to lose 
adequate weight during a lifestyle programme, it is essential to consider additional 
treatment options like weight loss medication and bariatric surgery. These interventions 
may help them to reduce their BMI and to ensure their access to fertility treatment. 
The combination of a lifestyle modification programme with weight loss medication, 
achieves more weight loss than a lifestyle programme alone (Wadden et al., 2005). The 
effect of weight loss medications is however modest and they are limited by side 
effects. Orlistat, an approved anti-obesity drug should not be used in women who anticipate 
conception because of lack of safety data on its use during early pregnancy. The 
pharmacokinetics of orlistat, however, are favourable because of a very low absorption and 
first-pass metabolism, resulting in a bioavailablity of less than 1% (Padwal and Majumdar, 
2007). Further studies are needed before sound recommendations can be made regarding 
the use of orlistat in women attempting to conceive. 
Insulin-sensitizing drugs are not considered weight loss medications, even though some 
evidence indicates that metformin therapy might contribute to weight loss (Knowler et al., 
2002). Not all studies on the use of metformin in women with PCOS could show that 
metformin use contributes to weight loss (Harborne et al., 2003; Lord et al., 2003; Legro et 
al., 2007). In anovulatory women with PCOS, metformin was studied extensively and may 
contribute to resumption of ovulation in a subset of patients (Tang et al., 2012). We 
performed a systematic review on the use of insulin-sensitizing drugs for weight loss, 
expressed as change in BMI, in comparison to placebo and diet and/or a lifestyle 
modification programme in women of reproductive age. Treatment with metformin showed 
a statistically significant decrease in BMI compared to placebo (weighted mean difference     







mg/day) revealed a more pronounced decrease in BMI when compared to low-dose 
metformin (<1500 mg/day), but treatment for less than 8 weeks did not show a significant 
decrease in BMI even after excluding trials on low-dose metformin. Data on the safety of 
metformin use in the first trimester of pregnancy are re-assuring (Gilbert et al. 2006; Lilja 
and Mathiesen, 2006). In women with infertility and severe obesity who have great 
difficulties achieving sufficient weight loss, treatment with high-dose metformin for more 
than 8 weeks may help them to achieve more weight loss and reach a target BMI in order to 
be considered for fertility treatment in fertility units that maintain BMI entry criteria. 
 
Women with a BMI >40 kg/m2 who can not reach sufficient weight loss, have to be 
informed about the option of bariatric surgery. Bariatric surgery leads to significant weight 
loss up to 5 years, with significant improvement and even resolution of type 2 diabetes 
mellitus, hypertension and hypertriglyceridaemia (Padwal et al., 2011). Bariatric surgery 
leads to significant improvement in obesity-related pregnancy complications, especially a 
decrease in gestational diabetes and pre-eclampsia (Maggard et al., 2008; Kominiarek, 
2010). The three most common bariatric surgery procedures are laparoscopic Roux-en-Y 
gastric bypass (LRYGB), laparoscopic sleeve gastrectomy (LSG) and laparoscopic 
adjustable gastric banding (LAGB). LRYGB leads to a higher degree of weight loss than 
LAGB (68% vs. 45% of preoperative weight after 4 years), and weight loss after LRYGB 
and LSG is comparable (Colquitt et al., 2009; Padwal et al., 2011). LAGB has less short 
term complications, but a higher rate of later re-operation than LRYGB due to band 
migration or erosion and inadequate weight loss. It is recommended that contraception 
should be used during the first 12 to 18 months after the operation, to benefit from maximal 
weight loss and to avoid the fetus being exposed to a maternal environment of rapid weight 
loss that may predispose to poor fetal growth (American College of Obstetricians and 
Gynecologists, 2005; Lesko and Peaceman, 2012).   
Data on female fertility after bariatric surgery are limited, but indicate that the amount of 
weight loss is the most important predictor of spontaneous conception (Musella et al., 
2011). After bariatric surgery, the nutritional status of the pregnant women should be 
optimised and iron, folic acid and vitamin B12 supplementation is advised. These women 
require special attention and care during pregnancy by a multi-disciplinary team because of 















Sample size and repeat measurements  
All infertile women with a BMI >29 kg/m2 attending the fertility clinic of the University 
Medical Center Groningen were considered for inclusion in a lifestyle intervention 
programme of 6 months. Of the 60 eligible women who agreed to participate, two did not 
undergo the baseline assessment due to early drop-out and pregnancy. One anovulatory 
woman with a BMI of 58 kg/m2 was excluded from the analysis because the CT could not 
be performed accurately due to physical constraints. See Table 3 of the introduction for a 
summary on how the study subjects were selected for the analyses of Chapters 3 to 6. The 
number of participants decreased due to drop-out and pregnancy (11 dropped out and six 
became pregnant during the first 3 months, and seven dropped out and six became pregnant 
during the last 3 months) of the lifestyle programme. The resulting small numbers of 
participants is a limiting factor for the analyses in Chapters 3 to 6. Small sample size may 
reduce statistical power and may be influenced by outlying values, but scatter plots did not 
reveal outlying values. Repeated measurements on the same subjects in this study revealed 
consistent and significant results. This indicates that the inter-subject variation between the 
different measurements was limited, which mitigates the effect of the small numbers on the 
analyses. 
Incomplete data due to drop-out in lifestyle intervention studies may compromise the 
longitudinal analysis of the data on the outcome of lifestyle intervention, because the 
number of subjects available for complete case analysis will be reduced (Ware, 2003). 
Various statistical methods are used in an effort to make maximum use of all available data 
(Liu and Gould 2002; Gadbury et al., 2003).  In the analysis of the change of IAF in 
anovulatory women (Chapter 6), we started with a complete case analysis using ANOVA 
which showed no significant differences but a trend of the findings. To analyse the trend, 
we performed Generalised Estimating Equations (GEE) in a longitudinal design making 
maximum use of the available data by including the data of the last measurement before 
drop-out or pregnancy.  
 
Validation between US and CT measurements of IAF and SAF 
IAF and SAF are measured by US as a distance in cm and by CT as a volume in cm3. The 
validation between US and CT measurements of IAF and SAF can not be determined 
because of the different measurement units. We therefore applied the Bland-Altman method 
comparison analysis to test the relative validity by comparing the distance measurement of 
IAF by US and CT in cm. The findings of Chapter 4 (i.e., the US measurement of IAF 
correlates with the CT measurement) can be applied in future studies on the role of IAF in 







can however not replace CT measurement of IAF in cm3 due to the lack of studies proving 
the absolute validity between US and CT measurement of IAF. However, considering the 
studies showing good relative validity, US measurements of IAF can be used in 
epidemiological research investigating the role of this adipose tissue compartment in female 
reproductive function. 
To limit the radiation exposure in women with obesity and infertility, we used a single-
sliced abdominal CT scan at the level of L4-L5 to capture the IAF and SAF distribution. 
Due to the individual variation of IAF and SAF distribution throughout the abdomen, whole 
abdominal CT or MRI measurement of the total volume of IAF and SAF is more accurate 
than measurement by a single-sliced abdominal CT scan at the level of L4-L5 (Thomas and 
Bell, 2003; Lee et al., 2004). Most previous validation studies also used CT or MRI slices 
at the level of L4-L5 or L2-L3, and their findings are in agreement with our data obtained at 
L4-L5 (Armellini et al., 1993; Stolk et al., 2001; De Lucia Rolfe et al., 2010; Gradmark et 
al., 2010). A study published after our study was launched (Kuk et al., 2010), indicates that 
in women the measurement of IAF by single-sliced CT scan at the level of L2-L3 shows 
better correlation with whole abdomen CT scan. Future validation studies on the 
measurement of IAF between CT and US in women should use the IAF measurement of a 














Implications for clinical practice  
Women with infertility who are overweight or obese are often prepared to conceive at all 
costs with little consideration for the associated decrease in live birth rates and serious risks 
during pregnancy and for the future child. Fertility doctors on the other hand are obliged to 
discuss these risks with their patients, but have the professional responsibility to provide 
good quality care and to decide whether access to fertility treatment is justified. We aim to 
formulate critical reasoning and arguments which can be used by fertility doctors in the 




All patients who are overweight or obese should be informed about the long term obesity-
related health risks such as cardiovascular disease, type 2 diabetes and several cancers. 
Women with infertility who are overweight or obese should be informed about the 
detrimental effect of overweight or obesity on female fertility and treatment outcome (i.e. 
lower chance of pregnancy and increased risk for miscarriage). The women should 
specifically be counselled on the serious obstetrical risks (e.g., hypertensive disorders and 
pre-eclampsia, gestational diabetes, thromboembolic disorders and increased caesarean 
delivery rates), perinatal risks (e.g., birth complications due to macrosomia, perinatal death, 
neural tube defects and cardiovascular anomalies) and the long-term health of the offspring 
(i.e. adult disease due to unfavourable fetal conditions). These women should be counselled 
that weight loss before conception may improve the live birth rate and will decrease the 
obstetric and perinatal risks associated with overweight and obesity (Balen et al., 2007, 
Nelson and Fleming, 2007).  
See Table 2 of the introduction for an overview of the effect of obesity on female 
reproduction. 
 
The following arguments can be used in the counselling and decision making process, 
based on the individual BMI level of the patient. 
 
BMI 25‒29.0 kg/m2 
Women with WHO II anovulation should be informed that generally weight loss leads to 
resumption of ovulation and is therefore considered the first line of fertility treatment. 







exercise increases the chance of resumption of ovulation. Ovulation induction should only 
be considered if more than 5% loss of body weight did not lead to resumption of ovulation. 
Women with overweight should be advised to lose weight before starting fertility treatment 
in order to improve the live birth rate and decrease the obesity-related pregnancy risks. 
Only the women that do not achieve any weight loss should be offered a structured lifestyle 
programme as mentioned below. 
 
BMI 30‒34.9 kg/m2 
Women with obesity and infertility should be advised to lose weight and be offered 
assistance in doing so. Preferably, fertility clinics should offer a structured lifestyle 
programme with individual guidance and a combination of diet, increased physical activity 
and behaviour modification based on evidence based guidelines (National Heart, Lung and 
Blood Institute/National Institutes of Diabetes and Digestive and Kidney diseases, 1998). 
Patients should be motivated to lose 5‒10% of the initial body weight in order to increase 
the live birth rate and decrease the obesity-related pregnancy risks. This focused effort of 
lifestyle intervention should be achievable in a 6 months period. 
 
BMI 35‒39.9 kg/m2 
Women with severe obesity and infertility should be informed about the serious obesity-
related maternal and perinatal risks. The fertility doctor should aim to convey this message 
in a sympathetic manner while on the other hand convincing the patient that fertility 
treatment above a BMI level of 35 kg/m2 will not be honoured. These women should be 
encouraged to participate in a structured lifestyle programme as mentioned above. The 
women should be informed that any delay in fertility treatment is in the best interest of the 
mother and the potential offspring. Women that are not able to achieve sufficient weight 
loss in spite of strict compliance to the lifestyle programme can be offered weight loss 
medication in order to achieve the target BMI level. The use of contraception should be 
advised during the use of orlistat. In selected patients with severe obesity who are unable to 
reach the target BMI of 35 kg/m2 and especially those women with type 2 diabetes mellitus 
and hypertension, bariatric surgery can be considered as mentioned below. 
 
BMI ≥40 kg/m2 
Women with morbid obesity should be counseled about the very serious obesity-related 
pregnancy risks for both mother and offspring and that no fertility treatment will be 
performed above a BMI level of 35 kg/m2. These women should be assessed in a multi-
disciplinary setting and advised on weight loss medication in addition to a structured 
lifestyle programme as mentioned above. In many of these women with morbid obesity, 
reaching a BMI level of 35 kg/m2 is an unrealistic target. These women should be counseled 







weight and achieve the target BMI level. After bariatric surgery, contraception should be 
advised during the period of rapid weight loss (12‒18 months) as this period of metabolic 
instability might also have a detrimental effect on pregnancy outcome, especially the risk of 
intra-uterine growth retardation. After bariatric surgery, enough time should be allowed 
before conception, to achieve sufficient weight loss in order to facilitate the decrease in 
obesity-related pregnancy complications.  
 
Obesity vs. age 
In women above the age of 35 years, age has been shown to have a stronger negative effect 
on fertility than BMI (Sneed et al., 2008; Luke et al., 2011). The gain associated with 
weight loss should be balanced against increasing age and decreasing fertility during the 
months of lifestyle intervention. In women above the age of 35 years and a BMI between 
35‒39.9 kg/m2, the severe obesity-related obstetrical and perinatal risks justify several 
months of structured lifestyle intervention to achieve sufficient weight loss in order to 
decrease these risks. The morbid obese women with a BMI ≥40 kg/m2 should not be offered 
fertility treatment, even if they are approaching the end of their reproductive period. 
 
Pregnancy 
During pregnancy, weight gain should be restricted according to pre-pregnancy BMI levels 
(Table 1) (Rasmussen et al., 2010), and lifestyle intervention and dietary intervention 
should be encouraged in order to decrease obesity-related pregnancy complication rates 
(Hui et al., 2012; Thangaratinam et al., 2012). 
 
Ethical considerations 
An extensive deliberation of the ethical considerations of lifestyle-related factors and access 
to medical assisted reproduction was published by the European Society of Human 
Reproduction and Embryology (ESHRE) Task Force on Ethics and Law (ESHRE Task 
Force on Ethics and Law, including et al., 2010).The following ethical considerations 




Table 1.  Recommendations for weight gain during pregnancy (adapted from Rasmussen et al., 2010) 
 
Prepregnancy BMI Classification Total weight gain  
(range in kg) 
BMI <18.5  Underweight 12.5‒18 
BMI   18.5‒24.9  Normal weight 11.5‒16 
BMI      25‒29.9  Overweight   7.0‒11.5 
BMI          ≥30  Obese   5.0‒9.0 
 







The primary aim of fertility treatment is to achieve the birth of a healthy child without 
exposing the future mother nor her offspring to dis-proportional risks. Professionals 
involved in fertility care have responsibilities for the welfare of their infertile patients and 
the off-spring. When considering fertility treatment, the fertility doctor has to balance the 
maternal risks involved and the welfare of the future child, and in case of a negative ratio of 
expected benefit and harm the ethical principle of non-maleficence (“first do no harm”) is 
violated, and fertility treatment should not be offered. When fertility treatment is 
collectively funded and costs related to maternal and neonatal (long-term) complications 
are covered by public health insurance, the fertility doctor has to take the interests of 
society into consideration as well. Doctors and society are allowed to require patient 
commitment and compliance with lifestyle recommendations that will decrease the risks for 
the future mother and child. Withholding fertility treatment in women with severe obesity 
(BMI >35 kg/m2) is therefore ethically justified, but fertility clinics and medical 
professionals offering reproductive assistance to women with obesity have the ethical 
obligation to assist these women to lose weight by offering or facilitating a structured 
lifestyle intervention programme. 
 
 
RECOMMENDATIONS FOR FUTURE RESEARCH 
 
Besides BMI level, other body-fat distribution parameters, US measurement of IAF and 
liver-fat accumulation should be recorded in women with overweight and obesity 
considering fertility treatment. These parameters should be correlated with live birth rates 
and pregnancy complications in order to identify prognostic factors which can be used to 
select women with obesity-related poor reproductive outcome. These data may identify 
more specific BMI levels and body-fat distribution parameters that can be implemented for 
targeted lifestyle intervention before starting fertility treatment with the aim to improve 
reproductive outcome.  
 
Lifestyle intervention programmes for women with infertility who are overweight or obese 
should be combined with studies assessing the mechanisms and effects of lifestyle 
intervention on female reproduction:  
• A current multicenter RCT (LIFESTYLE study) is underway to assess the costs and 
effects of a structured lifestyle programme in overweight and obese subfertile women 
to reduce the need for fertility treatment and improve reproductive outcome (Mutsaerts 
et al., 2010) (Dutch Trial Register NTR1530). The findings of this study will hopefully 








• For anovulatory women who are overweight or obese, different dietary compositions 
and different exercise programmes for targeted loss of IAF for resumption of ovulation 
should be assessed. The additional benefit of aerobic exercise with or without 
resistance training on resumption of ovulation should be evaluated in a randomised 
trial. 
• The effect of the lifestyle intervention on the changes in IAF, body-fat redistribution 
and accumulation of fat in ectopic sites should be investigated by using US as a 
measurement tool of IAF according to a strict measurement protocol. Quantitative 
hepatic fat assessment by US can be used in a research setting to measure liver-fat 
accumulation as a marker of ectopic fat accumulation. 
• Future studies should identify risk factors for drop-out during lifestyle intervention 
programmes. The outcomes of such studies can lead to individualised targeted 
intervention with the aim of decreasing the drop-out rate as a limiting factor in the 
success of lifestyle intervention programmes. 
 
Future studies should investigate the pathofysiological mechanisms of dysfunctional 
adipose tissue leading to fat redistribution with accumulation of fat in ectopic sites. These 
studies should combine the assessment of body-fat compartments, ectopic site fat 
accumulation and gene expression profile assessment of omental fat and the different 
subcutaneous fat regions. Genome-wide microarray analysis of the different fat 
compartments can identify candidate genes with abnormal expression involved in the 
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The female reproductive consequences of the rising prevalence of overweight (BMI 
25‒29.9) and obesity (BMI ≥30) world -wide are of great concern, and amongst other 
disciplines also require gynaecologists to prioritise this chronic disease in clinical 
management protocols and research.  In women with obesity, the chances of conceiving 
spontaneously are decreased and the risk of a miscarriage is increased. More women with 
obesity will therefore require fertility treatment, while these patients require more 
gonadotrophins for ovarian hyperstimulation and have lower pregnancy rates and live birth 
rates after ART. The obesity-related pregnancy complications are of great concern because 
of an increase in perinatal mortality and even in maternal mortality in cases of severe (BMI 
35‒39.9 kg/m2) and morbid (BMI >40 kg/m2) obesity. Obesity in pregnancy also 
predisposes to long-term disease of the offspring due to the concept of developmental onset 
of health and adult disease.  
The studies in this thesis were undertaken to assess various aspects of obesity and female 
infertility. The main focus was on the role and influence of body-fat distribution, especially 
intra-abdominal fat (IAF) and subcutaneous abdominal fat (SAF) in women with obesity 
and infertility undergoing a lifestyle program.  
Considering the above-mentioned consequences of obesity in women undergoing fertility 
treatment, it is likely that obesity has a negative impact on the cost-effectiveness of fertility 
treatment. In Chapter 2 a framework was developed to calculate the costs of fertility 
treatment (i.e., ovulation induction, intra-uterine insemination and in vitro fertilisation) and 
of pregnancy complications for ovulatory and anovulatory women separately, in a 
hypothetical cohort of 1000 normal weight, overweight and obese women each. The 
calculated costs per live birth in obese women compared to women of normal weight were 
€ 6045 and  € 3016 in anovulatory women, and € 10,355 and € 6096 in ovulatory women, 
respectively. Future prospective studies are awaited to determine whether lifestyle 
intervention aimed at weight loss before fertility treatment will improve the cost-
effectiveness of fertility treatment per live birth in women with obesity and infertility. 
Obesity is a heterogeneous condition in which accumulation of fat around the abdomen 
(abdominal obesity) is associated with a high cardio-metabolic risk profile and adverse 
female reproductive outcome. Abdominal obesity in women of reproductive age is 
associated with infertility and an increase in pregnancy complications. In individuals with 







(IR) and a high cardio-metabolic risk profile. Limited evidence indicates that in abdominal 
obesity the excess of IAF has a detrimental effect on female reproduction. In Chapter 3 we 
assessed the contribution of different body-fat distribution parameters (and especially IAF 
and SAF volume measured by abdominal Computerised Tomography (CT) scan) to 
anovulation in women with obesity and infertility. In spite of comparable BMI, anovulatory 
women had a higher waist circumference, significantly more trunk and abdominal fat on 
DEXA scan and significantly more SAF than ovulatory women. The volume of IAF was 
not significantly different between the ovulatory and anovulatory groups. After multiple 
logistic regression analysis, only trunk fat, abdominal fat and SAF were associated with 
anovulation. This association is however only based on the volume of these fat 
compartments and does not necessarily reflect the consequences of their metabolic activity. 
Reliable measurement of IAF and SAF in women with obesity and infertility is essential for 
adequate evaluation of the effect of these fat compartments on female reproductive 
function. Abdominal ultrasound (US) may be a good alternative for the measurement of 
IAF and SAF compared to the gold standard of CT or Magnetic Resonance Imaging (MRI), 
due to no radiation exposure, low costs and general availability of US in fertility and 
antenatal clinics. Validation studies showing that US is a reliable tool for the measurement 
of IAF and SAF when compared to CT or MRI, were mostly conducted in older 
populations and have not been performed in women of reproductive age before. Chapter 4 
presents our data on the correlation between the measurements of IAF and SAF by US and 
CT in women with obesity and infertility at fixed time points (baseline, month 3 and month 
6) of a lifestyle programme, as well as the measurements of the changes of IAF and SAF 
between these time points. The correlation between the IAF measurement by US and CT 
was good at all time points, but the correlation between the SAF measurement by US and 
CT was weak. The correlation between the measurement of the changes of IAF by US and 
CT was only significant between baseline and month 6. The method comparison analyses 
for the IAF measurements showed good agreement between the US and CT measurements 
of IAF. In women with obesity and infertility, US can be implemented as a tool for the 
measurements of IAF, but the measurement of the changes of IAF over time is only 
accurate if sufficient loss of IAF has occurred. The measurement of SAF by US in its 
present form is not reliable enough to be used in clinical settings and in future research. 
Adipose tissue is not only a site of lipid storage, but a complex endocrine organ expressing 
and secreting many bioactive peptides, collectively called adipokines. Adipokines, like 
leptin, adiponectin, interleukin-6 and tumour necrosis factor α may influence female 
reproduction by an effect on the hypothalamus, the ovary and the endometrium. It can be 
hypothesized that the measurement of serum adipokine levels could reflect the difference in 







compartments. Chapter 5 elaborates on whether PCOS status (i.e., defined as anovulation 
and polycystic ovaries on ultrasound and/or hyperandrogenaemia) is a determining factor in 
the association between body-fat distribution parameters and serum adipokine levels in 
women with obesity and infertility. Women with anovulatory PCOS had significantly more 
abdominal obesity (waist circumference and abdominal fat on DEXA scan) and 
significantly more SAF and no difference in IAF compared to ovulatory non-PCOS 
controls. In spite of these differences, linear regression analysis of the adipokines with 
body-fat distribution parameters revealed that PCOS status had no influence on the 
association between the body-fat distribution parameters and the serum adipokine levels. 
With higher BMI levels, the measurement of body-fat compartments and serum adipokine 
levels may not reflect the metabolic and reproductive consequences of obesity due to 
adipose tissue becoming dysfunctional. Dysfunctional adipose tissue leads to fat 
redistribution from IAF to SAF and ultimately to accumulation in ectopic fat sites like the 
liver, pancreas and skeletal muscle. Fat accumulation in ectopic sites is especially 
associated with IR and an adverse metabolic risk profile. The present study shows more 
liver-fat accumulation on US in women with anovulatory PCOS compared to the ovulatory 
non-PCOS controls. Assessment of ectopic fat site deposition, like hepatic fat 
accumulation, may be a tool to identify women with a further increase in risk of adverse 
reproductive outcome.  
Lifestyle intervention and weight loss in women who are overweight or obese improves the 
chances of spontaneous conception in anovulatory and ovulatory women. Pre-pregnancy 
weight loss and lifestyle intervention during pregnancy leads to a decrease in obesity-
related pregnancy complications. Weight loss in anovulatory women who are overweight or 
obese leads to resumption of ovulation in about 60% of women. On average, 5‒10% loss of 
initial body weight is associated with resumption of ovulation which is facilitated by a 
decrease in IR and hyperandrogenaemia. In women with PCOS, 5% loss of abdominal fat is 
required for resumption of ovulation, but it is not clear whether differential loss of IAF or 
SAF contributes to resumption of ovulation. Chapter 6 outlines our results comparing the 
changes in body-fat distribution parameters, and especially IAF and SAF, in a group of 
obese anovulatory women with PCOS who resumed ovulation to those who remained 
anovulatory during a 6-month lifestyle programme. Resumption of ovulation was 
associated with 12% and 19% loss of IAF at month 3 and month 6, respectively, whilst the 
women who remained anovulatory lost 5% and 9% of IAF at month 3 and month 6, 
respectively. Loss of SAF was not associated with resumption of ovulation. Future studies 
should assess the combination of diet and structured exercise programs aimed at loss of IAF 







Women with infertility who are overweight or obese experience great difficulty to achieve 
and maintain weight loss. A multifactorial approach based on diet, exercise and behaviour 
modification is advised to help these women achieve weight loss. Some women however do 
not achieve sufficient weight loss to reduce the obesity-related pregnancy complications 
and to reach the target BMI for fertility treatment required by some fertility clinics. The 
combination of a lifestyle intervention programme with weight loss medication achieves 
more weight loss than a lifestyle programme alone. Orlistat, the only FDA approved anti-
obesity drug should not be used in women who plan to conceive, because its safety during 
early pregnancy has not been proven. Previous studies have indicated that metformin 
therapy may contribute to weight loss. In anovulatory women with PCOS, metformin has 
been studied extensively and has been shown to contribute to resumption of ovulation in a 
subset of patients. Information on the safety of metformin use in the first trimester of 
pregnancy is reassuring. In women with obesity and infertility, metformin treatment may 
therefore be considered as an adjunct to lifestyle intervention in order to achieve more 
weight loss. In Chapter 7 we performed a systematic review to assess whether in women 
of reproductive age who are overweight or obese, treatment with insulin-sensitizing agents 
contributes to weight loss in comparison to placebo and diet and/or a lifestyle modification 
programme. This review showed that metformin treatment leads to a significant decrease in 
BMI when compared to placebo. Treatment with high-dose metformin (>1500 mg/day) 
revealed a more pronounced decrease in BMI when compared to the low-dose metformin 
(≤1500 mg/day) studies. Treatment for less than 8 weeks did not show a significant 
decrease in BMI, even after excluding the trials on low-dose metformin. Metformin 
treatment compared to diet as a co-intervention did not show a significant decrease in BMI.  
In women with obesity and infertility undergoing a lifestyle programme, drop-out is a 
major limiting factor in achieving the maximal weight loss for the improvement of female 
reproductive outcome. More studies should be performed to evaluate the patient-related 
factors that lead to high chances of drop-out and to improve the adherence to lifestyle 
intervention programs. 
In conclusion, obesity is a heterogeneous disorder and the female reproductive 
consequences of obesity are determined by body-fat distribution and especially 
accumulation of IAF. With increasing BMI, adipose tissue becomes dysfunctional, leading 
to redistribution of fat to ectopic fat sites like the liver, skeletal muscles and pancreas. 
Serum adipokine levels do not reflect body-fat distribution and the dysfunction of the 
different body-fat compartments. Future studies in women with obesity should measure 
IAF and liver-fat accumulation by means of US to assess their role in the female 







Fertility clinics should offer a structured lifestyle programme to women with obesity and 
infertility with the aim to achieve sufficient weight loss in order to increase the chance of 
spontaneous conception and to decrease obesity-related pregnancy complications. In view 
of the serious obesity-related pregnancy complications, women with a BMI >35 kg/m2 
should not undergo fertility treatment. In women with severe or morbid obesity who have 
great difficulty achieving sufficient weight loss, weight-loss medication including treatment 
with metformin may help them to achieve more weight loss, and in a select group of 













De gevolgen van wereldwijd in toenemende mate voorkomend overgewicht (BMI 25‒29.9) 
en obesitas (BMI >30) zijn zeer zorgelijk voor de vrouwelijke voortplanting. Deze 
gevolgen maken het nodig dat net als in andere disciplines ook gynaecologen prioriteit 
geven aan deze chronische ziekte in klinische behandelingsprotocollen en wetenschappelijk 
onderzoek. Bij vrouwen met obesitas zijn de kansen op spontane conceptie lager en is er 
een verhoogd risico op miskramen, in tegenstelling tot vrouwen van normaal 
lichaamsgewicht. Hierdoor hebben meer vrouwen met obesitas een vruchtbaarheids-
behandeling nodig, terwijl deze patiënten tegelijkertijd meer gonadotrofines voor ovariële 
hyperstimulatie nodig hebben en minder zwangerschappen en levend geboren kinderen 
verkrijgen met de ingestelde behandelingen. Deze aan obesitas gerelateerde zwanger-
schapscomplicaties vormen een grote zorg vanwege de toename van perinatale sterfte en 
zelfs van moedersterfte in gevallen van ernstige (BMI 35‒39.9 kg/m2) en morbide (BMI 
>40 kg/m2) obesitas. Obesitas tijdens zwangerschap leidt bij nakomelingen tot een 
verhoogde kans op ziektes op de lange termijn vanwege het ongunstige intra-uterien milieu 
tijdens de foetale ontwikkeling.  
De studies in dit proefschrift werden uitgevoerd om de verschillende aspecten van obesitas 
en vrouwelijke onvruchtbaarheid te onderzoeken. Het belangrijkste aandachtspunt was de 
rol en de invloed van de verdeling van lichaamsvet, in het bijzonder intra-abdominaal vet 
(IAF) en subcutane abdominaal vet (SAF), bij vrouwen met obesitas en onvruchtbaarheid 
die een leefstijlprogramma ondergingen.  
Gezien de mogelijke gevolgen van obesitas bij vrouwen die een vruchtbaarheids-
behandeling ondergaan, is het aannemelijk dat obesitas een negatieve invloed heeft op de 
kosteneffectiviteit van vruchtbaarheidsbehandeling. In Hoofdstuk 2 wordt een model 
ontwikkeld om de kosten van vruchtbaarheidsbehandelingen (d.w.z. ovulatie-inductie, 
intra-uteriene inseminatie en in-vitrofertilisatie) en van zwangerschapscomplicaties 
afzonderlijk te berekenen voor ovulatoire en anovulatoire vrouwen, met respectievelijk 
normaal gewicht, overgewicht en obesitas. De berekende kosten per levend geboren kind 
bij vrouwen met obesitas waren vergeleken met vrouwen met een normaal gewicht  
respectievelijk € 6045 en € 3016 bij anovulatoire vrouwen, en € 10.355 en € 6096 bij 
ovulatoire vrouwen. Toekomstige prospectieve studies zullen moeten uitwijzen of 
leefstijlinterventies gericht op gewichtsverlies voorafgaand aan een vruchtbaarheids-
behandeling de kosteneffectiviteit van vruchtbaarheidsbehandelingen per levend geboren 







Obesitas is een heterogene aandoening waarbij accumulatie van vet rond de buik 
(abdominale obesitas) in verband wordt gebracht met een hoog cardiometabool risicoprofiel 
en ongunstige uitkomsten van voortplanting bij vrouwen. Abdominale obesitas is 
gerelateerd aan onvruchtbaarheid en een toename van zwangerschapscomplicaties. Bij 
abdominale obesitas wordt de accumulatie van IAF, en niet van SAF, in verband gebracht 
met insulineresistentie (IR) en een hoog cardiometabool risicoprofiel. Er is beperkt bewijs 
dat bij vrouwen met abdominale obesitas de overmaat aan IAF een nadelig effect heeft op 
de voortplanting bij vrouwen. In Hoofdstuk 3 hebben we de invloed bepaald van de 
vetparameters (in het bijzonder IAF en SAF, gemeten met behulp van een CT-scan van het 
abdomen) op anovulatie bij vrouwen met obesitas en onvruchtbaarheid. Ondanks 
vergelijkbare BMI’s hadden anovulatoire vrouwen een hogere tailleomtrek, significant 
meer romp- en abdominaal vet op een DEXA-scan en beduidend meer SAF dan ovulatoire 
vrouwen. Er was geen significant verschil in het IAF volume tussen de ovulatoire en 
anovulatoire groepen. Na multipele logistische regressieanalyses konden alleen rompvet en 
SAF in verband gebracht worden met anovulatie. Dit verband is alleen aangetoond voor de 
omvang van deze vetcompartimenten en het weerspiegelt niet noodzakelijkerwijs de 
metabole effecten van deze compartimenten op de voortplanting. 
Betrouwbare metingen van IAF en SAF bij vrouwen met obesitas en onvruchtbaarheid zijn 
essentieel voor een adequate evaluatie van het effect van deze vetcompartimenten op de 
vrouwelijke vruchtbaarheid. Abdominale echografie kan een goed alternatief zijn voor het 
meten van IAF en SAF in vergelijking met de gouden standaard van CT of MRI, omdat er 
geen blootstelling aan straling is, de kosten laag zijn en de techniek in vruchtbaarheids- en 
prenatale klinieken algemeen beschikbaar is. Validatiestudies waaruit blijkt dat echografie 
een betrouwbaar instrument is voor het meten van IAF en SAF in vergelijking met CT of 
MRI zijn meestal uitgevoerd in oudere populaties en deze zijn nog niet eerder uitgevoerd 
bij vrouwen in de vruchtbare leeftijd. Hoofdstuk 4 vermeldt onze gegevens over de 
correlatie tussen de metingen van IAF en SAF met behulp van echografie en CT bij 
vrouwen met obesitas en onvruchtbaarheid op vaste tijdstippen (start van de evaluatie, 
maand 3 en maand 6) tijdens een leefstijlprogramma, evenals de metingen van 
veranderingen in IAF en SAF tussen deze tijdstippen. De correlatie tussen de IAF-metingen 
met behulp van echografie en CT was sterk op alle tijdstippen, maar de correlatie tussen de 
SAF-metingen met behulp van echografie en CT was gering. De correlatie tussen de meting 
van veranderingen in de tijd van IAF met behulp van echografie en CT was alleen 
significant tussen de start van de evaluatie en maand 6. De Bland-Altman analyse voor de 
IAF-metingen toonden een goede overeenkomst tussen de echografie- en CT-metingen. Bij 
vrouwen met obesitas en onvruchtbaarheid kan abdominale echografie geïmplementeerd 
worden als een instrument voor het meten van IAF, maar de meting van IAF veranderingen 







IAF heeft plaatsgevonden. De metingen van SAF met behulp van echografie zijn in de 
huidige vorm niet betrouwbaar genoeg voor gebruik in klinische toepassing en voor 
wetenschappelijk onderzoek.  
Vetweefsel is niet alleen een plaats voor lipide opslag, maar een complex endocrien orgaan 
dat veel bioactieve peptiden – adipokines genoemd – produceert en afscheidt. Adipokines 
zoals leptine, adiponectine, interleukine-6 en tumor necrosis factor α kunnen de 
vrouwelijke vruchtbaarheid beïnvloeden door hun effect op de hypothalamus, de 
eierstokken en het endometrium. Serum-adipokine-niveau metingen zouden het verschil in 
verdeling van lichaamsvetparameters en de morfologie en functie van de vetweefsel-
compartimenten kunnen weerspiegelen. Hoofdstuk 5 gaat verder in op de vraag of PCOS-
status (gedefinieerd als anovulatie, polycysteuze ovaria op echografie en/of 
hyperandrogenisme) een bepalende factor is in de relatie tussen de verdeling van 
lichaamsvetparameters en serum-adipokine-niveaus bij vrouwen met obesitas en 
onvruchtbaarheid. Anovulatoire PCOS patiënten hadden significant meer abdominale 
obesitas (tailleomtrek en abdominaal vet op de DEXA-scan) en significant meer SAF maar 
toonden geen verschil in IAF  vergeleken met ovulatoire non-PCOS-controles. Ondanks 
deze verschillen liet een lineaire regressieanalyse van de adipokines met de 
lichaamsvetparameters zien dat de PCOS-status geen invloed had op het verband tussen de 
lichaamsvetverdeling en de adipokine-serum-niveaus. Bij hogere BMI waarden 
weerspiegelen de metingen van lichaamsvetcompartimenten en serum-adipokine-niveaus 
mogelijk niet de gevolgen voor cardiometabole risico’s en de voortplanting omdat het 
vetweefsel disfunctioneel wordt. Disfunctioneel vetweefsel leidt tot een herverdeling van 
vet van IAF naar SAF en uiteindelijk tot accumulatie op ectopische vetlocaties zoals in de 
lever, pancreas en skeletspieren. Vetaccumulatie op ectopische locaties wordt vooral in 
verband gebracht met IR en een schadelijk metabool risicoprofiel. Vergeleken met de 
ovulatoire non-PCOS-controles, laat deze studie meer accumulatie van levervet zien op 
echo’s van vrouwen met anovulatoire PCOS. Meting van vetophoping op ectopische 
locaties, zoals in de lever, kan een instrument zijn om vast te stellen welke vrouwen een 
bijkomend risico hebben op de aan obesitas gerelateerde negatieve gevolgen voor de 
vruchtbaarheid.  
Leefstijlinterventie met gewichtsverlies bij vrouwen met overgewicht of obesitas verhoogt 
de kans op een spontane conceptie bij anovulatoire en ovulatoire vrouwen. Gewichtsverlies 
voorafgaand aan de zwangerschap en leefstijlinterventie tijdens de zwangerschap leidt tot 
een daling van de aan obesitas gerelateerde zwangerschapscomplicaties. Gewichtsverlies 
bij anovulatoire vrouwen met overgewicht of obesitas leidt tot herstel van de ovulatie bij 
ongeveer 60%. Gemiddeld genomen gaat een verlies van  5‒10% van het aanvangsgewicht 







hyperandrogenisme. Bij vrouwen met PCOS is 5% verlies van abdominaal vet nodig voor 
herstel van de ovulatie, maar het is niet duidelijk of differentieel verlies van IAF of SAF 
hieraan bijdraagt. Hoofdstuk 6 schetst onze resultaten van de vergelijking tussen de 
veranderingen in de verdeling van  lichaamsvetparameters – en in het bijzonder IAF en 
SAF – bij twee groepen anovulatoire vrouwen met PCOS en obesitas, waarvan de ene 
groep herstel van de ovulatie kreeg en de andere groep anovulatoir bleef tijdens een 
leefstijlprogramma van 6 maanden. Herstel van de ovulatie kon in verband gebracht worden 
met respectievelijk 12% en 19% verlies van IAF in maand 3 en maand 6, terwijl de 
vrouwen die anovulatoir bleven, respectievelijk 5% en 9% IAF verloren in maand 3 en 
maand 6. Het verlies van SAF was niet gerelateerd aan herstel van de ovulatie. 
Toekomstige studies zouden de combinatie van dieet en gestructureerde trainings-
programma’s gericht op het verlies van IAF en verbetering van IR voor het herstel van 
ovulatie moeten onderzoeken.  
Vrouwen met onvruchtbaarheid en overgewicht of obesitas hebben veel moeite met het 
realiseren en handhaven van gewichtsverlies. Om deze vrouwen te helpen gewichtsverlies 
te bewerkstelligen wordt een multifactoriële benadering geadviseerd, gebaseerd op dieet, 
lichaamsbeweging en gedragsverandering. Sommige vrouwen realiseren echter niet 
voldoende gewichtsverlies om de kans op zwangerschapscomplicaties te verminderen die te 
maken hebben met obesitas, en om de gewenste BMI te bereiken die door sommige 
klinieken vereist wordt voor vruchtbaarheidsbehandeling. Er zijn aanwijzingen dat de 
combinatie van een leefstijlinterventieprogramma met medicatie gericht op gewichtsverlies 
in de algemene populatie adipeuze patiënten tot meer gewichtsverlies leidt dan alleen een 
leefstijlinterventieprogramma. Orlistat, het enige FDA goedgekeurde geneesmiddel om 
gewichtsverlies te bevorderen, dient niet gebruikt worden door vrouwen die van plan zijn 
zwanger te worden, omdat de veiligheid van dit geneesmiddel gedurende de vroege 
zwangerschap niet is aangetoond. Eerdere studies hebben laten zien dat een behandeling 
met metformine kan bijdragen aan gewichtsverlies. Metformine is uitgebreid onderzocht bij 
anovulatoire vrouwen met PCOS en er is aangetoond dat metformine bijdraagt tot herstel 
van de ovulatie bij sommigen van deze patiënten. Gegevens over de veiligheid van het 
gebruik van metformine in de eerste 3 maanden van de zwangerschap zijn geruststellend. 
Behandeling met metformine bij vrouwen met obesitas en onvruchtbaarheid kan derhalve 
beschouwd worden als een aanvulling op leefstijlinterventie om meer gewichtsverlies te 
bereiken. In Hoofdstuk 7 hebben we een systematische review uitgevoerd om te bepalen of 
bij vrouwen in de vruchtbare leeftijd die overgewicht of obesitas hebben een behandeling 
met medicatie die de insulinegevoeligheid doet toenemen bijdraagt tot meer 
gewichtsverlies. In de systematische review is de medicatie die de insulinegevoeligheid 
doet toenemen vergeleken met een placebo en dieet en/of een leefstijl-







tot een significante afname van de BMI in vergelijking met het gebruik van een placebo. 
Behandeling met een hoge dosis metformine (>1500 mg/dag) liet een grotere afname van 
de BMI zien in vergelijking met behandelingen met een lage dosis (≤1500 mg/dag). Een 
behandeling van minder dan 8 weken liet geen significante daling in de BMI zien, ook niet 
na uitsluiting van studies met een lage dosis metformine. Een behandeling met metformine 
vergeleken met een dieet als co-interventie liet geen significante afname van de BMI zien. 
Bij vrouwen met obesitas en onvruchtbaarheid die een leefstijlinterventieprogramma 
ondergaan, is voortijdige uitval een belangrijke beperkende factor bij het niet bereiken van 
maximaal gewichtsverlies. Er zullen eerst meer studies moeten worden uitgevoerd naar 
patiënt-gerelateerde factoren die leiden tot grote kans op uitval, om vervolgens het 
voltooien van leefstijlinterventieprogramma’s te kunnen verbeteren. 
Samenvattend: obesitas is een heterogene aandoening en de gevolgen ervan voor de 
vrouwelijke voortplanting worden bepaald door de verdeling van lichaamsvet en in het 
bijzonder door de accumulatie van IAF. Bij een toename van de BMI wordt vetweefsel 
disfunctioneel, dit leidt tot een herverdeling van vet naar ectopische vetlocaties zoals de 
lever, skeletspieren en pancreas. Serum-adipokine-niveaus weerspiegelen niet de verdeling 
van lichaamsvet en de disfunctie van de verschillende lichaamsvet-compartimenten. 
Toekomstige studies bij vrouwen met obesitas zouden IAF en de ophoping van levervet 
kunnen meten met behulp van echografie, om te bepalen welke rol zij spelen bij de 
gevolgen voor de vrouwelijke voortplanting. Fertiliteitsklinieken zouden een gestructureerd 
leefstijlinterventieprogramma moeten bieden aan vrouwen met obesitas en 
onvruchtbaarheid met het doel voldoende gewichtsverlies te bereiken, zodat de kans op 
spontane zwangerschap wordt verhoogd en de zwangerschapscomplicaties die met obesitas 
samenhangen, worden verminderd. Gezien de ernstige, aan obesitas gerelateerde 
zwangerschapscomplicaties zou aan vrouwen met een BMI >35 kg/m2  geen vrucht-
baarheidsbehandeling moeten worden aangeboden. Bij vrouwen met een ernstige of 
morbide obesitas die grote problemen hebben met het bereiken van voldoende 
gewichtsverlies kan medicatie gericht op gewichtsverlies, waaronder behandeling met 
metformine, helpen om meer gewicht te verliezen, en bij een selecte groep vrouwen met 
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